# Hay_2015_Asenapine versus placebo for schizophrenia.

Cochrane
Library

Cochrane Database of Systematic Reviews

Asenapine versus placebo for schizophrenia (Review)

Hay A, Byers A, Sereno M, Basra MK, Dutta S

Hay A, Byers A, Sereno M, Basra MK, Dutta S. 
Asenapine versus placebo for schizophrenia. 
Cochrane Database of Systematic Reviews 2015, Issue 11. Art. No.: CD011458. 
DOI: 10.1002/14651858.CD011458.pub2.

www.cochranelibrary.com

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

T A B L E   O F   C O N T E N T S

ABSTRACT.....................................................................................................................................................................................................
PLAIN LANGUAGE SUMMARY.......................................................................................................................................................................
SUMMARY OF FINDINGS..............................................................................................................................................................................
BACKGROUND..............................................................................................................................................................................................
Figure 1..................................................................................................................................................................................................
OBJECTIVES..................................................................................................................................................................................................
METHODS.....................................................................................................................................................................................................
RESULTS........................................................................................................................................................................................................
Figure 2..................................................................................................................................................................................................
Figure 3..................................................................................................................................................................................................
Figure 4..................................................................................................................................................................................................
DISCUSSION..................................................................................................................................................................................................
AUTHORS' CONCLUSIONS...........................................................................................................................................................................
ACKNOWLEDGEMENTS................................................................................................................................................................................
REFERENCES................................................................................................................................................................................................
CHARACTERISTICS OF STUDIES..................................................................................................................................................................
DATA AND ANALYSES....................................................................................................................................................................................
Analysis 1.1. Comparison 1 ASENAPINE versus PLACEBO, Outcome 1 Global state: 1. No clinically important change (CGI-I) -
short-term (up to 12 weeks).................................................................................................................................................................
Analysis 1.2. Comparison 1 ASENAPINE versus PLACEBO, Outcome 2 Global state: 2. Average change score (CGI-S, high=poor).....
Analysis 1.3. Comparison 1 ASENAPINE versus PLACEBO, Outcome 3 Global state: 3. Relapse - medium-term (13 to 26 weeks).....
Analysis 1.4. Comparison 1 ASENAPINE versus PLACEBO, Outcome 4 Global state: 4. Use of any concomitant medication..........
Analysis 1.5. Comparison 1 ASENAPINE versus PLACEBO, Outcome 5 Global state: 5. Use of specific concomitant medication......
Analysis 1.6. Comparison 1 ASENAPINE versus PLACEBO, Outcome 6 Mental state: 1. No clinically important change (PANSS)
- short-term...........................................................................................................................................................................................
Analysis 1.7. Comparison 1 ASENAPINE versus PLACEBO, Outcome 7 Mental state: 2. Average change in total score (baseline-
to-endpoint) (PANSS, high=poor)........................................................................................................................................................
Analysis  1.8.  Comparison  1  ASENAPINE  versus  PLACEBO,  Outcome  8  Mental  state:  3.  Average  change  score  (baseline-to-
endpoint) (various scales, high=poor).................................................................................................................................................
Analysis 1.9. Comparison 1 ASENAPINE versus PLACEBO, Outcome 9 Adverse effects: 1. Incidence of serious adverse effects......
Analysis 1.10. Comparison 1 ASENAPINE versus PLACEBO, Outcome 10 Adverse effects: 2. Incidence of any adverse effects.......
Analysis  1.11.  Comparison  1  ASENAPINE  versus  PLACEBO,  Outcome  11  Adverse  effects:  3.  Incidence  of  adverse  effects  by
severity - short-term.............................................................................................................................................................................
Analysis  1.12.  Comparison  1  ASENAPINE  versus  PLACEBO,  Outcome  12  Adverse  effects:  4.  Specific  adverse  effects  -  4.1.
Cardiovascular: incidence - short-term...............................................................................................................................................
Analysis  1.13.  Comparison  1  ASENAPINE  versus  PLACEBO,  Outcome  13  Adverse  effects:  4.  Specific  adverse  effects  -  4.2.
Gastrointestinal: incidence - short-term..............................................................................................................................................
Analysis  1.14.  Comparison  1  ASENAPINE  versus  PLACEBO,  Outcome  14  Adverse  effects:  4.  Specific  adverse  effects  -  4.3.
Metabolic: incidence.............................................................................................................................................................................
Analysis  1.15.  Comparison  1  ASENAPINE  versus  PLACEBO,  Outcome  15  Adverse  effects:  4.  Specific  adverse  effects  -  4.4.
Metabolic: average change in prolactin levels (μg/L) (baseline-to-endpoint) - short-term..............................................................
Analysis  1.16.  Comparison  1  ASENAPINE  versus  PLACEBO,  Outcome  16  Adverse  effects:  4.  Specific  adverse  effects  -  4.5.
Metabolic: average change in weight (kg) (baseline-to-endpoint)....................................................................................................
Analysis 1.17. Comparison 1 ASENAPINE versus PLACEBO, Outcome 17 Adverse effects: 4. Specific adverse effects - 4.6. Other
specific adverse effects: incidence.......................................................................................................................................................
Analysis  1.18.  Comparison  1  ASENAPINE  versus  PLACEBO,  Outcome  18  Adverse  effects:  5.  Extrapyramidal  symptoms  -  5.1
Incidence................................................................................................................................................................................................
Analysis  1.19.  Comparison  1  ASENAPINE  versus  PLACEBO,  Outcome  19  Adverse  effects:  5.  Extrapyramidal  symptoms  -  5.2.
Average change (baseline-to-endpoint) (various scales, high=poor) - short-term...........................................................................
Analysis 1.20. Comparison 1 ASENAPINE versus PLACEBO, Outcome 20 Adverse effects: 6. Incidence of death (for any reason)
- short-term...........................................................................................................................................................................................
Analysis 1.21. Comparison 1 ASENAPINE versus PLACEBO, Outcome 21 Leaving the study early...................................................
ADDITIONAL TABLES....................................................................................................................................................................................

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1
2
3
6
7
7
7
13
14
16
17
23
25
26
27
32
45
52

52
53
53
54
55

56

56

58
58
59

59

60

61

63

63

63

67

68

69

69
71

i

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

CONTRIBUTIONS OF AUTHORS...................................................................................................................................................................
DECLARATIONS OF INTEREST.....................................................................................................................................................................
SOURCES OF SUPPORT...............................................................................................................................................................................
DIFFERENCES BETWEEN PROTOCOL AND REVIEW....................................................................................................................................
INDEX TERMS...............................................................................................................................................................................................

71
72
72
72
72

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ii

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

[Intervention Review]

Asenapine versus placebo for schizophrenia

Alistair Hay1, Amy Byers1, Marco Sereno1, Manpreet Kaur Basra1, Snigdha Dutta1

1Institute of Mental Health, The University of Nottingham, Nottingham, UK

Contact: Alistair Hay, Institute of Mental Health, The University of Nottingham, Jubilee Campus, Innovation Park, Triumph Road,
Nottingham, NG7 2TU, UK. alistairhay@hotmail.co.uk.

Editorial group: Cochrane Schizophrenia Group.
Publication status and date: New, published in Issue 11, 2015.

Citation:  Hay A, Byers A, Sereno M, Basra MK, Dutta S. Asenapine versus placebo for schizophrenia. Cochrane Database of Systematic
Reviews 2015, Issue 11. Art. No.: CD011458. DOI: 10.1002/14651858.CD011458.pub2.

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Background

A B S T R A C T

Schizophrenia  is  a  highly  prevalent  and  chronic  disorder  that  comprises  a  wide  range  of  symptomatology.  Asenapine  is  a  recently
developed atypical antipsychotic that is approved by the US Food and Drug Administration (FDA) for the treatment of schizophrenia.

Objectives

To determine the clinical effects of asenapine for adults with schizophrenia or other schizophrenia-like disorders by comparing it with
placebo.

Search methods

We searched the Cochrane Schizophrenia Group's Trials Register (July 04, 2014) which is based on regular searches of MEDLINE, EMBASE,
CINAHL, BIOSIS, AMED, PubMed, PsycINFO, and registries of clinical trials. There are no language, date, document type, or publication
status limitation for inclusion of records into the register. We inspected references of all included studies for further relevant studies.

Selection criteria

Our review includes randomised controlled trials (RCTs) comparing asenapine with placebo in adults (however defined) with schizophrenia
or  related  disorders,  including  schizophreniform  disorder,  schizoaffective  disorder  and  delusional  disorder,  again,  by  any  means  of
diagnosis.

Data collection and analysis

We inspected citations from the searches and identified relevant abstracts, and extracted data from all included studies. For binary data
we calculated risk ratio (RR) with 95% confidence intervals (CI), and for continuous data we calculated mean differences (MD). We used
the GRADE approach to produce a 'Summary of findings' table which included our outcomes of interest, where possible. We used a fixed-
effect model for our analyses.

Main results

We obtained and scrutinised 41 potentially relevant records, and from these we could include only six trials (n = 1835). Five of the six
trials had high risk of attrition bias and all trials were sponsored by pharmaceutical companies. Results showed a clinically important
change in global state (1 RCT, n = 336, RR 0.81, 95% CI 0.68 to 0.97, low-quality evidence) and mental state (1 RCT, n = 336, RR 0.72, 95%
CI 0.59 to 0.86, very low-quality evidence) at short-term amongst people receiving asenapine. People receiving asenapine demonstrated
significant  reductions  in  negative  symptoms  (1  RCT,  n  =  336,  MD  -1.10,  95%  CI  -2.29  to  0.09,  very  low-quality  evidence)  at  short-term.
Individuals receiving asenapine demonstrated significantly fewer incidents of serious adverse effects (1 RCT, n = 386, RR 0.29, 95% CI 0.14 to
0.63, very low-quality evidence) at medium-term. There was no clear difference in people discontinuing the study for any reason between

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

1

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

asenapine and placebo at short-term (5 RCTs, n = 1046, RR 0.91, 95% CI 0.80 to 1.04, very low-quality evidence). No trial reported data for
extrapyramidal symptoms or costs.

Authors' conclusions

There is some, albeit preliminary, evidence that asenapine provides an improvement in positive, negative, and depressive symptoms,
whilst  minimising  the  risk  of  adverse  effects.  However  due  to  the  low-quality  and  limited  quantity  of  evidence,  it  remains  difficult  to
recommend  the  use  of  asenapine  for  people  with  schizophrenia.  We  identify  a  need  for  large-scale,  longer-term,  better-designed  and
conducted randomised controlled trials investigating the clinical effects and safety of asenapine.

P L A I N   L A N G U A G E   S U M M A R Y

Asenapine versus placebo for schizophrenia

Review question

Asenapine is a newer antipsychotic drug developed in the early-to-mid 1990s. The review looks at the effects of asenapine in the treatment
of schizophrenia compared with placebo.

Background

People  with  schizophrenia  often  have  'positive  symptoms',  such  as  hearing  voices,  seeing  things  (hallucinations)  and  strange  beliefs
(delusions). People also have 'negative symptoms', including loss of emotions, apathy, social withdrawal, lack of pleasure and difficulty
speaking and communicating. Disorder of thoughts, anxiety and depression are common. The main treatment for these symptoms of
schizophrenia is antipsychotic drugs, which are divided into older drugs (typical or first generation) and newer drugs (atypical or second
generation). These drugs often have severe side effects, such as weight gain, muscle stiffness, involuntary shaking and tiredness. Asenapine
is a newer antipsychotic drug developed in the 1990s. At present there are no systematic reviews assessing the effects of this drug.

Study characteristics

The review includes six trials with 1835 people. The trials randomised people with schizophrenia to receive either asenapine or placebo.
Five of these trials had high rates of people leaving early and were sponsored by pharmaceutical companies.

Key results

There  is  some  evidence  that  asenapine,  when  compared  to  placebo,  improves  the  positive,  negative  and  depressive  symptoms  of
schizophrenia while having less risk of debilitating side effects.

Quality of the evidence

However, due to the low quantity and limited quality of evidence currently available, it remains difficult to recommend the use of asenapine
for schizophrenia. There is a need for large-scale, longer-term follow up, and bias-free randomised controlled trials investigating the effects
and safety of asenapine.

Ben Gray, Senior Peer Researcher, McPin Foundation. http://mcpin.org/

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

2

 
 
i

A
s
e
n
a
p
n
e
v
e
r
s
u
s
p
l
a
c
e
b
o
f
o
r
s
c
h
i
z
o
p
h
r
e
n
i
a
(
R
e
v
i
e
w

)

C
o
p
y
r
i
g
h
t

©
2
0
1
5
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

S U M M A R Y   O F   F I N D I N G S

Summary of findings for the main comparison.   ASENAPINE versus PLACEBO for schizophrenia

ASENAPINE versus PLACEBO for schizophrenia

Patient or population: adults with schizophrenia
Settings: inpatient and outpatient
Intervention: ASENAPINE versus PLACEBO

Outcomes

Illustrative comparative risks* (95% CI)

Assumed risk

Corresponding risk

Control

ASENAPINE versus PLACE-
BO

Global state: No clinically important
change 
CGI-I
Follow-up: up to 12 weeks

Study population

664 per 1000

Moderate

664 per 1000

Mental state: No clinically important
change 
PANSS
Follow-up: up to 12 weeks

Study population

672 per 1000

Moderate

672 per 1000

538 per 1000 
(451 to 644)

538 per 1000 
(452 to 644)

484 per 1000 
(397 to 578)

484 per 1000 
(396 to 578)

Relative effect
(95% CI)

No of Partici-
pants
(studies)

Quality of the
evidence
(GRADE)

Comments

RR 0.81 
(0.68 to 0.97)

336
(1 study)

⊕⊕⊝⊝
low 1,2,3

RR 0.72 
(0.59 to 0.86)

336
(1 study)

⊕⊝⊝⊝
very low 1,2,3,4

Mental state: Average change score in
negative symptoms 
PANSS Marder negative factor score
Follow-up: up to 12 weeks

The mean mental state: average change score in
negative symptoms in the intervention groups was
1.1 lower 
(2.29 lower to 0.09 higher)

336
(1 study)

⊕⊝⊝⊝
very low 1,2,3,4

Adverse effects: Incidence of serious
adverse effects 

Study population

3

RR 0.29 
(0.14 to 0.63)

386
(1 study)

⊕⊝⊝⊝

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Follow-up: 13-26 weeks

Adverse effects: Clinically significant
extrapyramidal symptoms 
AIMS
Follow-up: 13-26 weeks

Leaving the study early - any reason 
Follow-up: up to 12 weeks

141 per 1000

41 per 1000 
(20 to 89)

Moderate

141 per 1000

41 per 1000 
(20 to 89)

No trial reported this outcome.

Study population

488 per 1000

Moderate

484 per 1000

444 per 1000 
(390 to 507)

440 per 1000 
(387 to 503)

very low
2,3,5,6,7

RR 0.91 
(0.80 to 1.04)

1046
(5 studies)

⊕⊝⊝⊝
very low
10,11,12

Economic costs

No trial reported this outcome.

*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;

GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.

1 Risk of bias: 'Very serious' - Random sequence generation, allocation concealment and blinding (participants/personnel and outcome assessment) are poorly described.
2 Risk of bias: 'Very serious' - Attrition bias (method of analysis for dealing with incomplete data was last observation carried forward) and other bias (association with and funded
by pharmaceutical companies) were sources of high risk.
3 Inconsistency: 'No' - Only one study.
4 Indirectness: 'Serious' - Marder factor scores determined using factor analysis of PANSS items.
5 Risk of bias: 'Very serious' - Random sequence generation and allocation concealment are poorly described.
6 Risk of bias: 'Very serious' - Blinding of outcome assessment (possibility of biased judgement) and reporting bias (insufficient data reported for certain outcomes) were sources
of high risk.

i

A
s
e
n
a
p
n
e
v
e
r
s
u
s
p
l
a
c
e
b
o
f
o
r
s
c
h
i
z
o
p
h
r
e
n
i
a
(
R
e
v
i
e
w

)

C
o
p
y
r
i
g
h
t

©
2
0
1
5
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

4

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
7 Imprecision: 'Serious' - Low event rate.
8 Indirectness: 'Serious' - AIMS specifically assesses tardive dyskinesia.
9 Imprecision: 'Serious' - Wide confidence interval.
10 Risk of bias: 'Very serious' - Blinding of participants/personnel (four of five studies), attrition bias (four of five studies), selective reporting (four of five studies) and other bias
(all five studies) were sources of high risk.
11 Inconsistency: 'Serious' - This outcome had moderate levels of heterogeneity due to one study (I2 = 43%).
12 Imprecision: 'No' - Large event rate and sample with a narrow confidence interval.

i

A
s
e
n
a
p
n
e
v
e
r
s
u
s
p
l
a
c
e
b
o
f
o
r
s
c
h
i
z
o
p
h
r
e
n
i
a
(
R
e
v
i
e
w

)

C
o
p
y
r
i
g
h
t

©
2
0
1
5
T
h
e
C
o
c
h
r
a
n
e
C
o

l
l
a
b
o
r
a
t
i
o
n

.

P
u
b

l
i
s
h
e
d
b
y
J
o
h
n
W

i
l
e
y
&
S
o
n
s
,
L
t
d

.

5

L
i
b
r
a
r
y

C
o
c
h
r
a
n
e

B
e
t
t
e
r
h
e
a
l
t
h
.

T
r
u
s
t
e
d
e
v
i
d
e
n
c
e
.

I
n
f
o
r
m
e
d
d
e
c
i
s
i
o
n
s
.

C
o
c
h
r
a
n
e
D
a
t
a
b
a
s
e
o
f
S
y
s
t
e
m
a
t
i
c
R
e
v
i
e
w
s

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

B A C K G R O U N D

Description of the condition

Schizophrenia affects approximately 0.3% to 0.7% of people during
their lifetime, with an estimated 24 million individuals experiencing
the  disorder  worldwide  (McGrath  2008;  WHO  2014).  With  similar
prevalence and incidence rates globally, it is widely accepted that
schizophrenia is associated with significant global burden (Ayuso-
Mateos  2006).  The  prevalence  rates  of  schizophrenia  are  similar
for  men  and  women  (Saha  2005).  With  a  considerably  variable
age  of  onset,  schizophrenia  can  present  for  the  first  time  from
adolescence,  through  middle  age  (late-onset  schizophrenia),  and
up to old age (very late-onset schizophrenia-like psychosis) (Kohler
2007).  It  has  been  established  that  an  interaction  of  multiple
genetic and environmental factors are involved in the aetiology of
schizophrenia  (van  Os  2008).  Such  heterogeneous  aetiology  may
contribute to the diverse illness course and symptomatology seen
in the disease (Andreasen 1999; Walker 2004).

Schizophrenia is typically considered in relation to the dichotomy
of  positive  symptoms  such  as  delusions  and  hallucinations,
which  are  characterised  by  their  atypical  presence;  and  negative
symptoms,  such  as  poverty  of  speech,  flattened  affect,  lack  of
pleasure  (anhedonia),  and  lack  of  motivation  (avolition)  (Crow
1980).  Moreover,  patients  with  schizophrenia  can  express  a
disorganised  state  primarily  marked  by  disorganised  thought
and  speech,  known  as  formal  thought  disorder  (Liddle  1987).
Mood  symptoms  such  as  depression  and  anxiety  are  also  very
common in schizophrenia yet are heterogeneous in nature and so
require  thorough  investigation  (Siris  2000).  Furthermore,  there  is
increasing evidence that people with schizophrenia exhibit deficits
in  several  domains  of  cognitive  functioning  including  memory,
language, executive functioning and attention (Fioravanti 2005).

Description of the intervention

first-line  medication 

Antipsychotic  drugs  are  used  as 
for
schizophrenia.  Typical  (or  first-generation)  antipsychotics,  such
as  chlorpromazine  and  haloperidol,  have  been  available  since
the  1950s,  whilst  atypical  (or  second-generation)  antipsychotics,
such  as  clozapine  and  olanzapine,  have  been  introduced  from
the late 1980s (Lehmann 1997). Atypical antipsychotics have been
marked  as  producing  greater  reductions  in  negative  and  mood
symptoms,  whilst  minimising  adverse  effects  usually  observed

Cochrane Database of Systematic Reviews

during  typical  antipsychotic  treatment,  such  as  extrapyramidal
symptoms  and  hyperprolactinaemia  (Davis  2003;  Worrel  2000).
However,  atypical  antipsychotics  are  not  without  their  own
adverse effects including sedation, sexual dysfunction, weight gain,
diabetes, and cardiovascular problems (Muench 2010).

Asenapine  is  a  novel  second-generation  antipsychotic  originally
developed  by  Organon  in  the  early-to-mid  1990s,  which  was
approved  by  the  US  Food  and  Drug  Administration  (FDA)  in  2009
for  the  acute  treatment  of  adults  with  schizophrenia  and  bipolar
I  disorder  (Citrome  2009).  However,  in  the  European  Union  and
the UK it is currently approved for the acute treatment of bipolar I
disorder only and not for schizophrenia (EMA 2014).

Initial  investigation  of  the  properties  and  clinical  effects  of
asenapine has begun (Stoner 2012), although the use of placebo-
controlled clinical trials can be difficult to justify, particularly when
evidence-based  pharmacological  treatments  for  schizophrenia
already exist (Emsley 2013). However, aside from investigating the
comparative effects of novel antipsychotic drugs with others that
are  currently  available,  it  is  important  to  consider  the  absolute
effects  of  medication  purported  to  be  antipsychotic  (Storosum
1998).

How the intervention might work

Asenapine  is  predominantly  administered  sublingually  (5  mg  to
10  mg  twice  daily)  due  to  previous  reports  of  low  bioavailability
when administered orally, and typically reaches peak plasma levels
within 30 to 90 minutes following absorption via the oral mucosa
(FDA 2013).

Asenapine 
is  a  novel  second-generation  antipsychotic  drug
(see  Figure  1  for  its  chemical  structure).  It  has  a  somewhat
unique  pharmacological  profile  compared  to  alternative  atypical
antipsychotic  medication  and  has  a  greater  affinity  for  a  range
of  serotonergic,  dopaminergic,  noradrenergic,  and  histamine
receptors, acting through the antagonism of most of these receptor
subtypes,  whilst  expressing  low  affinity  to  muscarinic  receptors
(Shahid 2009). It has been proposed that antagonism of dopamine
and  noradrenergic  receptors  contributes  substantially  to  the
alleviation  of  positive  symptoms  in  schizophrenia  (Abi-Dargham
2004; Svensson 2003). Additionally, the antagonism of serotonergic
receptors may improve negative, cognitive and mood symptoms of
schizophrenia (Hedlund 2004; Meltzer 1999).

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

6

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 1.   Chemical structure of asenapine

Cochrane Database of Systematic Reviews

With  its  low  affinity  to  muscarinic  receptors,  asenapine  may
minimise  the  risk  of  anticholinergic  adverse  effects  reported
following the use of some antipsychotic drugs (Lieberman 2004).
However,  histamine  antagonism  is  known  to  produce  sedation
(Nicholson  1983),  which  is  one  of  several  adverse  effects  that
have  been  identified  following  the  use  of  asenapine,  in  addition
to  anxiety,  extrapyramidal  symptoms,  nausea/vomiting,  oral
hypoesthesia, and weight gain (Sycrest 2014).

Why it is important to do this review

It  is  well  known  that  both  typical  and  atypical  antipsychotics
can  be  costly  and  have  an  assorted  adverse  event  profile,  yet
they  still  do  not  fully  meet  the  treatment  needs  of  people  with
schizophrenia  (Campbell  1999).  As  asenapine  is  one  of  the  more
recently  developed  second-generation  antipsychotic  drugs  with
multi-targeted pharmacological action, it has been suggested that
it  may  have  the  potential  to  produce  clinical  improvements  in
negative and cognitive symptoms, as well as positive symptoms of
schizophrenia, whilst minimising the incidence of adverse effects
(Bishara 2009).

At  present  there  are  no  systematic  reviews  assessing  the  clinical
effects  of  asenapine,  although  there  are  two  currently  underway
comparing asenapine to typical antipsychotics and other atypical
antipsychotics (Kumar 2012; Preda 2010). Therefore, the purpose of
this systematic review is to summarise evidence from randomised
controlled  trials  comparing  the  clinical  effects  and  safety  of
asenapine to placebo amongst adults with schizophrenia and other
schizophrenia-like disorders.

O B J E C T I V E S

To  determine  the  clinical  effects  of  asenapine  for  adults  with
schizophrenia or other schizophrenia-like disorders by comparing
it with placebo.

M E T H O D S

Criteria for considering studies for this review

Types of studies

All  relevant  randomised  controlled  trials  (RCTs).  If  a  trial  had
been described as 'double-blind' and implied that randomisation
occurred but did not state it overtly, we intended to include it in
a sensitivity analysis (see Sensitivity analysis). If inclusion of such
trials did not result in a substantive difference, they were to remain
in  the  analyses.  If  their  inclusion  resulted  in  important  clinically
significant  (but  not  necessarily  clear  differences),  we  would  not
add  the  data  from  these  lower  quality  studies  to  the  results  of
the  better  trials,  but  present  such  data  within  a  subcategory.  We
excluded quasi-randomised studies, such as those that allocate to
treatment groups by alternate days of the week. Where people are
given  additional  treatments  within  asenapine,  we  only  included
the data if the adjunct treatment was evenly distributed between
groups and only asenapine was randomised.

Types of participants

Adults  with  schizophrenia  or  related  disorders,  however  defined,
including schizophreniform disorder, schizoaffective disorder and
delusional disorder, again, by any means of diagnosis. Where trials
included  participants  with  a  range  of  disorders  we  only  included
trials where over 50% of the participants have schizophrenia.

We  are  interested  in  making  sure  that  information  is  as  relevant
to  the  current  care  of  people  with  schizophrenia  as  possible,
so  where  information  was  available  we  highlighted  clearly  the
current  clinical  state  of  participants  (acute,  early  post-acute,
partial remission, remission) as well as the stage (prodromal, first
episode, early illness, persistent) and whether the studies primarily
focused on people with particular problems (for example, negative
symptoms, treatment-resistant illnesses).

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

7

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Types of interventions

1. Asenapine

3.2.3 Average change in specific cognitive functioning (baseline to
endpoint)

Any dose, any method of administration.

4. Behaviour

2. Placebo

Any method of administration.

Types of outcome measures

Where  possible,  we  divided  outcomes  into  short-term  (up  to  12
weeks), medium-term (13 weeks to 26 weeks) and long-term (over
26 weeks).

Primary outcomes

1. Global state

1.1 Clincally important change in global state as defined by each
study

2. Mental state

2.1 Clinically important change in mental state as defined by each
study

3. Adverse effects

3.1 Incidence of serious adverse effects

Secondary outcomes

1. Global state

1.1 Average endpoint in global state
1.2 Average change in global state (baseline to endpoint)
1.3 Relapse as defined by each study
1.4 Use of any concomitant medication
1.4.1 Use of specific concomitant medication
1.5 Adherence to trial medication

2. Mental state

2.1 General symptoms
2.1.1 Average endpoint in general mental state score
2.1.2  Average  change  in  general  mental  state  score  (baseline  to
endpoint)
2.2 Average endpoint in specific symptoms
2.2.1 Positive symptoms (delusions, hallucinations)
2.2.2 Negative symptoms (avolition, poor self care, blunted affect)
2.2.3 Mood (anxiety, depression, mania)
2.2.4 Other psychotic symptoms (e.g. disorganised thought)
2.3.  Average  change  in  specific  symptoms  (positive,  negative,
mood, other symptoms, baseline to endpoint)

3. Cognitive functioning

3.1 General cognitive functioning as defined by each study
3.1.1 Clinically important change in general cognitive functioning
as defined by each study
3.1.2 Average endpoint in general cognitive functioning
3.1.3 Average change in general cognitive functioning (baseline to
endpoint)
3.2 Specific cognitive functioning as defined by each study
3.2.1 Clinically important change in specific cognitive functioning
as defined by each study
3.2.2 Average endpoint in specific cognitive functioning

4.1 General behaviour as defined by each study
4.1.1 Clinically important change in general behaviour as defined
by each study
4.1.2 Average endpoint in general behaviour
4.1.3 Average change in general behaviour (baseline to endpoint)
4.2 Specific behaviour as defined by each study
4.2.1 Clinically important change in specific behaviour as defined
by each study
4.2.2 Average endpoint in specific behaviour
4.2.3 Average change in specific behaviour (baseline to endpoint)

5. Functioning

5.1 General functioning as defined by each study
5.1.1 Clinically important change in general functioning as defined
by each study
5.1.2 Average endpoint in general functioning
5.1.3 Average change in general functioning (baseline to endpoint)
5.2 Specific functioning as defined by each study
5.2.1 Clinically important change in specific functioning as defined
by each study
5.2.2 Average endpoint in specific functioning
5.2.3 Average change in specific functioning (baseline to endpoint)

6. Adverse effects

6.1 Incidence of any adverse effects
6.1.1 Incidence of adverse effects by severity as defined by each
study (excluding serious adverse effects)
6.2 Incidence of other specific adverse effects as defined by each
study
6.3 Extrapyramidal symptoms
6.3.1 Incidence of extrapyramidal symptoms
6.3.2 Clinically important extrapyramidal symptoms as defined by
each study
6.3.3 Average score/change in extrapyramidal symptoms
6.4 Deaths, by suicide or natural causes

7. Leaving the study early - for any reason

8. Service utilisation outcomes

8.1 Hospital admissions
8.2 Days in hospital

9. Quality of life

9.1 Clinically important change in quality of life
9.2 Average endpoint in quality of life
9.3 Average change in quality of life (baseline to endpoint)

10. Economic outcomes

'Summary of findings' table

We used the GRADE approach to interpret findings (Schünemann
2011), and use GRADEPRO profiler to import data from RevMan 5
(Review Manager) to create a 'Summary of findings' table. This table
provides  outcome-specific  information  concerning  the  overall
quality of evidence from each included study in the comparison, the
magnitude of effect of the interventions examined, and the sum of
available data on all outcomes we rate as important to patient-care

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

8

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

and decision making. We selected the following main outcomes for
inclusion in Summary of findings for the main comparison:

Data extraction and management

1. Extraction

• Global  state  -  clinically  important  change  in  global  state  as

defined by each study

• Mental  state  -  clinically  important  change  in  mental  state  as

defined by each study

• Mental state - average change in negative symptoms
• Adverse effects - incidence of serious adverse effects
• Adverse effects - clinically significant extrapyramidal symptoms
• Leaving the study early - for any reason
• Economic outcome

Search methods for identification of studies

Electronic searches

The  Trials  Search  Coordinator  (TSC)  searched  the  Cochrane
Schizophrenia  Group’s  Trials  Register  (04  July,  2014)  using  the
following search strategies:

Review authors AH and AB extracted data from all included studies.
In  addition,  to  ensure  reliability,  MS  independently  extracted
data  from  a  random  sample  of  these  studies,  comprising  10%
of  the  total.  Again,  any  disagreement  was  discussed,  decisions
documented  and,  if  necessary,  authors  of  studies  contacted  for
clarification.  We  extracted  data  presented  only  in  graphs  and
figures whenever possible, but we only included these data if two
reviewers independently obtained the same result. We attempted
to  contact  authors  through  an  open-ended  request  in  order  to
obtain missing information or for clarification whenever necessary.
For  multi-centred  studies,  where  possible,  we  extracted  data
relevant to each component centre separately.

2. Management

2.1 Forms

We extracted data onto standard, pre-designed simple forms.

((Saphris  or  "ORG  5222"  or  asenapine)  and  placebo)  in  Title  or
Abstract Fields of REFERENCE Records or (asenapine and placebo)
in Intervention Fields of STUDY Records.

2.2 Scale-derived data

We included continuous data from rating scales only if:

The  Cochrane  Schizophrenia  Group’s  Trials  Register  is  compiled
by  systematic  searches  of  major  resources  (including  MEDLINE,
EMBASE, AMED, BIOSIS, CINAHL, PsycINFO, PubMed, and registries
of  clinical  trials)  and  their  monthly  updates,  handsearches,  grey
literature, and conference proceedings (see Group Module). There
are  no  language,  date,  document  type,  or  publication  status
limitation for inclusion of records into the register.

Searching other resources

1. Reference searching

We inspected references of all included studies for further relevant
studies.

2. Personal contact

If necessary we contacted the first author, relevant pharmaceutical
companies,  and  drug  approval  agencies  of  trials  for  additional
information. We noted the outcome of this contact in the included
or awaiting assessment studies tables.

Data collection and analysis

Selection of studies

AH, AB, MS, MB, SD and IJ independently inspected citations from
the  searches  and  identified  relevant  abstracts.  A  random  20%
sample was independently re-inspected by AH, AB, MS, MB and SD
to ensure reliability. If disputes arose, we acquired the full report
for  more  detailed  scrutiny.  AH,  AB,  MS,  MB  and  SD  obtained  and
inspected full reports of the abstracts meeting the review criteria.
Again, AH, AB, MS, MB and SD re-inspected a random 20% of reports
in order to ensure reliable selection. If it was not possible to resolve
disagreement by discussion, we attempted to contact the authors
of the study for clarification.

• the psychometric properties of the measuring instrument had
been described in a peer-reviewed journal (Marshall 2000); and
• the measuring instrument had not been written or modified by

one of the trialists for that particular trial.

Ideally  the  measuring  instrument  should  be  either  a  self-report,
or  a  report  completed  by  an  independent  rater  or  relative  (not
the therapist). We realise that this is not often reported clearly; in
Description of studies we noted if this is the case or not.

2.3 Endpoint versus change data

There are advantages of both endpoint and change data. Change
data  can  remove  a  component  of  between-person  variability
from  the  analysis,  however,  calculation  of  change  needs  two
assessments  (baseline  and  endpoint)  which  can  be  difficult  to
achieve  in  unstable  and  difficult-to-measure  conditions  such  as
schizophrenia. We decided primarily to use endpoint data, and only
use  change  data  if  the  former  were  not  available.  We  combined
endpoint  and  change  data  in  the  analysis  as  we  prefered  to  use
mean differences (MD) rather than standardised mean differences
throughout (Higgins 2011a).

2.4 Skewed data

Continuous  data  on  clinical  and  social  outcomes  are  often  not
normally  distributed.  To  avoid  the  pitfall  of  applying  parametric
tests to non-parametric data, we applied the following standards to
all data before inclusion.

For large studies and change data

We entered all relevant useable endpoint data from studies of at
least  200  participants  in  the  analysis,  because  skewed  data  pose
less of a problem in large studies. We also entered all change data,
as when continuous data are presented on a scale that includes a
possibility of negative values (such as change data), it is difficult to
tell whether data are skewed or not.

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

9

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

For endpoint data from smaller studies (< 200)

• When a scale starts from the ﬁnite number zero, we subtracted
the  lowest  possible  value  from  the  mean,  and  divided  this  by
the standard deviation. If this value is lower than one, it strongly
suggests  a  skew  and  we  excluded  the  study  data.  If  this  ratio
is higher than one but below two, there is suggestion of skew.
We entered the study data and tested whether its inclusion or
exclusion would change the results substantially. Finally, if the
ratio is larger than two we included the study data, because skew
is less likely (Altman 1996; Higgins 2011a).

• If a scale starts from a positive value (such as the Positive and
Negative  Syndrome  Scale  (PANSS  (Kay  1986),  which  can  have
values from 30 to 210), we modified the calculation described
above to take the scale starting point into account. In these cases
skew is present if 2 SD > (S - S min), where S is the mean score
and 'S min' is the minimum score.

We noted the level of risk of bias in both the text of the review and
in the 'Summary of findings' table.

Measures of treatment effect

1. Binary data

For binary outcomes we calculated a standard estimation of the risk
ratio (RR) and its 95% confidence interval (CI). It has been shown
that RR is more intuitive than odds ratios (Boissel 1999), and that
odds ratios tend to be interpreted as RR by clinicians (Deeks 2000).
The number needed to treat for an additional beneficial outcome
(NNTB)/number needed to treat for an additional harmful outcome
(NNTH) statistic with its confidence intervals is intuitively attractive
to clinicians but is problematic both in its accurate calculation in
meta-analyses  and  interpretation  (Hutton  2009).  For  binary  data
presented in Summary of findings for the main comparison, where
possible, we calculated illustrative comparative risks.

2.5 Common measure

2. Continuous data

To  facilitate  comparison  between  trials,  we  converted,  where
relevant, variables that can be reported in different metrics, such as
days in hospital (mean days per year, per week or per month) to a
common metric (e.g. mean days per month).

2.6 Conversion of continuous to binary

Where possible, we made efforts to convert outcome measures to
dichotomous data. This can be done by identifying cut-off points
on rating scales and dividing participants accordingly into 'clinically
improved' or 'not clinically improved'. It is generally assumed that
if  there  is  a  50%  reduction  in  a  scale-derived  score  such  as  the
Brief Psychiatric Rating Scale (BPRS) (Overall 1962), or the Positive
and  Negative  Syndrome  Scale  (PANSS)  (Kay  1986),  this  could  be
considered as a clinically significant response (Leucht 2005). If data
based on these thresholds were not available, we used the primary
cut-off presented by the original authors.

2.7 Direction of graphs

Where  possible,  we  entered  data  in  such  a  way  that  the  area  to
the  left  of  the  line  of  no  effect  indicates  a  favourable  outcome
for  asenapine.  Where  keeping  to  this  makes  it  impossible  to
avoid  outcome  titles  with  clumsy  double-negatives  (e.g.  'Not  un-
improved') we reported data where the left of the line indicates an
unfavourable outcome. We noted this in the relevant graphs.

Assessment of risk of bias in included studies

Again  review  authors  AB,  SD  and  MS,  worked  independently  to
assess  risk  of  bias  by  using  criteria  described  in  the  Cochrane
Handbook  for  Systematic  Reviews  of  Interventions  to  assess  trial
quality (Higgins 2011b). This set of criteria is based on evidence of
associations between overestimate of effect and high risk of bias of
the article such as sequence generation, allocation concealment,
blinding, incomplete outcome data and selective reporting.

If the raters disagreed, we made the final rating by consensus, with
the  involvement  of  another  member  of  the  review  group.  Where
inadequate  details  of  randomisation  and  other  characteristics  of
trials  are  provided,  we  attempted  to  contact  the  authors  of  the
studies  in  order  to  obtain  further  information.  If  there  was  non-
concurrence  in  quality  assessment  we  would  have  reported  this,
and if disputes had arisen regarding the category to which a trial
was to be allocated, again, we would have resolved by discussion.

For  continuous  outcomes  we  estimated  mean  difference  (MD)
between groups. We prefered not to calculate effect size measures
(standardised  mean  difference  (SMD)).  However,  if  scales  of  very
considerable similarity had been used, we would have presumed
there was a small difference in measurement, and we would have
calculated effect size and transformed the effect back to the units
of one or more of the specific instruments.

Unit of analysis issues

1. Cluster trials

Studies  increasingly  employ  'cluster  randomisation'  (such  as
randomisation by clinician or practice), but analysis and pooling of
clustered data poses problems. Firstly, authors often fail to account
for  intra-class  correlation  in  clustered  studies,  leading  to  a  'unit
of analysis' error whereby P values are spuriously low, confidence
intervals unduly narrow and statistical significance overestimated
(Divine 1992). This causes type I errors (Bland 1997; Gulliford 1999).

In future versions of this review where clustering is not accounted
for in primary studies, we will present data in the analysis, with a (*)
symbol to indicate the presence of a probable unit of analysis error.
We will seek to contact first authors of studies to obtain intra-class
correlation  coefficients  for  their  clustered  data  and  to  adjust  for
this by using accepted methods (Gulliford 1999). Where clustering
has been incorporated into the analysis of primary studies, we will
present these data as if from a non-cluster randomised study, but
adjust for the clustering effect.

We have sought statistical advice and were advised that the binary
data presented in a report should be divided by a 'design effect'.
This is calculated using the mean number of participants per cluster
(m) and the intra-class correlation coefficient (ICC) [Design effect =
1 + (m - 1) *ICC] (Donner 2002). If the ICC is not reported it will be
assumed to be 0.1 (Ukoumunne 1999).

If  cluster  studies  are  appropriately  analysed  taking  into  account
intra-class correlation coefficients and relevant data documented
in the report, synthesis with other studies will be possible using the
generic inverse variance technique.

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

10

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

2. Cross-over trials

A major concern of cross-over trials is the carry-over effect. It occurs
if an effect (e.g. pharmacological, physiological or psychological) of
the treatment in the first phase is carried over to the second phase.
As  a  consequence  on  entry  to  the  second  phase  the  participants
can differ systematically from their initial state despite having had
a  wash-out  phase.  For  the  same  reason  cross-over  trials  are  not
appropriate if the condition of interest is unstable (Elbourne 2002).
As both effects are very likely in severe mental illness, we only used
data from the first phase of cross-over studies.

3. Studies with multiple treatment groups

Where a study involves more than two treatment arms, if relevant,
we  would  have  presented  the  additional  treatment  arms  in
comparisons.  If  data  are  binary  these  would  have  simply  been
added  and  combined  within  the  two-by-two  table.  If  data  were
continuous  we  would  have  combined  the  data  following  the
formula  in  section  7.7.3.8  (Combining  groups)  of  the  Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011a).
Where the additional treatment arms were not relevant, we did not
use these data.

Dealing with missing data

1. Overall loss of credibility

At some degree of loss of follow-up the data must lose credibility
(Xia 2009). We chose that, for any particular outcome, should more
than 50% of the data be unaccounted for, we would not reproduce
these data or use them within analyses. If, however, more than 50%
of those in one arm of a study were lost, but the total loss is less than
50%, we addressed this within Summary of findings for the main
comparison  by  down-rating  quality.  Finally,  we  also  downgraded
quality within Summary of findings for the main comparison should
loss be between 25% to 50% in total.

2. Binary

When attrition for a binary outcome is between 0% and 50%, and
where these data are not clearly described, we presented data on
a  'once-randomised-always-analyse'  basis  (an  intention-to-treat
analysis).  We  assumed  those  leaving  the  study  early  to  have  the
same rates of negative outcome as those who completed the study,
with the exception of the outcome of death and adverse effects. For
these outcomes we used the rate of those who stay in the study - in
that particular arm of the trial - for those who did not. We intended,
if possible, to undertake a sensitivity analysis testing how prone the
primary outcomes are to change when data only from people who
complete the study to that point are compared to the intention-to-
treat analysis using the above assumptions.

3. Continuous

3.1 Attrition

Cochrane Database of Systematic Reviews

for  group  means,  and  either  P  value  or  't'  value  are  available
for differences in the mean, we calculated them according to the
rules described in the Cochrane Handbook for Systematic Reviews
of  Interventions  (Higgins  2011a).  When  only  the  standard  error
(SE)  is  reported,  standard  deviations  (SDs)  can  be  calculated  by
the  formula  SD  =  SE  *  square  root  (n).  Chapters  7.7.3  (Higgins
2011a)  and  16.1.3  (Higgins  2011c)  of  the  Cochrane  Handbook  for
Systematic Reviews of Interventions present detailed formulae for
estimating  SDs  from  P  values,  t  or  F  values,  CIs,  ranges  or  other
statistics.  If  these  formulae  do  not  apply,  we  calculated  the  SDs
according to a validated imputation method based on the SDs of the
other  included  studies  (Furukawa  2006).  Although  some  of  these
imputation strategies can introduce error, the alternative would be
to exclude a given study’s outcome and thus to lose information. We
intended to examine the validity of the imputations in a sensitivity
analysis excluding imputed values.

3.3 Assumptions about participants who left the trials early or were
lost to follow-up

Various  methods  are  available  to  account  for  participants  who
left  trials  early  or  are  lost  to  follow-up.  Some  trials  present  only
the  results  of  study  completers,  others  use  the  method  of  last
observation carried forward (LOCF), while more recently methods
such as multiple imputation or mixed effects models for repeated
measurements  (MMRM)  have  become  more  common.  While  the
latter  methods  seem  to  be  somewhat  better  than  LOCF  (Leon
2006),  we  feel  that  the  high  percentage  of  participants  leaving
the  studies  early  and  differences  in  the  reasons  for  leaving  the
studies between groups is often the core problem in randomised
schizophrenia  trials.  We  therefore  did  not  exclude  studies  based
on  the  statistical  approach  used.  We  prefered  to  use  the  more
sophisticated  approaches.  e.g.  MMRM  or  multiple-imputation  to
LOCF,  and  completer  analysis  was  only  presented  if  some  kind
of  intention-to-treat  data  were  not  available  at  all.  Moreover,  we
addressed this issue in the item 'incomplete outcome data' in the
risk of bias tool.

Assessment of heterogeneity

1. Clinical heterogeneity

Initially  we  considered  all  included  studies,  without  seeing
comparison  data,  to  judge  clinical  heterogeneity.  We  simply
inspected all studies for clearly outlying people or situations that
we had not predicted would arise. We discussed any such situations
or participant groups when they arose.

2. Methodological heterogeneity

Initially  we  considered  all  included  studies,  without  seeing
comparison  data,  to  judge  methodological  heterogeneity.  We
simply inspected all studies for clearly outlying methods that we
had not predicted would arise. We discussed any methodological
outliers.

We  used  and  entered  data  into  analyses  when  attrition  for  a
continuous outcome was between 0% and 50%, and data only from
people who completed the study to that point were reported.

3. Statistical heterogeneity

3.1 Visual inspection

3.2 Standard deviations

If  standard  deviations  were  not  reported,  we  first  tried  to  obtain
the  missing  values  from  the  authors.  If  these  were  not  available,
where there are missing measures of variance for continuous data,
but an exact standard error and confidence intervals are available

We  inspected  graphs  visually  to  investigate  the  possibility  of
statistical heterogeneity.

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

11

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

3.2 Employing the I2 statistic

Subgroup analysis and investigation of heterogeneity

We  investigated  heterogeneity  between  studies  by  considering
the  I2  statistic  alongside  the  Chi2  P  value.  The  I2  provides  an
estimate  of  the  percentage  of  inconsistency  thought  to  be  due
to  chance  (Higgins  2003).  The  importance  of  the  observed  value
of  I2  depends  firstly  on  magnitude  and  direction  of  effects  and
secondly on the strength of evidence for heterogeneity (e.g. P value
from  Chi2    test,  or  a  confidence  interval  for  I2).  An  I2  estimate
greater than or equal to around 50% accompanied by a statistically
significant  Chi2  statistic,  is  interpreted  as  evidence  of  substantial
levels of heterogeneity (Cochrane Handbook for Systematic Reviews
of  Interventions  Section  9.5.2;  Deeks  2011).  If  substantial  levels
of  heterogeneity  were  found  in  the  primary  outcome,  we  would
have  explored  reasons  for  heterogeneity  (Subgroup  analysis  and
investigation of heterogeneity).

Assessment of reporting biases

1. Protocol versus full study

Reporting biases arise when the dissemination of research findings
is  influenced  by  the  nature  and  direction  of  results.  These
are  described  in  section  10.1  of  the  Cochrane  Handbook  for
Systematic  Reviews  of  Interventions  (Higgins  2011a).  We  tried  to
locate  protocols  of  included  randomised  trials.  If  the  protocol
was available, we compared outcomes in the protocol and in the
published report. If the protocol was not available, we compared
outcomes listed in the methods section of the trial report with the
results actually reported.

2. Funnel plot

Reporting biases arise when the dissemination of research findings
is  influenced  by  the  nature  and  direction  of  results  (Egger  1997).
Again, these are described in Section 10 of the Cochrane Handbook
for Systematic Reviews of Interventions (Sterne 2011). We are aware
that  funnel  plots  may  be  useful  in  investigating  reporting  biases
but  have  limited  power  to  detect  small-study  effects.  We  did  not
use funnel plots for outcomes where there are ten or fewer studies,
or where all studies are of similar sizes. In future versions of this
review, if funnel plots are possible, we will seek statistical advice in
their interpretation.

Data synthesis

We understand that there is no closed argument for preference for
use of fixed-effect or random-effects models. The random-effects
method incorporates an assumption that the different studies are
estimating  different,  yet  related,  intervention  effects.  This  often
seems  to  be  true  to  us  and  the  random-effects  model  takes  into
account differences between studies, even if there is no statistically
significant heterogeneity. There is, however, a disadvantage to the
random-effects model as it puts added weight onto small studies,
which  are  often  the  most  biased.  Depending  on  the  direction  of
effect these studies can either inflate or deflate the effect size. We
chose  to  use  a  fixed-effect  model  for  all  analyses.  The  reader  is,
however,  able  to  choose  to  inspect  the  data  using  the  random-
effects model.

1. Subgroup analyses

1.1 Primary outcomes

To treat schizophrenia, asenapine is currently administered twice
a  day  in  a  5  mg  or  10  mg  dose  (FDA  2013).  We  intended  to
conduct a subgroup analysis by asenapine dose (5 mg twice a day
versus placebo, 10 mg twice a day versus placebo) on any primary
outcome where there was significant heterogeneity (defined as I2≤
75;  Higgins  2011a).  We  did  not  anticipate  any  subgroup  analyses
concerning  the  form  of  administration  of  asenapine  as  it  is
predominantly administered sublingually (FDA 2013).

1.2 Clinical state, stage or problem

We proposed to undertake this review and provide an overview of
the effects of asenapine for people with schizophrenia in general.
In addition we intended, if possible, to report data on subgroups of
people in the same clinical state, stage and with similar problems.

2. Investigation of heterogeneity

We reported if inconsistency is high. Firstly we investigated whether
data  had  been  entered  correctly.  Secondly,  if  data  were  correct,
we inspected the graph visually and successively removed outlying
studies  to  see  if  homogeneity  was  restored.  For  this  review  we
decided  that  should  this  occur  with  data  contributing  no  more
than  around  10%  of  the  total  weighting  to  the  summary  finding,
data  were  to  be  presented.  If  not,  data  would  have  been  pooled
and issues discussed. We know of no supporting research for this
10% cut off, but are investigating use of prediction intervals as an
alternative to the current unsatisfactory state.

When  unanticipated  clinical  or  methodological  heterogeneity  is
obvious we will simply state hypotheses regarding them for future
reviews or versions of this review. We do not anticipate undertaking
analyses  relating  to  unanticipated  clinical  or  methodological
heterogeneity.

Sensitivity analysis

1. Implication of randomisation

We  aimed,  if  possible,  to  include  trials  in  a  sensitivity  analysis
if  they  were  described  in  some  way  that  implied  randomisation.
For the primary outcomes we would have included these studies
and  if  there  was  no  substantive  difference  when  the  implied
randomised studies were added to those with better description of
randomisation, then all data from these studies would have been
employed.

2. Assumptions for lost binary data

If  assumptions  had  to  be  made  regarding  people  lost  to  follow-
up (see Dealing with missing data) we would have compared the
findings of the primary outcomes when we used our assumptions
and when we used data only from people who completed the study
to that point. If there had been a substantial difference, we would
have reported results and discussed them, but continued to employ
our assumption.

For  continuous  data,  if  assumptions  had  to  be  made  regarding
missing  SDs  (see  Dealing  with  missing  data),  we  would  have
compared  the  findings  of  the  primary  outcomes  when  we  used
our  assumptions  and  when  we  used  data  only  from  people  who

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

12

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

completed the study to that point. A sensitivity analysis would have
been  undertaken  testing  how  prone  results  are  to  change  when
completer-only data are compared to the imputed data using the
above  assumption.  If  there  is  a  substantial  difference,  we  would
have reported results and discussed them, but continued to employ
our assumption.

5. Fixed-effect and random-effects

All data were synthesised using a fixed-effect model, however, we
also  synthesised  data  for  the  primary  outcome  using  a  random-
effects model to evaluate whether this altered the significance of
the results

3. Risk of bias

We intended, if required, to analyse the effects of excluding trials
that  are  judged  to  be  at  high  risk  of  bias  across  one  or  more  of
the  domains  of  randomisation  (i.e.  implied  as  randomised  with
no further details available), allocation concealment, blinding, and
outcome reporting for the meta-analysis of the primary outcome. If
the exclusion of trials at high risk of bias did not substantially alter
the direction of effect or the precision of the effect estimates, then
data from these trials would have been included in the analysis.

4. Imputed values

We  also,  if  required,  intended  to  undertake  a  sensitivity  analysis
to  assess  the  effects  of  including  data  from  trials  where  we  used
imputed  values  for  ICC  in  calculating  the  design  effect  in  cluster
randomised trials.

R E S U L T S

Description of studies

in-depth  descriptions  of 

For 
see
Characteristics  of  included  studies;  Characteristics  of  excluded
studies;  Characteristics  of  studies  awaiting  classification;  and
Characteristics of ongoing studies.

studies  please 

the 

Results of the search

Electronic  searches  identified  37  references  with  4  additional
records  identified  through  other  sources.  After  duplicates  were
removed, we screened 41 records and nine of these reports (seven
trials)  did  not  meet  the  inclusion  criteria  (see  Characteristics  of
excluded studies) and had to be excluded. Additionally, two trials
(two reports) are awaiting classification, and one trial (one report)
is currently ongoing. Six trials (29 reports) are included (Figure 2).

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

13

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Figure 2.   Study flow diagram.

Cochrane Database of Systematic Reviews

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

14

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Included studies

1.1 Methods

The six included studies were explicitly described as randomised
(Chapel 2009; Kane 2011; NCT00151424; Kane 2010; NCT00156117;
Potkin  2007).  Six  weeks  was  a  common  trial  length  (Kane  2010;
Potkin 2007) and the duration varied from the shortest trial lasting
16 days (Chapel 2009) and the longest trial lasting 52 weeks (Kane
2011).

1.2 Setting

Three  trials  involved  inpatients  and  outpatients  (NCT00151424;
Kane 2010; Potkin 2007), The settings of the other studies were not
clearly specified.

1.3 Participants

All  studies  reported  participants  to  have  schizophrenia  or
schizoaffective disorder using the Diagnostic and Statistical Manual
of Mental Disorders, Fourth Edition (DSM-IV) or DSM-IV Text Revision
(DSM-IV-TR). Data from 1835 people are included in the review.

1.4 Study size

The  mean  number  of  participants  in  each  trial  was  305,  ranging
from 148 (Chapel 2009) to 458 (Kane 2010).

1.5 Interventions

1.5.1 Asenapine

The dose of asenapine ranged from 5mg to 20mg twice a day (BID).
Asenapine was administered sublingually.

1.5.2 Placebo

All  trials  compared  asenapine  with  placebo  which  were
indistinguishable from each other. Placebo was administered orally
or sublingually.

1.5.3 Other drug treatment arms

Five  of  the  the  trials  included  one  more  intervention  arm  along
with  placebo  and  asenapine.  These  were  quetiapine  (Chapel
2009),  risperidone  (Potkin  2007),  olanzapine  (NCT00151424;
NCT00156117),  and  haloperidol  (Kane  2010).  The  data  for  these
arms were not included in the review.

1.6 Outcomes

The  outcomes  reported  by  included  studies  were  global  state,
mental  state,  adverse  effects  and 
leaving  the  study  early.
None  of  the  included  studies  had  any  evidence  of  the  clinical
effects of asenapine/placebo on cognitive functioning, behaviour,
functioning, service utilisation, quality of life, or reported economic
data.

The following scales were used and provided data for the analysis.

1.6.1 Global state

The  Clinical  Global  Impression  rating  scales  are  used  in  various
mental disorders in order to quantify symptom severity, treatment
response and efficacy of treatment.

Cochrane Database of Systematic Reviews

A scale (seven points) is used in which clinicians are required to rate
the  severity  of  the  patient’s  illness,  with  higher  scores  indicating
increased  severity/reduced  recovery.  This  measure  requires  the
clinician to use all available information including the history of the
patient, symptoms, social environment and impact on the patient's
functioning.

1.6.1.2 Clinical Global Impression – Severity of Illness (CGI-S)

A sub-scale of the CGI which requires clinicians to rate the current
severity  of  the  patient’s  illness  compared  to  the  clinician’s  past
experience  with  patients.  Mental  illness  is  assessed  on  a  seven-
point scale, scores ranging from one to seven, where a higher score
indicates a higher severity of illness.

1.6.1.3 Clinical Global Impression – Improvement (CGI–I)

A  sub-scale  of  the  CGI  which  requires  the  clinicians  to  rate  the
extent to which the patient's illness has deteriorated or improved
in comparison with a baseline state at the start of the intervention.
Again  this  uses  a  seven-point  scale,  scores  ranging  from  one  to
seven. A score of one indicates 'very much improved', four indicates
'no change', and seven indicates 'very much worse'.

1.6.2 Mental state

1.6.2.1 Positive and Negative Syndrome Scale (PANSS) (Kay 1987)

This is widely used in the form of a clinical interview with patients
with schizophrenia to measure the severity of their symptoms. The
interview  items  include  three  sub-scales,  positive  (seven  items),
negative  (seven  items)  and  general  psychopathology  (16  items)
whereby patients are rated from one to seven on the 30 different
symptoms. Therefore the lowest a patient can score on the PANSS
scale  is  30.  A  higher  score  indicates  a  higher  severity  of  illness.
The first two scales refer to the positive (hallucinations/delusions)
and  negative  (blunted  effect/social  and  emotional  withdrawal)
symptoms  of  schizophrenia.  The  general  psychopathology  scale
includes  16  items  of  which  some  include  anxiety/guilt  feelings,
tension,  mannerisms,  depression  and  motor  retardation.  Often
scores are given separately for the three different scales.

An  alternative  approach  to  scoring  the  PANSS  is  through  the  use
of clinician-rated Marder factor sub-scales (Marder 1997). Following
factor  analysis  of  the  PANSS,  five  symptom  dimensions  were
identified. The sub-scales include positive symptoms (eight items;
score range of 8 - 56); negative symptoms (seven items; score range
of 7 - 49); disorganized thought (seven items; score range of 7 - 49);
hostility/excitement (four items; score range of 4 - 28); and anxiety/
depression (four items; score range of 4 - 28).

1.6.2.2  Calgary  Depression  Scale 
(Addington 1993)

for  Schizophrenia 

(CDSS)

This  clinician-rated  scale  is  used  in  order  to  assess  depressive
symptoms,  usually  in  the  form  of  a  semi-structured  interview,
with  patients  with  schizophrenia.  The  items  on  the  scale  include
depressed mood, guilt (delusions/ pathological), hopelessness, low
self-esteem, observed depression, weight loss, disrupted sleep and
suicide.  Scores  range  from  0  -  4,  where  a  higher  score  indicates
higher severity of depression.

1.6.3 Adverse effects

1.6.1.1 Clinical Global Impression (CGI) (Guy 1976)

1.6.3.1 Abnormal Involuntary Movement Scale (AIMS) (Munetz 1988)

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

15

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

A  clinician-rated  scale  used  to  assess  the  severity  of  tardive
dyskinesia, particularly in patients taking neuroleptic medications.
There are 12 Items, with scores ranging from zero to four, assessing
facial  movements,  global  severity,  extremities,  trunk  movements
and dental status. A higher score indicates higher severity.

were  not  randomised  (Castle  2013;  Leucht  2013;  The  National
Horizon  Scanning  Centre  2010).  A  further  three  did  not  have  a
placebo control (Cazorla 2008; NCT00156065; NCT01142596). Since
we are only including studies with adult participants we excluded
NCT01190254 as this focused on adolescents.

1.6.3.2 Simpson – Angus Scale (SAS) (Simpson 1970)

Studies awaiting classification

A  ten-item  clinician-rated  scale  which  assesses  neuroleptic-
induced  Parkinsonism  (NIP)  in  schizophrenia.  Signs  assessed
include head dropping, shoulder shaking, salivation, tremors and
elbow/wrist rigidity. A five-point scale with scores ranging from 0
-  40  is  used  to  assess  the  severity,  the  higher  the  score  the  more
severe NIP.

NCT00156091  and  NCT01098110  meet  our  inclusion  criteria  and
would  have  been  listed  in  the  included  studies  if  sufficient
information  had  been  available.  NCT01098110  has  been  recently
completed  (April  2014).  It  is  possible  that  their  data  analysis  has
been  completed  since  the  time  of  writing  and  we  will  add  this
information to future versions of this review if it is available.

1.6.3.3 Barnes Akathisia Scale (BAS) (Barnes 1989)

Ongoing studies

A  clinician-rated  rating  scale  in  which  drug-induced  akathisia
severity  is  assessed.  Items  assess  the  frequency  and  objective
presence of akathisia, the individual's awareness and distress, and
the global severity. The objective and subjective ratings are scored
from zero to three where a higher score indicates higher severity
of  restlessness,  awareness  of  restlessness  and  distress  related  to
restlessness. A six-point scale is used to assess global severity with
scores  ranging  from  zero  to  five,  a  higher  score  specifies  higher
severity.

Excluded studies

Seven  studies  were  excluded  in  this  review.  These  are  listed  in
the Characteristics of excluded studies table. Three of the studies

One  ongoing  study  has  been  identified  (NCT01617187).  This
randomised study was started in December 2012 and is estimated
to  include  354  adults  with  schizophrenia.  The  study  assesses
the  effects  of  two  doses  of  asenapine  (2.5  mg  and  5  mg  BID)
versus placebo on global and mental state in a six-week trial. The
estimated date of completion for the study is September 2014. This
trial is being sponsored by Merck.

Risk of bias in included studies

Information for risk of bias across the included studies is illustrated
in Figure 3 and Figure 4.

Figure 3.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

16

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Figure 4.   Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

Allocation

Blinding

The  six  studies  do  not  explicitly  describe 
the  method
used  for  randomisation  of  participants,  although  they  were
"randomised"  (Chapel  2009;  Kane  2011;  NCT00151424;  Kane
2010; NCT00156117; Potkin 2007). Furthermore, no study provides
information on allocation concealment. As a result we had to rate
all studies as being of 'unclear' risk of bias.

All  the  included  studies  described  blinding  as  "double-blind",
however four of the six provide no further detail as to how this was
achieved (Chapel 2009; NCT00151424; Kane 2010; NCT00156117).
For  this  reason,  we  have  rated  them  as  'unclear  risk'.  Potkin
2007  and  Kane  2011  we  rated  'low  risk'  as  both  studies  provide
some  description  of  how  the  blinding  was  conducted.  A  double
dummy  design  was  used  where  asenapine  and  placebo  tablets
were  identical  in  appearance  and  the  patients  and  sites  were
unaware of the identity of the tablets (Kane 2011, Potkin 2007).

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

17

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

The authors judge Kane 2011, to be 'high risk' in the assessment of
an outcome. The rest of the studies do not describe how blinding
was done to assess the outcomes, therefore, they were deemed as
'unclear risk'.

Incomplete outcome data

All  six  included  studies  report  loss  to  follow  up  and  attrition
due  to  adverse  effects,  although  this  is  not  well  documented  in
some.  Some  attempt  was  made  by  five  studies  to  address  the
attrition by using the intention-to-treat (ITT) approach (Kane 2011;
NCT00151424; Kane 2010; NCT00156117; Potkin 2007; ). However,
in  Kane  2011;  NCT00151424;  Kane  2010;  Potkin  2007  ,  the  ITT
approach  was  used  in  conjunction  with  last  observation  carried
forward (LOCF) for some of the outcomes. This can introduce bias as
it makes assumptions about the people who did not complete the
study. None of these studies attempted to validate the assumptions
made about these people and because of this, we have rated them
as  'high  risk'.  Chapel  2009  does  not  document  how  the  loss  of
participants  was  addressed  for  analysis  and  this,  too,  has  been
rated as 'high risk'.

Selective reporting

Most  of  the  studies  had  some  degree  of  selective  reporting  or
insufficient  reporting  of  data  -  with  the  exception  of  Kane  2010
which  we  thought  was  'low  risk'  as  it  provides  usable  data  for
most outcomes. NCT00151424 and NCT00156117 are unpublished
trials  with  full  data  sets  unavailable,  however,  we  were  able  to
utilise  some  data  for  mental  state,  leaving  the  study  early  and
adverse effects. The majority of studies provided tables, graphs and
visual representations of data. Some studies reported no means or
standard deviations for certain outcomes (Kane 2011; Potkin 2007).
Chapel 2009 had unreported data of endpoint characteristics for its
primary outcome. We rated Chapel 2009; Kane 2011; NCT00151424;
NCT00156117; Potkin 2007 as 'high risk' due to missing, incomplete
or unusable reporting of data.

1.2.2 Medium-term (13 to 26 weeks)

In this subgroup we only found one relevant trial (n = 382) (Kane
2011). There was a clear difference between asenapine and placebo
(MD -0.6, 95% CI -0.77 to -0.43, Analysis 1.2).

1.3 Global state: 3. Relapse - medium-term (13 to 26 weeks)

For this outcome we only found one relevant trial (n = 386) (Kane
2011). There was a clear difference between asenapine and placebo
(RR 0.26, 95% CI 0.18 to 0.40, Analysis 1.3).

1.4 Global state: 4. Use of any concomitant medication

1.4.1 Short-term

In this subgroup we only found one relevant trial (n = 340) (Kane
2010). There was a clear difference between asenapine and placebo
(RR 0.84, 95% CI 0.74 to 0.97, Analysis 1.4).

1.4.2 Medium-term

In this subgroup we only found one relevant trial (n = 386) (Kane
2011).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 0.87, 95% CI 0.71 to 1.07, Analysis 1.4).

1.5 Global state: 5. Use of specific concomitant medication

1.5.1 Acetaminophen - short-term

In this subgroup we only found one relevant trial (n = 340) (Kane
2010).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 0.74, 95% CI 0.48 to 1.12, Analysis 1.5).

1.5.2 Antiparkinsonian medication - short-term

In this subgroup we found two relevant trials (n = 461). There was
no clear difference between asenapine and placebo (RR 1.21, 95%
CI 0.78 to 1.88, Analysis 1.5). This subgroup had moderate levels of
heterogeneity (Chi2 = 1.62; degrees of freedom (df) = 1; P = 0.203;
I2 = 38%).

Other potential sources of bias

1.5.3 Benzatropine - short-term

All  six  studies  were  funded  and  supported  by  pharmaceutical
companies  (Merck,  Organon,  Pfizer  Inc,  Schering-Plough).  Nearly
all  authors  were  affiliated  with  or  employed  by  pharmaceutical
companies. This could lead to bias in the reporting. As a result, we
classed all the studies at 'high risk'.

Effects of interventions

See: Summary of findings for the main comparison ASENAPINE
versus PLACEBO for schizophrenia

COMPARISON 1: ASENAPINE versus PLACEBO

1.1 Global state: 1. No clinically important change (CGI-I) - short-
term (up to 12 weeks)

For this outcome we only found one relevant trial (n = 336) (Kane
2010). There was a clear difference between asenapine and placebo
(RR 0.81, 95% CI 0.68 to 0.97, Analysis 1.1).

1.2 Global state: 2. Average change score (CGI-S, high = poor)

In this subgroup we only found one relevant trial (n = 340) (Kane
2010).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 1.05, 95% CI 0.43 to 2.57, Analysis 1.5).

1.5.4 Ibuprofen - short-term

In this subgroup we only found one relevant trial (n = 340) (Kane
2010).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 0.61, 95% CI 0.30 to 1.22, Analysis 1.5).

1.5.5 Lorazepam - short-term

In this subgroup we found two relevant trials (n = 461). There was
no clear difference between asenapine and placebo (RR 0.85, 95%
CI 0.71 to 1.02, Analysis 1.5).

1.5.6 Lorazepam - medium-term

In this subgroup we only found one relevant trial (n = 386) (Kane
2011).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 0.45, 95% CI 0.16 to 1.27, Analysis 1.5).

1.2.1 Short-term (up to 12 weeks)

1.5.7 Trihexyphenidyl - short-term

In this subgroup we only found one relevant trial (n = 336) (Kane
2010). There was a clear difference between asenapine and placebo
(MD - 0.35, 95% CI -0.55 to -0.15, Analysis 1.2).

In this subgroup we only found one relevant trial (n = 340) (Kane
2010).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 1.70, 95% CI 0.83 to 3.50, Analysis 1.5).

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

18

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

1.5.8 Trihexyphenidyl - medium-term

1.8.5 PANSS Marder disorganized thought factor score - short-term

In this subgroup we only found one relevant trial (n = 386) (Kane
2011).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 0.66, 95% CI 0.19 to 2.30, Analysis 1.5).

In this subgroup we only found one relevant trial (n = 336) (Kane
2010). There was a clear difference between asenapine and placebo
(MD -1.25, 95% CI -2.20 to -0.30, Analysis 1.8).

1.5.9 Zolpidem - short-term

1.8.6 PANSS Marder disorganized thought factor score - medium-term

In this subgroup we found two relevant trials (n = 461). There was
no clear difference between asenapine and placebo (RR 1.00, 95%
CI 0.71 to 1.40, Analysis 1.5).

In this subgroup we only found one relevant trial (n = 382) (Kane
2011). There was a clear difference between asenapine and placebo
(MD -2.40, 95% CI -2.95 to -1.85, Analysis 1.8).

1.5.10 Zolpidem - medium-term

1.8.7 PANSS Marder hostility/excitement factor score - short-term

In this subgroup we only found one relevant trial (n = 386) (Kane
2011).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 0.33, 95% CI 0.07 to 1.61, Analysis 1.5).

In this subgroup we only found one relevant trial (n = 336) (Kane
2010). There was a clear difference between asenapine and placebo
(MD -0.50, 95% CI -1.21 to 0.21, Analysis 1.8).

1.6 Mental state: 1. No clinically important change (PANSS) -
short-term

For this outcome we only found one relevant trial (n = 336) (Kane
2010). There was a clear difference between asenapine and placebo
(RR 0.72, 95% CI 0.59 to 0.86, Analysis 1.6).

1.7 Mental state: 2. Average change in total score (baseline-to-
endpoint) (PANSS, high = poor)

1.7.1 PANSS total score - short-term

In this subgroup we found two relevant trials (n = 627). There was a
clear difference between asenapine and placebo (MD -3.77, 95% CI
-6.50 to -1.04, Analysis 1.7).

1.7.2 PANSS total score - medium-term

In this subgroup we only found one relevant trial (n = 382) (Kane
2011). There was a clear difference between asenapine and placebo
(MD -10.80, 95% CI -13.57 to -8.03, Analysis 1.7).

1.8 Mental state: 3. Average change score (baseline-to-endpoint)
(various scales, high = poor)

1.8.1 CDSS total score - short-term

In this subgroup we only found one relevant trial (n = 336) (Kane
2010). There was a clear difference between asenapine and placebo
(MD -0.86, 95% CI -1.62 to -0.10, Analysis 1.8).

1.8.2 CDSS total score - medium-term

In this subgroup we only found one relevant trial (n = 382) (Kane
2011). There was a clear difference between asenapine and placebo
(MD -0.70, 95% CI -1.25 to -0.15, Analysis 1.8).

1.8.3 PANSS Marder anxiety/depression factor score - short-term

In this subgroup we only found one relevant trial (n = 336) (Kane
2010). There was a clear difference between asenapine and placebo
(MD -0.55, 95% CI -1.26 to 0.16, Analysis 1.8).

1.8.4 PANSS Marder anxiety/depression factor score - medium-term

In this subgroup we only found one relevant trial (n = 382) (Kane
2011). There was a clear difference between asenapine and placebo
((MD -1.40, 95% CI -1.95 to -0.85), Analysis 1.8).

1.8.8 PANSS Marder hostility/excitement factor score - medium-term

In this subgroup we only found one relevant trial (n = 382) (Kane
2011). There was a clear difference between asenapine and placebo
(MD -2.00, 95% CI -2.55 to -1.45, Analysis 1.8).

1.8.9 PANSS Marder negative factor score - short-term

In this subgroup we only found one relevant trial (n = 336) (Kane
2010). There was a clear difference between asenapine and placebo
(MD -1.10, 95% CI -2.29 to 0.09, Analysis 1.8).

1.8.10 PANSS Marder negative factor score - medium-term

In this subgroup we only found one relevant trial (n = 382) (Kane
2011). There was a clear difference between asenapine and placebo
(MD -1.70, 95% CI -2.53 to -0.87, Analysis 1.8).

1.8.11 PANSS Marder positive factor score - short-term

In this subgroup we only found one relevant trial (n = 336) (Kane
2010). There was a clear difference between asenapine and placebo
(MD -2.40, 95% CI -3.83 to -0.97, Analysis 1.8).

1.8.12 PANSS Marder positive factor score - medium-term

In this subgroup we only found one relevant trial (n = 382) (Kane
2011). There was a clear difference between asenapine and placebo
(MD -3.40, 95% CI -4.23 to -2.57, Analysis 1.8).

1.9 Adverse effects: 1. Incidence of serious adverse effects

1.9.1 Short-term

In this subgroup we found three relevant trials (n = 644). There was
no clear difference between asenapine and placebo (RR 1.12, 95%
CI 0.63 to 2.00, Analysis 1.9).

1.9.2 Medium-term

In this subgroup we only found one relevant trial (n = 386) (Kane
2011). There was a clear difference between asenapine and placebo
(RR 0.29, 95% CI 0.14 to 0.63, Analysis 1.9).

1.10 Adverse effects: 2. Incidence of any adverse effects

1.10.1 Any adverse effects - short-term

In this subgroup we found two relevant trials (n = 461). There was
no clear difference between asenapine and placebo (RR 0.99, 95%
CI 0.89 to 1.11, Analysis 1.10).

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

19

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

1.10.2 Any treatment-emergent adverse effects - medium-term

1.13.3 Constipation

In this subgroup we only found one relevant trial (n = 386) (Kane
2011).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 0.83, 95% CI 0.68 to 1.01, Analysis 1.10).

In this subgroup we only found one relevant trial (n = 121) (Potkin
2007).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 1.05, 95% CI 0.36 to 3.08, Analysis 1.13).

1.10.3 Any treatment-related adverse effects - short-term

1.13.4 Dyspepsia

In this subgroup we only found one relevant trial (n = 340) (Kane
2010).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 1.18, 95% CI 0.91 to 1.52, Analysis 1.10).

In this subgroup we only found one relevant trial (n = 121) (Potkin
2007).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 0.84, 95% CI 0.24 to 2.98, Analysis 1.13).

1.10.4 Any treatment-related adverse effects - medium-term

1.13.5 Vomiting

In this subgroup we only found one relevant trial (n = 386) (Kane
2011).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 0.84, 95% CI 0.59 to 1.19, Analysis 1.10).

In this subgroup we found two relevant trials (n = 461). There was
no clear difference between asenapine and placebo (RR 1.31, 95%
CI 0.61 to 2.84, Analysis 1.13).

1.11 Adverse effects: 3. Incidence of adverse effects by severity -
short-term

1.14 Adverse effects: 4. Specific adverse effects - 4.3. Metabolic:
incidence

1.11.1 Mild adverse effects

1.14.1 Clinically significant fasting glucose levels - short-term

In this subgroup we only found one relevant trial (n = 340) (Kane
2010).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 0.88, 95% CI 0.66 to 1.18, Analysis 1.11).

1.11.2 Moderate adverse effects

In this subgroup we only found one relevant trial (n = 340) (Kane
2010).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 1.01, 95% CI 0.71 to 1.42, Analysis 1.11).

1.11.3 Severe adverse effects

In this subgroup we found three relevant trials (n = 644). There was
no clear difference between asenapine and placebo (RR 1.52, 95%
CI 0.80 to 2.91, Analysis 1.11).

1.12 Adverse effects: 4. Specific adverse effects - 4.1.
Cardiovascular: incidence - short-term

1.12.1 QTc interval > 450 ms

In this subgroup we found two relevant trials (n = 232). There was a
clear difference between asenapine and placebo (RD - 0.01, 95% CI
- 0.07 to 0.05, Analysis 1.12).

1.12.2 Sinus tachycardia

In this subgroup we only found one relevant trial (n = 121) (Potkin
2007). There was a clear difference between asenapine and placebo
(RD 0.01, 95% CI -0.11 to 0.12, Analysis 1.12).

1.13 Adverse effects: 4. Specific adverse effects - 4.2.
Gastrointestinal: incidence - short-term

1.13.1 Clinically significant gamma-glutamyl transpeptidase levels

In  this  subgroup  we  only  found  one  relevant  trial  (n  =  183)
(NCT00151424).  There  was  a  clear  difference  between  asenapine
and placebo (RR 3.62, 95% CI 1.24 to 10.57, Analysis 1.13).

1.13.2 Clinically significant alanine aminotransferase levels

In  this  subgroup  we  only  found  one  relevant  trial  (n  =  183)
(NCT00151424).  There  was  a  clear  difference  between  asenapine
and placebo (RR 2.58, 95% CI 1.2 to 5.56, Analysis 1.13).

In this subgroup we found three relevant trials (n = 641). There was
a clear difference between asenapine and placebo (RR 2.24, 95% CI
1.06 to 4.75, Analysis 1.14). This subgroup had moderate levels of
heterogeneity (Chi2 = 3.97; df = 2; P = 0.14; I2 = 50%).

1.14.2 Clinically significant fasting triglycerides levels - short-term

In  this  subgroup  we  only  found  one  relevant  trial  (n  =  183)
(NCT00151424).  There  was  a  clear  difference  between  asenapine
and placebo (RR 8.27, 95% CI 1.06 to 64.77, Analysis 1.14).

1.14.3 Clinically significant HbA1C levels - short-term

In  this  subgroup  we  only  found  one  relevant  trial  (n  =  183)
(NCT00151424). There was no clear difference between asenapine
and placebo (RR 7.23, 95% CI 0.38 to 138.03, Analysis 1.14).

1.14.4 Clinically significant hyperprolactinaemia - short-term

In this subgroup we found two relevant trials (n = 458). There was
no clear difference between asenapine and placebo (RR 3.28, 95%
CI 0.97 to 11.06, Analysis 1.14).

1.14.5 Clinically significant hyperprolactinaemia - medium-term

In this subgroup we only found one relevant trial (n = 386) (Kane
2011).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 0.62, 95% CI 0.21 to 1.86, Analysis 1.14).

1.14.6 Clinically significant weight gain - short-term

In this subgroup we found three relevant trials (n = 623). There was
a clear difference between asenapine and placebo (RR 3.48, 95% CI
1.19 to 10.15, Analysis 1.14).

1.14.7 Clinically significant weight gain - medium-term

In this subgroup we only found one relevant trial (n = 386) (Kane
2011).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 6.93, 95% CI 0.86 to 55.77, Analysis 1.14).

1.14.8 Clinically significant weight loss - short-term

In this subgroup we only found one relevant trial (n = 340) (Kane
2010).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 0.85 CI 0.14 to 5.02, Analysis 1.14).

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

20

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

1.14.9 Clinically significant weight loss - medium-term

1.17.5 Anxiety - short-term

In this subgroup we only found one relevant trial (n = 386) (Kane
2011). There was a clear difference between asenapine and placebo
(RR 0.33, 95% CI 0.13 to 0.81, Analysis 1.14).

In this subgroup we found two relevant trials (n = 461). There was
no clear difference between asenapine and placebo (RR 1.01, 95%
CI 0.52 to 1.96, Analysis 1.17).

1.14.10 Weight gain - medium-term

1.17.6 Anxiety - medium-term

In this subgroup we only found one relevant trial (n = 386) (Kane
2011).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 1.84, 95% CI 0.75 to 4.51, Analysis 1.14).

In this subgroup we only found one relevant trial (n = 386) (Kane
2011).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 0.75, 95% CI 0.41 to 1.40, Analysis 1.17).

1.14.11 Weight loss - medium-term

1.17.7 Delusions - medium-term

In this subgroup we only found one relevant trial (n = 386) (Kane
2011).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 0.43 , 95%CI 0.18 to 1.03, Analysis 1.14).

In this subgroup we only found one relevant trial (n = 386) (Kane
2011). There was a clear difference between asenapine and placebo
(RR 0.18, 95% CI 0.04 to 0.80, Analysis 1.17).

1.15 Adverse effects: 4. Specific adverse effects - 4.4. Metabolic:
average change in prolactin levels (μg/L) (baseline-to-endpoint)
- short-term

For  this  outcome  we  only  found  one  relevant  trial  (n  =  340)
(Kane 2010). There was no clear difference between asenapine and
placebo (MD 6.01, 95% CI - 3.35 to 15.37, Analysis 1.15).

1.16 Adverse effects: 4. Specific adverse effects - 4.5. Metabolic:
average change in weight (kg) (baseline-to-endpoint)

1.16.1 Short-term

In this subgroup we only found one relevant trial (n = 340) (Kane
2010).  There  was  no  clear  difference  between  asenapine  and
placebo (MD 1.05, 95% CI -0.03 to 2.13, Analysis 1.16).

1.16.2 Medium-term

In this subgroup we only found one relevant trial (n = 386) (Kane
2011).  There  was  no  clear  difference  between  asenapine  and
placebo (MD 1.20, 95% CI 0.46 to 1.94, Analysis 1.16).

1.17.8 Dizziness - short-term

In this subgroup we only found one relevant trial (n = 121) (Potkin
2007).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 0.58, 95% CI 0.21 to 1.64, Analysis 1.17).

1.17.9 Fatigue - short-term

In this subgroup we only found one relevant trial (n = 121) (Potkin
2007).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 0.53, 95% CI 0.10 to 2.76, Analysis 1.17).

1.17.10 Hallucinations - medium-term

In this subgroup we only found one relevant trial (n = 386) (Kane
2011). There was a clear difference between asenapine and placebo
(RR 0.08, 95% CI 0.01 to 0.58, Analysis 1.17).

1.17.11 Headache - short-term

In this subgroup we found two relevant trials (n = 461). There was
a clear difference between asenapine and placebo (RR 0.39, 95% CI
0.22 to 0.71, Analysis 1.17).

1.17 Adverse effects: 4. Specific adverse effects - 4.6. Other
specific adverse effects: incidence

1.17.12 Headache - medium-term

1.17.1 Agitation - short-term

In this subgroup we found two relevant trials (n = 461). There was
a clear difference between asenapine and placebo (RR 0.50, 95% CI
0.28 to 0.89, Analysis 1.17).

1.17.2 Agitation - medium-term

In this subgroup we only found one relevant trial (n = 386) (Kane
2011).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 0.36, 95% CI 0.12 to 1.11, Analysis 1.17).

1.17.3 Akathisia - short-term

In this subgroup we only found one relevant trial (n = 340) (Kane
2010).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 1.84, 95% CI 0.61 to 5.53, Analysis 1.17).

1.17.4 Akathisia - medium-term

In this subgroup we only found one relevant trial (n = 386) (Kane
2011).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 1.32, 95% CI 0.3 to 5.82, Analysis 1.17).

In this subgroup we only found one relevant trial (n = 386) (Kane
2011).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 2.97, 95% CI 0.61 to 14.53, Analysis 1.17).

1.17.13 Insomnia - short-term

In this subgroup we found two relevant trials (n = 461). There was
no clear difference between asenapine and placebo (RR 0.81, 95%
CI 0.50 to 1.31, Analysis 1.17). This subgroup had important levels
of heterogeneity (Chi2 = 2.79; df = 1; P = 0.09; I2 = 64%).

1.17.14 Insomnia - medium-term

In this subgroup we only found one relevant trial (n = 386) (Kane
2011). There was a clear difference between asenapine and placebo
(RR 0.46, 95% CI 0.24 to 0.88, Analysis 1.17).

1.17.15 Nausea - short-term

In this subgroup we only found one relevant trial (n = 121) (Potkin
2007).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 1.44, 95% CI 0.62 to 3.34, Analysis 1.17).

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

21

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

1.17.16 Oral hypoesthesia - short-term

1.18.3 Dystonia - short-term

In this subgroup we only found one relevant trial (n = 340) (Kane
2010).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 1.89, 95% CI 0.53 to 6.74, Analysis 1.17).

In this subgroup we only found one relevant trial (n = 340) (Kane
2010).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 7.39, 95% CI 0.42 to 130.15, Analysis 1.18).

1.17.17 Pain - short-term

1.18.4 Hyperkinesia - short-term

In this subgroup we only found one relevant trial (n = 121) (Potkin
2007).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 0.79, 95% CI 0.18 to 3.37, Analysis 1.17).

1.17.18 Psychosis - short-term

In this subgroup we only found one relevant trial (n = 121) (Potkin
2007).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 1.58, 95% CI 0.47 to 5.31, Analysis 1.17).

1.17.19 Schizophrenia - medium-term

In this subgroup we only found one relevant trial (n = 386) (Kane
2011). There was a clear difference between asenapine and placebo
(RR 0.29, 95% CI 0.14 to 0.59, Analysis 1.17).

1.17.20 Sedation - short-term

In this subgroup we only found one relevant trial (n = 340) (Kane
2010).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 0.68, 95% CI 0.21 to 2.18, Analysis 1.17).

1.17.21 Somnolence - short-term

In this subgroup we found two relevant trials (n = 461). There was
no clear difference between asenapine and placebo (RR 1.88, 95%
CI 0.86 to 4.08, Analysis 1.17).

1.17.22 Somnolence - medium-term

In this subgroup we only found one relevant trial (n = 386) (Kane
2011).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 0.49, 95% CI 0.05 to 5.41, Analysis 1.17).

1.17.23 Upper respiratory tract infection - short-term

In this subgroup we only found one relevant trial (n = 121) (Potkin
2007).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 1.4, 95% CI 0.33 to 6.00, Analysis 1.17).

1.17.24 Worsening psychotic symptoms - short-term

In this subgroup we only found one relevant trial (n = 340) (Kane
2010).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 0.51, 95% CI 0.21 to 1.22, Analysis 1.17).

1.18 Adverse effects: 5. Extrapyramidal symptoms - 5.1.
Incidence

1.18.1 Any extrapyramidal symptoms - short-term

In this subgroup we found two relevant trials (n = 523). There was
a clear difference between asenapine and placebo (RR 1.74, 95% CI
1.02 to 2.96, Analysis 1.18).

1.18.2 Any extrapyramidal symptoms - medium-term

In this subgroup we only found one relevant trial (n = 386) (Kane
2011).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 0.66, 95% CI 0.24 to 1.82, Analysis 1.18).

In this subgroup we only found one relevant trial (n = 121) (Potkin
2007). No one experienced this outcome (Analysis 1.18).

1.18.5 Hypertonia - short-term

In this subgroup we only found one relevant trial (n = 121) (Potkin
2007).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 0.21, 95% CI 0.01 to 4.28, Analysis 1.18).

1.18.6 Muscle rigidity - short-term

In this subgroup we only found one relevant trial (n = 340) (Kane
2010).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 8.53, 95% CI 0.49 to 148.12, Analysis 1.18).

1.18.7 Parkinsonism - short-term

In this subgroup we only found one relevant trial (n = 340) (Kane
2010).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 1.51, 95% CI 0.61 to 3.76, Analysis 1.18).

1.18.8 Parkinsonism - medium-term

In this subgroup we only found one relevant trial (n = 386) (Kane
2011).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 0.33, 95% CI 0.03 to 3.14, Analysis 1.18).

1.19 Adverse effects: 5. Extrapyramidal symptoms - 5.2. Average
change (baseline-to-endpoint) (various scales, high = poor) -
short-term

1.19.1 AIMS

In this subgroup we only found one relevant trial (n = 333) (Kane
2010). There was a clear difference between asenapine and placebo
(MD -0.13, 95% CI -0.43 to 0.17, Analysis 1.19).

1.19.2 BAS

In this subgroup we only found one relevant trial (n = 333) (Kane
2010). There was a clear difference between asenapine and placebo
(MD 0.11, 95% CI -0.05 to 0.27, Analysis 1.19).

1.19.3 SAS

In this subgroup we only found one relevant trial (n = 333) (Kane
2010).  There  was  no  clear  difference  between  asenapine  and
placebo (MD 0.50, 95% CI -0.04 to 1.04, Analysis 1.19).

1.20 Adverse effects: 6. Incidence of death (for any reason) -
short-term

In this outcome we found two relevant trials (n = 523). There was no
clear difference between asenapine and placebo (RD -0.01, 95% CI
-0.02 to 0.01, Analysis 1.20).

1.21 Leaving the study early

1.21.1 Any reason - short-term

In this subgroup we found five relevant trials (n = 1046). There was
no clear difference between asenapine and placebo (RR 0.91, 95%

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

22

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

CI 0.80 to 1.04, Analysis 1.21). This subgroup had moderate levels of
heterogeneity (Chi2 = 7.02; df = 4; P = 0.13; I2 = 43%).

2. Subgroup analyses

No subgroup analyses were conducted.

1.21.2 Any reason - medium-term

In this subgroup we only found one relevant trial (n = 386) (Kane
2011). There was a clear difference between asenapine and placebo
(RR 0.49, 95% CI 0.38 to 0.62, Analysis 1.21).

1.21.3 Due to adverse effects - short-term

In this subgroup we found three relevant trials (n = 644). There was
no clear difference between asenapine and placebo (RR 0.89, 95%
CI 0.54 to 1.47, Analysis 1.21).

1.21.4 Due to adverse effects - medium-term

In this subgroup we only found one relevant trial (n = 386) (Kane
2011). There was a clear difference between asenapine and placebo
(RR 0.3, 95% CI 0.18 to 0.50, Analysis 1.21).

1.21.5 Due to lack of efficacy - short-term

In this subgroup we found two relevant trials (n = 457). There was
a clear difference between asenapine and placebo (RR 0.56, 95% CI
0.38 to 0.81, Analysis 1.21).

1.21.6 Due to loss to follow up - medium-term

In  this  subgroup  we  only  found  one  relevant  trial  (n=386)  (Kane
2011).  There  was  not  a  clear  difference  between  asenapine  and
placebo (RR 0.99 CI 0.2 to 4.84, Analysis 1.21).

1.21.7 Due to other reasons - short-term

In this subgroup we found two relevant trials (n = 457). There was
no clear difference between asenapine and placebo (RR 1.22, 95%
CI 0.83 to 1.80, Analysis 1.21).

1.21.8 Due to other reasons - medium-term

In this subgroup we only found one relevant trial (n = 386) (Kane
2011).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 0.84, 95% CI 0.38 to 1.82, Analysis 1.21).

1.21.9 Due to relapse (not considered adverse effect) - medium-term

In this subgroup we only found one relevant trial (n = 386) (Kane
2011). There was a clear difference between asenapine and placebo
(RR 0.25, 95% CI 0.13 to 0.49, Analysis 1.21).

1.21.10 Due to specific adverse effect: relapse - medium-term

In this subgroup we only found one relevant trial (n = 386) (Kane
2011). There was a clear difference between asenapine and placebo
(RR 0.27 CI, 95% 0.16 to 0.47, Analysis 1.21).

1.21.11 Due to specific adverse effect: worsening of schizophrenia -
medium-term

In this subgroup we only found one relevant trial (n = 386) (Kane
2011). There was a clear difference between asenapine and placebo
(RR 0.25, 95% CI 0.14 to 0.45, Analysis 1.21).

1.21.12 Due to withdrawal of consent - medium-term

In this subgroup we only found one relevant trial (n = 386) (Kane
2011).  There  was  no  clear  difference  between  asenapine  and
placebo (RR 1.57, 95% CI 0.78 to 3.14, Analysis 1.21).

3. Sensitivity analyses

3.1 Implication of randomisation

No  sensitivity  analyses  were  possible,  as  all  included  studies  for
the primary outcomes were explicitly described as having random
allocation procedures.

3.2 Assumptions for lost binary data

For  the  primary  outcomes,  no  sensitivity  analyses  were  possible,
as  no  included  study  reported  binary  data  for  completer-only
populations.

3.3 Risk of bias

No  sensitivity  analyses  were  possible,  as  all  included  studies  for
the primary outcomes were judged to be of high risk of bias in one
or more domains (randomisation, allocation concealment, blinding
and outcome reporting).

3.4 Imputed values

No  sensitivity  analyses  were  possible,  as  none  of  the  included
studies for the primary outcomes were cluster-randomised trials.

3.5 Fixed and random effects

For  the  primary  outcomes,  there  was  no  difference  in  the  results
when  synthesising  data  using  a  fixed-effect  model  or  a  random-
effects model.

D I S C U S S I O N

Summary of main results

1. General

Six  studies  (29  reports)  met  the  inclusion  criteria  for  our  review.
The summary below discusses the outcomes included in Summary
of findings for the main comparison. We have also considered the
impact  of  our  findings  upon  clinical  practice,  patients'  decision-
making and policy-related directives.

2. Treatment effects

2.1 Clinically important change in global state

One short-term study (Kane 2010; n = 336) reported the outcome of
clinically important change in global state (considered by this study
as a CGI-I score of one or two). Compared with placebo, asenapine
was found to produce significantly greater clinical change in global
state.  Although  encouraging,  this  finding  must  be  considered
with  caution  because  of  the  'low-quality'  and  limited  quantity  of
evidence.

2.2 Clinically important change in mental state

The same short-term study (Kane 2010; n = 336) reported 'clinically
important change in mental state' (considered as a > 30% decrease
in PANSS score). Compared with placebo, asenapine was found to
produce significantly greater clinical change in mental state. Again,
interpretation  must  be  undertaken  with  caution  because  of  the
'very low-quality' and limited quantity of evidence.

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

23

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

2.3 Average change in negative symptoms

2.7 Economic costs

Again, the same short-term study (Kane 2010; n = 336) reported on
the outcome of average change in negative symptoms (measured
in this study using the PANSS Marder negative factor). Compared
with placebo, asenapine was found to produce significantly greater
reduction  in  negative  symptoms.  Again,  caution  must  be  taken
when  interpreting  this  result  due  to  the  'very  low-quality'  and
limited quantity of evidence. This needs much more independent
verification.

2.4 Incidence of serious adverse effects

One  medium-term  study  (Kane  2011;  n=386)  reported  on  the
outcome  of  incidence  of  serious  adverse  effects.  Compared  with
placebo,  asenapine  was  found  to  produce  significantly  fewer
incidents of serious adverse effects. Again, caution must be taken
when  interpreting  this  result  due  to  the  'very  low-quality'  and
limited quantity of evidence. Additionally, Analysis 1.9 shows three
short-term studies also indicate no differences between asenapine
and placebo in the incidence of serious adverse effects. One would
expect an active drug to have adverse effects and some of these,
perhaps occasionally, to be serious. It could be that asenapine is
not associated with adverse effects that are serious. It could also
be that more trial-derived data are needed, as well as information
from other non-trial sources. It is also feasible that, in these trials,
selective reporting is more than a possibility. More independently-
derived data are needed.

2.5 Clinically significant extrapyramidal symptoms

Although  four  studies  reported  on  incidence  of  extrapyramidal
symptoms, and two reported on average change of extrapyramidal
symptoms  from  baseline-to-endpoint  (using  the  AIMS,  BAS  and
SAS),  no  included  trial  reported  on  the  incidence  of  clinically
significant  extrapyramidal  symptoms.  Continuous  measures  are
important  fine-grain  ways  of  identifying  symptoms  or  signs.
However,  it  adds  little  complexity  to  a  study  to  ask  raters  or
participants about how important they really feel that problem to
be. Not to do this could impose a spurious importance to data, or
serve to help ignore issues that really bother people. This omission
is an indication that these studies were designed less for research
into the well being of people with schizophrenia and more for the
needs of companies.

2.6 Leaving the study early - for any reason

Five  short-term  studies  (n  =  1046)  reported  on  the  outcome  of
'leaving  the  study  early  for  any  reason'.  Analysis  1.21  indicates
that  there  is  no  difference  between  the  discontinuation  rates
of  asenapine  and  placebo  across  the  studies.  While  this  may
appear  encouraging  for  the  use  of  asenapine,  discontinuation
rates  for  asenapine  (42.5%)  and  placebo  (48.7%)  were  both
very  high.  Although  our  analysis  was  characterised  by  moderate
heterogeneity  (I2  =  43%),  and  differences  in  discontinuation
became  clear,  favouring  asenapine,  when  the  one  outlying  study
Chapel  2009  (˜2%  weighting)  is  removed  to  gain  homogeneity,
losses to follow up are still enormous. While four studies attempt
to report on specific reasons for discontinuation, the similarly high
rates  of  attrition  are  likely  to  reflect  poor  study  design  and  trial
management. The most chaotic of clinical situations would still be
hard  pressed  to  lose  nearly  half  the  people  with  schizophrenia  it
was responsible for within a matter of six weeks. This indicates how
odd and removed from real world care these trials are.

We considered the direct and indirect economic costs of asenapine
treatment to be a highly important outcome that could influence
its  potential  circulation  in  clinical  practice  for  schizophrenia.
Suprisingly, no studies reported any data related to this outcome.
No  study  reported  service  use  outcomes  such  as  'relapse'  or
'hospitalisation'. These can often be used as a proxy in an economic
consideration  of  an  intervention.  With  economics  being  such  an
important part of consideration of care, it is notable that there are
no data at all for this new compound. It is hard not to conclude that
the companies producing these trials are hesitant about reporting
any data which would lead to economic consideration.

3. Publication bias

Due to the limited number of studies, it was not sensible to conduct
funnel  plot  analyses  to  investigate  publication  bias.  However  we
were  unable  to  find  full  publications  for  two  included  studies
(NCT00151424; NCT00156117) that were considered to be 'negative
trials' by their authors.

4. Subgroup analyses

We did not conduct subgroup analyses.

5. Sensitivity analyses

No  sensitivity  analyses  were  possible  for  the  implication  of
randomisation, assumptions for lost binary data, risk of bias, and
imputed values. The results for the primary outcomes did not differ
when a random-effects model was applied instead of a fixed-effect
model.

Overall completeness and applicability of evidence

1. Completeness

1.1 Outcomes

The  outcomes  that  were  reported  by  the  studies  that  have  been
included are global state, mental state, adverse effects and leaving
the study early.

For  the  primary  outcomes,  only  Kane  2010  reported  on  clinically
important change in global state and clinically important change
in  mental  state.  Therefore  we  consider  that  our  included  studies
insufficiently reported these primary outcomes.

Similarly,  our  included  studies  inconsistently  reported  on  the
majority  of  our  secondary  outcomes.  Of  our  analyses,  only  the
outcome 'leaving the study early' (Analysis 1.21) was reported on
by all six of our included studies.

None  of  the  included  studies  had  any  evidence  of  the  effects
of asenapine versus placebo on cognitive functioning, behaviour,
functioning, service utilisation, quality of life, and economic costs.
Of the secondary outcomes, we believe the insufficient reporting
of 'relapse', and not reporting service outcomes such as 'admitted',
particularly disappointing.

1.2 Duration

Of our included studies, five were short-term and one was medium-
term. We found no long-term studies.

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

24

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

2. Applicability

2.1 Patients

Four of our included studies were global multicentred trials which
indicates  the  applicability  of  asenapine  across  different  cultures.
However  no  included  study  reported  a  breakdown  of  participant
sample size and demographics of each centre from which we could
draw stronger conclusions.

The  majority  of  included  studies  predominately  consisted  of
patients  with  schizophrenia  (DSM-IV/DSM-IV-TR)  which  limits
the  applicability  of  our 
findings  to  other  schizophrenia-
like  disorders  (e.g.  schizo-affective  disorder,  schizophreniform
disorder,  delusional  disorder).  Furthermore,  no  included  study
clearly  reported  upon  the  presence  of  psychiatric  and  physical
co-morbidities.  In  addition,  several  included  studies  explicitly
excluded  co-morbid  conditions,  which  does  not  reflect  everyday
clinical  practice.  Therefore  it  is  unclear  whether  our  findings  are
applicable to co-morbid populations.

2.2 Dosage

The dose of asenapine ranged from 5 mg to 20 mg twice a day (BID).
The dosage used by five of the included studies adhered to the FDA
recommendations  (5  -  10  mg  BID)  (FDA  2013),  suggesting  clinical
applicability of the findings. Only one study (Chapel 2009) exceeded
the recommended dosage, using up to 20 mg BID.

2.3 Setting

Three  included  studies  conducted  the  trial  on  an  inpatient  and
outpatient  basis.  However  no  study  reported  a  breakdown  of
outcome findings from each setting type. The settings of the other
included studies have not been clearly specified. In this respect, the
applicability of the findings is unclear.

2.4 Outcome term lengths

Five of our included studies were short-term and one was medium-
term. We found no long-term studies. Considering schizophrenia is
a chronic illness and may require long-term medication treatment,
we consider the applicability of the short-term studies to be limited,
as far as the long-term prognosis of patients with schizophrenia is
concerned.

Quality of the evidence

We  judged  the  bias  of  the  included  trials  to  be  unclear/high
(Figure  3;  Figure  4),  and  the  quality  of  the  current  evidence  to
be  low  or  very  low  using  GRADE  (Summary  of  findings  for  the
main  comparison)  (Schünemann  2011).  This  is  largely  due  to
poor trial design and management, methodological inadequacies
(randomisation  and  blinding),  and  high  rates  of  discontinuation.
In addition, the included studies were characterised by missing or
unreported outcomes and poor clarity of follow-up. All trials were
sponsored  by  pharmaceutical  companies  and  nearly  all  authors
were affiliated with, or employed by these companies.

Potential biases in the review process

We adhered to the protocol by independently inspecting citations
and  full  articles  of  potentially  relevant  studies.  Furthermore  we
independently  extracted  data  onto  simple  forms,  and  discussed
any inconsistencies or disagreements that arose.

Cochrane Database of Systematic Reviews

Agreements and disagreements with other studies or
reviews

To  our  knowledge,  there  are  no  other  systematic  reviews  of
asenapine  versus  placebo  for  schizophrenia.  However,  a  small
number  of  pooled  analyses  and  literature  reviews  (Bishara  2009;
Citrome 2009; Leucht 2014; Stoner 2012; Szegedi 2012) were in line
with  the  findings  from  our  review,  as  many  of  the  studies  they
reported were included in our analyses.

A U T H O R S '   C O N C L U S I O N S

Implications for practice

1. For people with schizophrenia

Asenapine appears to be a promising atypical antipsychotic. There
is  some,  albeit  preliminary,  evidence  of  improvement  in  positive
symptoms  (delusions  and  hallucinations),  negative  symptoms
(which may include reduced affect, and reduced motivation), and
depressive  symptoms.  However  due  to  the  limited  quality  and
quantity of evidence, it remains difficult to recommend the use of
asenapine  for  schizophrenia.  There  are  missing  trials  which  may
add to the argument about which the study authors have not been
forthcoming.

2. For clinicians

The dosage used by five of the included studies adhered to the FDA
recommendations  (5  -  10  mg  BID)  (FDA  2013),  suggesting  clinical
applicability of the findings. At present it is not possible to be fully
confident  that  asenapine  is  really  suitable  for  the  treatment  of
people  with  schizophrenia,  as  ongoing  trials  are  not  complete  or
data are missing from important studies that are completed. It is
certainly impossible to make conclusive judgements on the long-
term effects of asenapine.

3. For managers/policy makers

The availability of asenapine is still relatively limited. We have no
real  service  data  or  economics  to  work  with.  For  such  a  drug  to
enter clinical practice, we suggest that such information should be
routinely produced as part of the output of evaluative studies.

Implications for research

1. General

Future studies investigating the clinical effects of asenapine need
to be well reported, and adhere to the CONSORT statement (Moher
2010). All outcomes from all trials must be easily accessible and all
data should be reported as numbers.

2. Specific

2.1 Reviews

This review will require updates in the future as, at present, there
are two studies awaiting classification, and one ongoing trial.

Five of our included studies involved an additional active treatment
arm.  As  detailed  elsewhere,  these  data  were  excluded  from  this
review  but  could  be  used  elsewhere  (Table  1).  However  it  is
important to identify the comparative effects of asenapine to other
antipsychotic agents. There are two Cochrane Systematic Reviews
currently underway comparing asenapine to typical antipsychotics
(Kumar 2012) and other atypical antipsychotics Preda 2010).

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

25

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

2.2 Trials

We  identify  a  great  need  for  larger-scale,  longer-term  and  more
independent randomised controlled trials investigating the clinical
effects  and  safety  of  asenapine.  Future  long-term  clinical  trials
should  clearly  describe  the  random  sequence  generation  and
concealment of allocation, as well as the thoroughly-tested double-
blinding procedures, whilst recruiting a sample size that provides
high statistical power. Outcome measures that should additionally
be  investigated  include  relapse,  functioning,  service  utilisation,
quality  of  life/satisfaction  with  care,  and  economic  costs.  There
are,  however,  studies  underway  or  completed  that  may  add
enough to this review to allow more firm conclusions to be drawn
(NCT00156091; NCT01098110; NCT01617187).

A C K N O W L E D G E M E N T S

The  Cochrane  Schizophrenia  Group  Editorial  Base  in  Nottingham
produces  and  maintains  standard  text  for  use  in  the  Methods
section of their reviews. We have used this text as the basis of what
appears here and adapted it as required.

Additionally, we would like to acknowledge our use of RevMAN HAL
software to aid the write up of results.

The  search  term  was  developed  by  the  Farhad  Shokraneh  (Trials
Search Coordinator of the Cochrane Schizophrenia Group) and the
contact authors of this protocol (Ajit Kumar & Manoj Narayan).

We would like to thank Professor Clive Adams (Coordinating Editor
of  the  Cochrane  Schizophrenia  Group,  Faculty  of  Medicine  and
Health  Sciences,  University  of  Nottingham)  for  providing  advice,
guidance and support throughout the undertaking of this review.
We  would  also  like  to  thank  Claire  Irving  for  providing  further
editorial  support  and  Tom  Barton  for  peer  review.  The  team
would  also  like  to  acknowledge  Stephanie  Miers'  and  Iram  Jalil's
contribution to the development of this review. Stephanie provided
a  methodological,  clinical  and  policy  perspective,  also  helped
with  writing  the  abstract,  background  and  discussion  sections.
Iram  helped  with  screening  retrieved  papers  against  eligibility
criteria, extracting qualitative data from papers, provided notes for
background section.

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

26

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

R E F E R E N C E S

References to studies included in this review

Chapel 2009 {published data only}

*  Chapel S, Hutmacher MM, Haig G, Bockbrader H, De Greef R,
Preskorn SH, et al. Exposure-response analysis in patients
with schizophrenia to assess the effect of asenapine
on QTc prolongation. Journal of Clinical Pharmacology
2009;49(11):1297-308.

Preskorn AS, Chapel S, Panagides J. Effect of asenapine
versus quetiapine and placebo on QTc interval in patients
with schizophrenia. European Neuropsychopharmacology
2007;17(Suppl 4):S453.

Preskorn SH, Chapel S, Panagides J. Effects of asenapine
versus placebo on QTc interval in patients with schizophrenia.
American Psychiatric Association, 161st Annual Meeting, May
3-8, 2008, Washington, DC. 2008.

Kane 2010 {published data only}

Citrome L. Asenapine for schizophrenia and bipolar disorder: a
review of the efficacy and safety profile for this newly approved
sublingually absorbed second-generation antipsychotic. The
International Journal of Clinical Practice 2009;63:1762-84.

Kane J, Zhao J, Cohen M, Panagides J. Efficacy and safety of
asenapine in patients with acute exacerbation of schizophrenia.
Schizophrenia Research 2008;98:14.

*  Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and
safety of asenapine in a placebo- and haloperidol-controlled
trial in patients with acute exacerbation of schizophrenia.
Journal of Clinical Psychopharmacology 2010;30(2):106-15.

Kane JM, Zhao J, Cohen M, Panagides J. Efficacy and safety
of asenapine in patients with acute schizophrenia. American
Psychiatric Association, 161st Annual Meeting, May 3-8, 2008,
Washington, DC. 2008.

NCT00156104. A multicenter, randomized, double-blind, fixed-
dose, 6-week trial of the efficacy and safety of asenapine
compared with placebo using haloperidol positive control in
subjects with an acute exacerbation of schizophrenia. http://
clinicaltrials.gov/show/NCT00156104 2008.

Potkin SG, Kane JM, Emsley RA, Naber D, Panagides J.
Asenapine in schizophrenia: an overview of clinical trials in the
Olympia program. Society of Biological Psychiatry, 63rd Annual
Scientific Convention and Meeting, May 1-3, 2008, Washington,
DC. 2008.

Kane 2011 {published data only}

*  Kane JM, Mackle M, Snow-Adami L, Zhao J, Szegedi A,
Panagides J. A randomized placebo-controlled trial of
asenapine for the prevention of relapse of schizophrenia
after long-term treatment. Journal of Clinical Psychiatry
2011;72(3):349-55.

Kane JM, Mackle M, Snow-Adami L, Zhao J, Szegedi A,
Panagides J. Double-blind, placebo-controlled trial
of asenapine in prevention of relapse after long-term

treatment of schizophrenia. International Journal of
Neuropsychopharmacology 2010;13:223.

Mackle M, Snow-Adami L, Zhao J, Szegedi A, Panagides J.
Double-blind, placebo-controlled trial of asenapine
in prevention of relapse after long-term treatment of
schizophrenia. European Neuropsychopharmacology. 2009;
Vol. Conference Start: 20090912 Conference End: 20090916.
Conference Publication:, issue Suppl 3:pp S543.

NCT00150176. A randomized, placebo-controlled, double-blind
trial of asenapine in the prevention of relapse after long-term
treatment of schizophrenia. http://clinicaltrials.gov/show/
NCT00150176 2005.

NCT00151424 {published data only}

Citrome L. Asenapine for schizophrenia and bipolar disorder: A
review of the efficacy and safety profile for this newly approved
sublingually absorbed second-generation antipsychotic. The
International Journal of Clinical Practice 2009;63:1762-84.

*  NCT00151424. A multicenter, randomized, double-blind,
flexible-dose, 6-week trial of the efficacy and safety of
asenapine compared with placebo using olanzapine positive
control in subjects with an acute exacerbation of schizophrenia.
http://clinicaltrials.gov/show/NCT00151424 2005.

Potkin SG, Kane JM, Emsley RA, Naber D, Panagides J.
Asenapine in schizophrenia: an overview of clinical trials in the
Olympia program. Society of Biological Psychiatry, 63rd Annual
Scientific Convention and Meeting, May 1-3, 2008, Washington,
DC. 2008.

Szegedi A, Verweij P, Van Duijnhoven W, Mackle M, Cazorla P,
Fennema H. Meta-analyses of the efficacy of asenapine for
acute schizophrenia: comparisons with placebo and other
antipsychotics. Journal of Clinical Psychiatry 2012;73:1533-40.

NCT00156117 {published data only}

Citrome L. Asenapine for schizophrenia and bipolar disorder: a
review of the efficacy and safety profile for this newly approved
sublingually absorbed second-generation antipsychotic. The
International Journal of Clinical Practice 2009;63:1762-84.

Leucht S, Zhao J. Early improvement as a predictor of treatment
response and remission in patients with acute schizophrenia:
effects of asenapine. European Neuropsychopharmacology
2013; Vol. 23:S470.

Leucht S, Zhao J. Early improvement as a predictor of treatment
response and remission in patients with schizophrenia: a
pooled, post-hoc analysis from the asenapine development
program. Journal of Psychopharmacology 2014;28:387-94.

NCT00156117. A multicenter, randomized, double-blind, fixed-
dose, 6-week trial of the efficacy and safety of asenapine
compared with placebo using olanzapine positive control in
subjects with an acute exacerbation of schizophrenia. http://
clinicaltrials.gov/show/NCT00156117 2005.

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

27

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Potkin SG, Kane JM, Emsley RA, Naber D, Panagides J.
Asenapine in schizophrenia: an overview of clinical trials in the
Olympia program. Society of Biological Psychiatry, 63rd Annual
Scientific Convention and Meeting, May 1-3, 2008, Washington,
DC. 2008.

Szegedi A, Verweij P, van Duijnhoven W, Mackle M, Cazorla P,
Fennema H. Meta-analyses of the efficacy of asenapine for
acute schizophrenia: comparisons with placebo and other
antipsychotics. Journal of Clinical Psychiatry 2012;73:1533-40.

Potkin 2007 {published data only}

Citrome L. Asenapine for schizophrenia and bipolar disorder: a
review of the efficacy and safety profile for this newly approved
sublingually absorbed second-generation antipsychotic. The
International Journal of Clinical Practice 2009;63:1762-84.

Fleming K, Potkin SG, Binneman B, Keller D, Alphs L,
Panagides J. Effects of asenapine on cognitive function in acute
schizophrenia: a placebo- and risperidone-controlled trial.
European Neuropsychopharmacology 2007;17(Suppl 4):S466.

Potkin SG, Cohen M, Panagides J, Jina AS. Asenapine
efficacy in acute schizophrenia: a randomized, placebo-
and risperidone-controlled trial. International Journal of
Neuropsychopharmacology 2006;9(Suppl 1):S275.

Potkin SG, Cohen M, Panagides J, Jina AS. Asenapine efficacy,
safety, and tolerability in the treatment of acute schizophrenia:
a randomized, placebo- and risperidone-controlled trial.
Biological Psychiatry 2006;59(8 Suppl):154S.

Potkin SG, Cohen M, Panagides J, Jina AS. Asenapine safety
and tolerability during acute schizophrenia: a placebo- and
risperidone controlled trial. Proceedings of the 159th Annual
Meeting of the American Psychiatric Association; 2006 May
20-25, Toronto, Canada. 2006.

Potkin SG, Kane JM, Emsley RA, Naber D, Panagides J.
Asenapine in schizophrenia: an overview of clinical trials in the
Olympia program. Society of Biological Psychiatry, 63rd Annual
Scientific Convention and Meeting, May 1-3, 2008, Washington,
DC. 2008.

Potkin S, Fleming K, Binneman B, Keller DS, Alphs L,
Panagides J. Asenapine improves cognitive function in acute
schizophrenia: a placebo- and risperidone- controlled trial.
Proceedings of the 160th Annual Meeting of the American
Psychiatric Association; 2007 May 19-24; San Diego, CA. 2007.

Potkin S, Fleming K, Binneman B, Keller S. Asenapine
cognitive function effects in acute schizophrenia: a placebo-
and risperidone-controlled trial. Schizophrenia Bulletin
2007;33(2):454.

Potkin SG, Cohen M, Baker RA, Jina AS, Nettler S, Alphs L, et
al. Asenapine, a novel psychotherapeutic agent with efficacy
in positive and negative symptoms during acute episodes
of schizophrenia: a randomized, placebo- and risperidone-
controlled trial. Neuropsychopharmacology 2005;30(Suppl
1):S112-3.

Potkin SG, Cohen M, Jina AS, Nettler S, Alphs L, Panagides J.
Asenapine efficacy during acute episodes of schizophrenia:
a randomized placebo and risperidone controlled trial.
Proceedings of the 44th Annual Meeting of the American College
of Neuro-Psychopharmacology; 2005 Dec 11-15; Waikoloa,
Hawaii. 2005.

Potkin SG, Cohen M, Jina AS, Nettler S, Alphs L, Panagides J.
Asenapine efficacy during acute episodes of schizophrenia: a
randomized placebo- and risperidone-controlled trial. 13th
Biennial Winter Workshop on Schizophrenia Research, February
4-10, 2006, Davos, Switzerland. 2006.

*  Potkin SG, Cohen M, Panagides J. Efficacy and tolerability
of asenapine in acute schizophrenia: a placebo- and
risperidone-controlled trial. Journal of Clinical Psychiatry
2007;68(10):1492-500.

Potkin SG, Cohen M, Panagides J, Jina A. Asenapine safety and
tolerability in acute schizophrenia: a placebo- and risperidone-
controlled trial. European Neuropsychopharmacology
2006;16(Suppl 4):S401.

References to studies excluded from this review

Castle 2013 {published data only}

Castle D, Jensen JKS. Management of depressive symptoms in
schizophrenia: a pooled, post hoc analysis from the asenapine
development program. (Manuscript submitted for peer-review,
journal not currently known).

Castle D, Jensen JKS. Management of depressive symptoms in
schizophrenia: a pooled, post hoc analysis from the asenapine
development program. European Neuropsychopharmacology
2013;23:S502-3.

Cazorla 2008 {published data only}

Cazorla P, Panagides J, Alphs L, Kouassi A, Buchanan R.
Asenapine versus olanzapine in patients with predominant,
persistent negative symptoms of schizophrenia. American
Psychiatric Association, 161st Annual Meeting, May 3-8, 2008,
Washington, DC. 2008.

Cazorla P, Panagides J, Alphs L, Kouassi A, Buchanan R,
Szegedi A. Asenapine versus olanzapine in patients with
predominant, persistent negative symptoms of schizophrenia.
International Journal of Neuropsychopharmacology
2008;11(Suppl 1):138-9.

NCT00156065 {published data only}

Meltzer H, Cohen M, Snow-Adami L, Mackle M, Zhao J,
Szegedi A, et al. Long-term safety and maintenance of effect of
asenapine in patients with acute exacerbation of schizophrenia.
European Neuropsychopharmacology 2009;19:S536-S537.

NCT00156065. A multicenter, double-blind, flexible dose, long-
term extension trial of the safety and maintenance of effect
of asenapine using a haloperidol positive control in subjects
who complete protocol 041023. http://clinicaltrials.gov/show/
NCT00156065 2005.

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

28

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT01142596 {published data only}

Altman 1996

NCT01142596. Long-term extension trial of asenapine
in subjects with schizophrenia (study p06125). http://
clinicaltrials.gov/show/NCT01142596 2010.

NCT01190254 {published data only}

NCT01190254. Fixed dose efficacy and safety study of asenapine
for the treatment of schizophrenia in adolescents (study
p05896). http://clinicaltrials.gov/show/NCT01190254 2010.

The National Horizon Scanning Centre 2010 {published data
only}

The National Horizon Scanning Centre. Asenapine (Saphris)
for schizophrenia. The National Horizon Scanning Centre,
Department of Public Health and Epidemiology, University of
Birmingham. University of Birmingham, 2010.

Altman DG, Bland JM. Detecting skewness from summary
information. BMJ 1996;313(7066):1200.

Andreasen 1999

Andreasen NC. A unitary model of schizophrenia. Bleuler's
"fragmented phrene" as schizencephaly. Archives of General
Psychiatry 1999;56:781-7.

Ayuso-Mateos 2006

Ayuso-Mateos JL. Global burden of schizophrenia in the
year 2000. http://www.who.int/healthinfo/statistics/
bod_schizophrenia.pdf 2006.

Barnes 1989

Barnes TR. A rating scale for drug-induced akathisia. The British
Journal of Psychiatry 1989;154:672-6.

References to studies awaiting assessment

Bishara 2009

NCT00156091 {published data only}

NCT00156091. A multicenter, double-blind, flexible-dose, long-
term extension trial of the safety and maintenance of effect of
asenapine using olanzapine positive control in subjects who
complete protocols 041021/041022. http://clinicaltrials.gov/
show/NCT00156091 2005.

NCT01098110 {published data only}

Nct. 6-week trial of the efficacy and safety of asenapine
compared to placebo in subjects with an acute exacerbation of
schizophrenia (Study P06124). http://clinicaltrials.gov/show/
NCT01098110 2010.

References to ongoing studies

NCT01617187 {published data only}

NCT01617187. A study of the efficacy and safety of asenapine
in participants with an acute exacerbation of schizophrenia
(p05688 am2). http://clinicaltrials.gov/show/NCT01617187
2012.

Additional references

Abi-Dargham 2004

Abi-Dargham A. Do we still believe in the dopamine hypothesis?
New data bring new evidence. International Journal of
Neuropsychopharmacology 2004;7:S1-5.

Adams 2013

Adams CE, Bergman H, Irving CB, Lawrie S. Haloperidol versus
placebo for schizophrenia. Cochrane Database of Systematic
Reviews 2013, Issue 11. [DOI: 10.1002/14651858.CD003082.pub3;
CD003082]

Addington 1993

Addington D, Addington J, Maticka-Tyndale E. Assessing
depression in schizophrenia: the Calgary Depression Scale. The
British Journal of Psychiatry 1993;163:39-44.

Bishara D, Taylor D. Asenapine monotherapy in the acute
treatment of both schizophrenia and bipolar I disorder.
Neuropsychiatric Disease and Treatment 2009;5:483-90.

Bland 1997

Bland JM. Statistics notes. Trials randomised in clusters. BMJ
1997;315:600.

Boissel 1999

Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F,
Buyse M, et al. The problem of therapeutic efficacy indices.
3. Comparison of the indices and their use [Apercu sur la
problematique des indices d'efficacité thérapeutique, 3:
comparaison des indices et utilisation. Groupe d'Etude des
Indices D'efficacité]. Thérapie 1999;54(4):405-11. [PUBMED:
10667106]

Campbell 1999

Campbell M, Young PI, Bateman DN, Smith JM, Thomas SHL.
The use of atypical antipsychotics in the management of
schizophrenia. British Journal of Clinical Pharmacology
1999;47:13-22.

Citrome 2009

Citrome L. Asenapine for schizophrenia and bipolar disorder: a
review of the efficacy and safety profile for this newly approved
sublingually absorbed second-generation antipsychotic. The
International Journal of Clinical Practice 2009;63:1762-84.

Crow 1980

Crow TJ. Molecular pathology of schizophrenia: more than one
disease process?. British Medical Journal 1980;280:66-8.

Davis 2003

Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy
of second-generation antipsychotics. Archives of General
Psychiatry 2003;60:553-64.

Deeks 2000

Deeks J. Issues in the selection for meta-analyses of binary
data. Proceedings of the 8th International Cochrane

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

29

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Colloquium; 2000 Oct 25-28; Cape Town. Cape Town: The
Cochrane Collaboration, 2000.

provide accurate results. Journal of Clinical Epidemiology
2006;59(7):7-10.

Deeks 2011

Gulliford 1999

Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing
data and undertaking meta-analyses. In: Higgins JPT, Green
S (editors). Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 (updated March 2011). The
Cochrane Collaboration, 2011. Available from www.cochrane-
handbook.org.

Divine 1992

Divine GW, Brown JT, Frazier LM. The unit of analysis error in
studies about physicians' patient care behavior. Journal of
General Internal Medicine 1992;7(6):623-9.

Donner 2002

Gulliford MC. Components of variance and intraclass
correlations for the design of community-based surveys and
intervention studies: data from the Health Survey for England
1994. American Journal of Epidemiology 1999;149:876-83.

Guy 1976

Guy W. ECDEU Asessment Manual for Psychopharmacology.
Rockville, 1976.

Hedlund 2004

Hedlund PB, Sutcliffe JG. Functional, molecular and
pharmacological advances in 5-HT7 receptor research. Trends in
Pharmacological Sciences 2004;25:481-6.

Donner A, Klar N. Issues in the meta-analysis of cluster
randomized trials. Statistics in Medicine 2002;21:2971-80.

Higgins 2003

Duggan 2005

Duggan L, Fenton M, Rathbone J, Dardennes R, El-
Dosoky A, Indran S. Olanzapine for schizophrenia. Cochrane
Database of Systematic Reviews 2005, Issue 2. [DOI:
10.1002/14651858.CD001359.pub2; CD001359]

Egger 1997

Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis
detected by a simple, graphical test. BMJ 1997;315:629-34.

Elbourne 2002

Elbourne D, Altman DG, Higgins JPT, Curtina F,
Worthingtond HV, Vaile A. Meta-analyses involving cross-
over trials: methodological issues. International Journal of
Epidemiology 2002;31(1):140-9.

EMA 2014

European Medicines Agency. Sycrest: EPAR - Product
information. http://www.ema.europa.eu/docs/en_
 GB/document_ library/EPAR_ -_ Product_ Information/
human/001177/WC500096895.pdf 2014.

Emsley 2013

Emsley R, Fleischhacker WW. Is the ongoing use of placebo in
relapse-prevention clinical trials in schizophrenia justified?.
Schizophrenia Research 2013;150:427-33.

FDA 2013

Food, Drug Administration. Saphris (asenapine) prescribing
information. http://www.accessdata.fda.gov/drugsatfda_ docs/
label/2013/022117s012lbl.pdf 2013.

Fioravanti 2005

Fioravanti M, Carlone O, Vitale B, Cinti ME, Clare L. A meta-
analysis of cognitive deficits in adults with a diagnosis of
schizophrenia. Neuropsychology Review 2005;15:73-95.

Furukawa 2006

Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N.
Imputing missing standard deviations in meta-analyses can

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring
inconsistency in meta-analyses. BMJ 2003;327:557-60.

Higgins 2011a

Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies
and collecting data. In: Higgins JPT, Green S (editors), Cochrane
Handbook for Systematic Reviews of Interventions Version 5.1.0
(updated March 2011). The Cochrane Collaboration, 2011.
Available from www.cochrane-handbook.org..

Higgins 2011b

Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8:
Assessing risk of bias in included studies. In: Higgins JPT,
Green S (editors). Cochrane Handbook for Systematic Reviews
of Interventions Version 5.1.0 (updated March 2011). The
Cochrane Collaboration, 2011. Available from www.cochrane-
handbook.org.

Higgins 2011c

Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special
topics in statistics. In: Higgins JPT, Green S (editors), Cochrane
Handbook for Systematic Reviews of Interventions Version 5.1.0
(updated March 2011). The Cochrane Collaboration, 2011..
Available from www.cochrane-handbook.org.

Hutton 2009

Hutton JL. Number needed to treat and number needed to
harm are not the best way to report and assess the results
of randomised clinical trials. British Journal of Haematology
2009;146(1):27-30.

Kay 1986

Kay SR, Opler LA, Fiszbein A. Positive and Negative Syndrome
Scale (PANSS) Manual. North Tonawanda, NY: Multi-Health
Systems, 1986.

Kay 1987

Kay SR, Fiszbein A, Opfer LA. The positive and negative
syndrome scale (PANSS) for schizophrenia. Schizophrenia
Bulletin 1987;13:261-76.

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

30

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Kohler 2007

Marshall 2000

Kohler S, Van Os J, De Graaf R, Vollebergh W, Verhey F,
Krabbendam L. Psychosis risk as a function of age at onset.
Social Psychiatry and Psychiatric Epidemiology 2007;4:288-94.

Kumar 2012

Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M.
Unpublished rating scales: a major source of bias in randomised
controlled trials of treatments for schizophrenia. British Journal
of Psychiatry 2000;176:249-52.

Kumar A, Narayan M, Raja H, Mathen Manoj J. Asenapine
versus typical antipsychotics for schizophrenia. Cochrane
Database of Systematic Reviews 2012, Issue 11. [DOI:
10.1002/14651858.CD010230; CD010230]

McGrath 2008

McGrath J, Saha S, Chant D, Welham J. Schizophrenia: a
concise overview of incidence, prevalence, and mortality.
Epidemiological Reviews 2008;30:67-76.

Lankappa 2012

Meltzer 1999

Lankappa S, Gandhi R. Quetiapine versus placebo for
schizophrenia. Cochrane Database of Systematic Reviews 2012,
Issue 7. [DOI: 10.1002/14651858.CD009935; CD009935]

Meltzer HY. The role of serotonin in antipsychotic drug action.
Neuropsychopharmacology 1999;21:106S-15S.

Moher 2010

Lehmann 1997

Lehmann HE, Ban TA. The history of the psychopharmacology
of schizophrenia. Canadian Journal of Psychiatry
1997;42:152-62.

Moher D, Hopewell S, Schulz KF, Montori V, Gotzsche PC,
Devereaux PJ, et al. CONSORT 2010 explanation and
elaboration: updated guidelines for reporting parallel group
randomised trials. BMJ 2010;340:c869.

Leon 2006

Muench 2010

Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG,
Archer GE, Chartier K. Attrition in randomized controlled clinical
trials: methodological issues in psychopharmacology. Biological
Psychiatry 2006;59(11):1001-5. [PUBMED: 16905632]

Leucht 2005

Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR.
What does the PANSS mean?. Schizophrenia Research
2005;79(2-3):231-8. [PUBMED: 15982856]

Leucht 2013

Leucht S, Zhao J. Early improvement as a predictor of treatment
response and remission in patients with acute schizophrenia:
effects of asenapine. European Neuropsychopharmacology
2013; Vol. 23:S470.

Muench J, Hamer AN. Adverse effects of antipsychotic
medications. American Family Physician 2010;81:617-22.

Munetz 1988

Munetz MR, Benjamin S. How to examine patients using the
Abnormal Involuntary Movement Scale. Hospital & Community
Psychiatry 1988;39:1172-7.

Nicholson 1983

Nicholson AN. Antihistamines and sedation. The Lancet
1983;322:211-2.

Overall 1962

Overall JE, Gorham DR. The brief psychiatric rating scale.
Psychological Reports 1962;10:799-812.

Leucht 2014

Preda 2010

Leucht S, Zhao J. Early improvement as a predictor of treatment
response and remission in patients with schizophrenia: a
pooled, post-hoc analysis from the asenapine development
program. Journal of Psychopharmacology 2014;28:387-94.

Preda A, Faziola L. Asenapine versus other atypical
antipsychotics for schizophrenia. Cochrane
Database of Systematic Reviews 2010, Issue 12. [DOI:
10.1002/14651858.CD008902; CD008902]

Liddle 1987

Rattehalli 2010

Liddle PF. The symptoms of chronic schizophrenia. A re-
examination of the positive-negative dichotomy. British Journal
of Psychiatry 1987;151:145-51.

Lieberman 2004

Lieberman JA. Managing anticholinergic side effects. The
Primary Care Companion to the Journal of Clinical Psychiatry
2004;6:20-3.

Rattehalli Ranganath D, Jayaram Mahesh B, Smith M.
Risperidone versus placebo for schizophrenia. Cochrane
Database of Systematic Reviews 2010, Issue 1. [DOI:
10.1002/14651858.CD006918.pub2; CD006918]

Saha 2005

Saha S, Chant D, Welham J, McGrath J. A systematic review of
the prevalence of schizophrenia. PLoS Medicine 2005;2:0413-33.

Marder 1997

Schünemann 2011

Marder SR, Davis JM, Chouinard G. The effects of risperidone
on the five dimensions of schizophrenia derived by factor
analysis: Combined results of the North American trials. Journal
of Clinical Psychiatry 1997;58:538-46.

Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ,
Glasziou P, et al. Chapter 12: Interpreting results and drawing
conclusions. In: Higgins JPT, Green S (editors), Cochrane
Handbook for Systematic Reviews of Interventions Version 5.1.0
(updated March 2011). The Cochrane Collaboration, 2011.

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

31

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Available from www.cochrane-handbook.org. The Cochrane
Collaboration, 2011.

Shahid 2009

Shahid M, Walker GB, Zorn SH, Wong E. Asenapine: a novel
psychopharmacologic agent with a unique human receptor
signature. Journal of Psychopharmacology 2009;23:65-73.

Szegedi 2012

Szegedi A, Verweij P, van Duijnhoven W, Mackle M, Cazorla P,
Fennema H. Meta-analyses of the efficacy of asenapine for
acute schizophrenia: Comparisons with placebo and other
antipsychotics. Journal of Clinical Psychiatry 2012;73:1533-40.

Ukoumunne 1999

Simpson 1970

Simpson GM, Angus JWS. A rating scale for extrapyramidal side
effects. Acta Psychiatrica Scandinavica 1970;45:11-9.

Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ.
Methods for evaluating area-wide and organisation-based
intervention in health and health care: a systematic review.
Health Technology Assessment 1999;3(5):1-75.

Siris 2000

van Os 2008

Siris SG. Depression in schizophrenia: perspective in the era of
"atypical" antipsychotic agents. American Journal of Psychiatry
2000;157:1379-89.

Van Os J, Rutten BPF, Poulton R. Gene-environment interactions
in schizophrenia: review of epidemiological findings and future
directions. Schizophrenia Bulletin 2008;34:1066-82.

Sterne 2011

Walker 2004

Walker E, Kestler L, Bollini A, Hochman KM. Schizophrenia:
etiology and course. Annual Review of Psychology
2004;55:401-30.

WHO 2014

World Health Organization. Schizophrenia. http://www.who.int/
mental_health/management/schizophrenia/en/ 2014.

Worrel 2000

Worrel JA, Marken PA, Beckman SE, Ruehter VL. Atypical
antipsychotic agents: a critical review. American Journal of
Health-System Pharmacy 2000;57:238-55.

Xia 2009

Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H,
et al. Loss to outcomes stakeholder survey: the LOSS study.
Psychiatric Bulletin 2009;33(7):254-7.

* Indicates the major publication for the study

Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing
reporting biases. In: Higgins JPT, Green S (editors). Cochrane
Handbook for Systematic Reviews of Intervention. Version 5.1.0
(updated March 2011). The Cochrane Collaboration, 2011.
Available from www.cochrane-handbook.org.

Stoner 2012

Stoner SC, Pace HA. Asenapine: a clinical review of a
second-generation antipsychotic. Clinical Therapeutics
2012;34:1023-40.

Storosum 1998

Storosum JG, Elferink AJA, Van Zwieten BJ. Schizophrenia:
do we really need placebo-controlled studies?. European
Neuropsychopharmacology 1998;8:279-86.

Svensson 2003

Svensson TH. a-Adrenoceptor modulation hypothesis
of antipsychotic atypicality. Progress in Neuro-
Psychopharmacology & Biological Psychiatry 2003;27:1145-58.

Sycrest 2014

Sycrest. Sycrest patient information leaflet. http://
www.sycrest.co.uk/siteuploads/PIL.pdf 2014.

C H A R A C T E R I S T I C S   O F   S T U D I E S

Characteristics of included studies [ordered by study ID]

Chapel 2009 

Methods

Allocation: random allocation.

Blindness: double-blind.

Duration: 16 days.

Funding: Organon - a part of Schering-Plough Corporation and Pfizer Inc.

Country: six sites in the United States and one site in South Africa.

Participants

Diagnosis: schizophrenia or schizoaffective disorder (DSM-IV).

N: 148.

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

32

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Chapel 2009  (Continued)

Age: 18 to 65 years (mean age 42.6 years).

Sex: 114 men and 34 women.

History: no details.

Cochrane Database of Systematic Reviews

Interventions

1. Asenapine: 5 mg for 10 days followed by 10 mg for six days (BID) N = 38.

2. Asenapine: 15 mg for 10 days followed by 20 mg for six days (BID) N = 38.

3. Quetiapine: 375 mg for 16 days N = 37.

4. Placebo: for 16 days N=35.

Outcomes

Usable:

Adverse effects (QTc prolongation-incidence, ECG, blood samples).

Leaving study early.

Unusable:

Adverse effects (QTc average change; and blood sample data not fully reported for placebo; weight: on-
ly reported baseline data).

Did not use data for quetiapine trial arm.

Authors' judgement

Support for judgement

Unclear risk

"Randomised" - but no further details provided.

Unclear risk

No details provided.

Unclear risk

"Double-blind" - but no further description provided.

Unclear risk

No details provided.

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

From 148 participants, "Twenty- three patients withdrew before day 10 (eight
owing to adverse events), and 11 additional patients withdrew before day 16
(one owing to an adverse event)".

No description of how the loss was addressed in the analysis.

Selective reporting (re-
porting bias)

High risk

Endpoint population characteristics not provided for QTc and weight.

Other bias

High risk

"Financial support for this work was provided by Pfizer, Inc and Schering -
Plough".

The authors were employed by Schering- Plough or Pfizer, Inc at the time of
trial.

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

33

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Kane 2010 

Methods

Allocation: random allocation; (1:1:1:1 distribution).

Blindness: double-blind.

Duration: six-week trial.

Funding: sponsored by Organon, Pfizer Inc.

Country: 43 sites in five countries (United States, Russia, India, Romania & Canada).

Participants

Diagnosis: acute exacerbated schizophrenia (DSM–IV-TR).

91% diagnosis of paranoid schizophrenia.

N: 458.

Age: mean age range – 37 to 40 years.

Sex: 52% male.

History: mean age at onset of illness is 26 years (range 6 - 60 years).

50% exhibited current or past prominent negative symptoms.

54% had four or more previous episodes of acute schizophrenia requiring hospitalisation.

29% had a history of one or more suicide attempts.

Majority of patients in each treatment group had a history of smoking within the past six months.

Interventions

1. Asenapine (5 mg, BID) N = 114.

2. Asenapine (10 mg, BID) N = 106.

3. Placebo N = 123.

4. Haloperidol (4 mg, BID) N = 115.

Outcomes

Usable

Global State (CGI-S, CGI-I; concomitant drugs).

Mental State (change in PANSS total score; CDSS).

Adverse effects (AIMS, BAS, SAS; fasting glucose; prolactin; weight; deaths).

Leaving the study early.

Unusable

Mental state (ISST - no data reported).

Cognitive functioning (CNS vital signs - no data reported).

Adverse effects (weekly lab assessments; ECG - insufficient data reported).

Quality of life (QLS, Q-LSQ, PETIT - no data reported).

Readiness to discharge (no data reported).

Notes

Did not use data for haloperidol trial arm.

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

34

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kane 2010  (Continued)

Cochrane Database of Systematic Reviews

For follow up: patients who complete six-week trial given option to continue for 52-week trial
(NCT00156065).

Authors' judgement

Support for judgement

Unclear risk

"Randomised" - but no further details provided.

Unclear risk

No details provided.

Unclear risk

"Double-blind" - but no further description provided.

Unclear risk

No details provided.

High risk

"In all, 272 patients (61% of the ITT population) completed the study".

ITT population and LOCF and MMRM method of analysis were used.

Low risk

Most outcomes reported with mean and standard deviations.

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Selective reporting (re-
porting bias)

Other bias

High risk

Four of the authors were employed at Merck or Pfizer, Inc at the time of trial.
The lead author was affiliated with Bristol - Myers Squibb, Otsuka Pharmaceu-
ticals, Eli- Lilly and Co, Janssen, Johnson & Johnson PRD, MDS Pharma Ser-
vices, Pfizer Inc, Solvay Pharmaceutical Inc, Wyeth Pharmaceuticals, Lund-
beck, Vanda Pharmaceuticals, Astra- Zeneca, Cephalon, Dainippon Sumitomo,
Glaxo Smith Kline, Intracellular therapeutics, PGxHealth, Proteus, Takeda and
Schering- Plough.

"....funded by Schering- Plough Corporation, now Merck & Co, Inc, (Whitehouse
Station, NJ, USA)".

Kane 2011 

Methods

Allocation: random allocation.

Blindness: double-blind.

Duration: 52-week extended trial. Two phases: 26 weeks of open label treatment of asenapine; 26
weeks of double-blind treatment (where they continued with asenapine or were switched to placebo).

Funding: Merck

Country: United States, Russian Federation, Ukraine, India, Latvia and Croatia.

Participants

Diagnosis: schizophrenia (DSM-IV-TR)

N: 386

Age: range 18 to 78 years.

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

35

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Kane 2011  (Continued)

Cochrane Database of Systematic Reviews

Sex: asenapine men (N = 105), asenapine women (N = 89), placebo men (N = 116), placebo women (N =
76).

History: more than one prior acute schizophrenia episode during the preceding three years and schizo-
phrenia requiring continuous anti-psychotic treatment for more than one year preceding screening.

Interventions

1. Asenapine (10 mg BID) N = 194

2. Placebo N = 192

Outcomes

Usable:

Global State (CGI-S; relapse; concomitant drugs).

Mental State (PANSS total score, PANSS Marder factor scores; mood - CDSS).

Adverse effects (weight, incidence of EPS – AIMS, BAS, SAS).

Leaving the study early.

Unusable:

Global State (time to relapse/impending relapse - no data reported for asenapine reported).

Mental state (Modified ISST - no data reported).

Adverse effects (average change – no SDs reported for BAS, AIMS, SAS; ECG; hyperprolactinaemia).

Leaving the study early (time to early discontinuation – no average value reported for each group).

Subgroup analyses reported calculating incidence of concomitant medication used in patients who ex-
perienced relapse/impending relapse; not to be included in meta-analyses.

Authors' judgement

Support for judgement

Unclear risk

"Randomised" - but no further details provided.

Unclear risk

No details provided.

Low risk

"Double-blind".

"asenapine and placebo sublingual tablets were identical in appearance".

"neither patients nor sites were aware of the tablet identity".

Probably done.

Incidence of relapse: "Determination of relapse/impending relapse was based
on investigator judgement in 75%".

Possibility of biased judgement - high risk.

All other outcomes: no details provided - unclear risk.

Of 386 patients entered "only 207" completed the study.They used ITT popula-
tion.

"Period end point is the last non-missing post baseline assessment on or be-
fore last double blind dose date plus 3d".

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

High risk

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

36

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Kane 2011  (Continued)

Selective reporting (re-
porting bias)

This suggests that LOCF method of analysis was used.

High risk

Data for time to relapse reported only for placebo and not for asenapine.

No standard deviations reported for specific adverse effects.

Other bias

High risk

"This study was funded by Merck and Pfizer Inc".

All of the authors were either affiliated with or employed by Merck or Scher-
ing-Plough.

NCT00151424 

Methods

Allocation: random allocation.

Blindness: double-blind.

Duration: six-week trial

Funding: Organon.

Country: not provided.

Participants

Diagnosis: schizophrenia.

N: treated sample: 275.

Age: over 18 years old.

Sex: men and women.

History: patients currently experiencing acute exacerbation of schizophrenia.

Interventions

1. Asenapine (5 - 10 mg BID) N = 90.

2. Olanzapine (10 - 20 mg QD) N = 92.

3. Placebo N = 93.

Outcomes

Usable:

Adverse effects (EPS, deaths, weight gain).

Leaving the study early.

Unusable:

Global state (CGI-S, CGI-I - no data reported).

Mental state (anxiety, depression, suicidal thinking - no data reported; PANSS - odds ratios only, not
able to input to generic inverse variance without faulting - statistical advice being sought).

Cognitive functioning (no data reported).

Functioning (no data reported).

Adverse effects (EPS, laboratory parameters, vital signs, weight, ECGs - no data reported).

Quality of life (no data reported).

Readiness to discharge (no data reported).

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

37

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT00151424  (Continued)

Cochrane Database of Systematic Reviews

Notes

Three study authors contacted regarding further information about trial:

1. Prof. Potkin emailed twice, awaiting response.

2. Dr. Szegedi emailed once using Merck address, failed to deliver, unable to locate current email ad-
dress.

3. Prof. Leucht provided contact details of colleagues considered better suited to provide information,
awaiting response from provided contacts.

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Authors' judgement

Support for judgement

Unclear risk

"Randomised" - but no further details provided.

Unclear risk

No details provided.

Unclear risk

Double-blind - no further description.

Unclear risk

No details provided.

High risk

LOCF method was used for analysis.

Selective reporting (re-
porting bias)

High risk

No data reported for multiple outcomes: global state (CGI-S, CGI-I), mental
state (PANSS, anxiety, depression, suicidal thinking), cognitive functioning,
functioning, specific adverse events, quality of life, readiness to discharge.

Other bias

High risk

Sponsored by Organon and Pfizer Inc.

Unpublished trial.

NCT00156117 

Methods

Allocation: random allocation.

Blindness: double blind.

Duration: six-week trial.

Funding: Merck Sharp & Dohme Corp.

Country: not provided.

Participants

Diagnosis: schizophrenia.

N: ITT sample: 386.

Age: over 18 years old.

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

38

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

NCT00156117  (Continued)

Sex: men and women.

Cochrane Database of Systematic Reviews

History: currently suffering from an acute exacerbation of schizophrenia.

Interventions

1. Asenapine (5 mg BID) N = 102.

2. Asenapine (10 mg BID) N = 96.

3. Olanzapine (15 mg QD) N = 95.

4. Placebo N = 93.

Outcomes

Usable:

Mental state (PANSS).

Leaving study early

Unusable (no data reported):

Global state (CGI-S, CGI-I).

Mental state (PANSS, anxiety, suicidal thinking).

Cognitive functioning.

Functioning.

Adverse effects (EPS, laboratory parameters, vital signs, weight, ECGs).

Quality of life.

Readiness to discharge.

Notes

Four authors contacted regarding further information regarding trial:

1. Prof. Potkin emailed twice, awaiting response.

2. Dr. Szegedi emailed once using Merck address, failed to deliver, unable to locate current email ad-
dress.

3. Prof. Leucht graciously provided contact details of colleagues considered better suited to provide in-
formation, awaiting response from provided contacts.

4. Prof. Castle graciously provided manuscript submitted for peer review.

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 

Authors' judgement

Support for judgement

Unclear risk

"Randomised" - but no further details provided.

Unclear risk

No details provided.

Unclear risk

"Double-Blind (subject, caregiver, investigator, outcomes assessor)".

No further description.

Unclear risk

No details provided.

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

39

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT00156117  (Continued)

All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

Unclear risk

ITT sample was used for the study.

Selective reporting (re-
porting bias)

High risk

No data reported for multiple outcomes: global state (CGI-S, CGI-I), mental
state (PANSS, anxiety, suicidal thinking), cognitive functioning, functioning,
specific adverse events, quality of life, readiness to discharge.

Other bias

High risk

The study is funded by Schering-Plough.

Unpublished trial.

Potkin 2007 

Methods

Allocation: random allocation.

Blindness: double-blind; double-dummy design: asenapine patients also received placebo BID.

Duration: six-week trial.

Funding: Organon Pharmaceuticals Inc.; Pfizer Inc.

Country: 21 sites in United States.

Participants

Diagnosis: schizophrenia (DSM-IV); subtypes (including paranoid, disorganized, undifferentiated)

N: randomised 180*.

Age: over 18 years old.

Sex: ˜78% men, ˜22% women.

History: duration of present episode:

Up to one month: 34 (58%) asenapine, 39 (63%) placebo.

One to six months: 21 (36%) asenapine, 16 (26%) placebo.

Over six months: 3 (5%) asenapine, 6 (10%) placebo.

Not specified or not obtained: 1 (2%) asenapine, 1 (2%) placebo.

Interventions

1. Asenapine (5 mg BID - titrated) sublingual + oral placebo (BID) N = 59.

2. Placebo (BID) oral + sublingual placebo (BID) N = 62.

3. Risperidone (3 mg BID) oral + oral placebo (BID) N = 59.*

Outcomes

Usable:

Global State (use of concomitant drugs).

Adverse effects (ECG assessments, prolactin, glucose, incidence of QTc prolongation, sinus tachycardia,
weight gain).

Leaving the study early.

Unusable:

Global state (CGI-S - loss of data > 50%; adherence to trial - no data reported).

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

40

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Potkin 2007  (Continued)

Mental state (PANSS - loss of data > 50%).

Cognitive functioning (neurocognitive battery – no data reported).

Adverse effects (blood pressure, heart rate, temperature, respiratory rate, cholesterol, triglycerides,
QTc, weight gain – data without SDs, SEs or P values; EPS – data without SDs, SEs, or P values for BAS,
SAS, AIMS).

*Did not use risperidone trial arm.

Authors' judgement

Support for judgement

Unclear risk

"Randomised" - but no further details provided.

Unclear risk

No details provided.

Low risk

"Double-blind"

"In this double-dummy design, asenapine-treated patients also received oral
placebo BID...and patients in the placebo-control group received oral and sub-
lingual placebo BID".

Probably done.

Unclear risk

No details provided.

Notes

Risk of bias

Bias

Random sequence genera-
tion (selection bias)

Allocation concealment
(selection bias)

Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes

Blinding of outcome as-
sessment (detection bias) 
All outcomes

Incomplete outcome data
(attrition bias) 
All outcomes

High risk

Selective reporting (re-
porting bias)

High risk

"For the intention-to-treat population...the primary outcome measure (change
from baseline in PANSS total score with asenapine vs. placebo at end point
or last observation carried forward [LOCF]) was analysed using least-squares
means based on two-way analysis of variance, with treatment and center as
factors. For secondary outcome measures, similar comparisons were made for
asenapine versus placebo..."

Discontinuation rate > 50%; ITT population and LOCF method of analysis were
used.

No SDs reported for changes in PANSS total, positive, negative and general
psychopathology scores; changes in CGI-S scores; actual weight gain, changes
in total cholesterol, fasting triglycerides and QTc.

Only adverse events in ≧10% patients of any treatment group (of treated pop-
ulation) were reported.

Other bias

High risk

"Financial support for this trial was provided by Organon Pharmaceuticals USA
Inc".

Funded and supported by Organon Pharmaceuticals USA/International Inc.
and Pfizer Inc.

General abbreviations
BID - bis in die (twice daily)
CNS - Central nervous system
DSM-IV - Diagnostic and Statistical Manual - Fourth Edition
DSM-IV-TR - Diagnostic and Statistical Manual - Fourth Edition, Text Revision

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

41

 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

ECG - Electrocardiogram
EPS - Extrapyramidal symptoms
ITT - Intention–to–treat
LOCF - Last observation carried forward
MMRM - Mixed model of repeated measures
QD - quaque die (everyday)
SD - Standard deviation
SE - Standard error
Scales
AIMS - Abnormal involuntary movement scale
BAS - Barnes akathisia scale
CDSS - The Calgary depression scale for schizophrenia
CGI-I – Clinical global impression – Improvement scale
CGI-S – Clinical global impression – Severity scale
ISST – InterSePT scale for suicidal thinking
PANSS - Positive and negative syndrome scale
PETIT - Personal evaluation of transitions in treatment
QLS - The quality of life scale for schizophrenia
Q-LES-Q – Quality of life enjoyment and satisfaction questionnaire
Q-LSQ - Quality of life in depression scale
RDQ - Readiness to discharge questionnaire
SAS - Simpson-Angus Scale

Characteristics of excluded studies [ordered by study ID]

Study

Castle 2013

Reason for exclusion

Allocation: not randomised, pooled analysis of three asenapine vs. placebo RCTs (Potkin 2007;
Kane 2010; NCT00156117).

Cazorla 2008

Allocation: random allocation

Participants: adults (over 18 years old) diagnosed with schizophrenia.

Intervention: asenapine versus olanzapine; no placebo control.

NCT00156065

Allocation: random allocation

Participants: adults (over 18 years old) diagnosed with schizophrenia.

Intervention: asenapine 5 - 10 mg BID versus asenapine 5 - 10 mg plus placebo BID versus haloperi-
dol 2 - 8 mg BID; no placebo control.

NCT01142596

Allocation: random allocation

Participants: adults (over 20 years old) diagnosed with schizophrenia.

Intervention: asenapine 5 mg BID versus asenapine 10 mg BID; no placebo control.

NCT01190254

Allocation: random allocation

Participants: adolescents (12 to 18 years old) diagnosed with schizophrenia, not adults.

Allocation: not randomised; summary of information from clinical trials of asenapine.

The National Horizon Scan-
ning Centre 2010

BID - Bis in die (twice daily)
RCT - Randomised controlled trial.

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

42

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Characteristics of studies awaiting assessment [ordered by study ID]

NCT00156091 

Methods

Allocation: random allocation

Blindness: double-blind

Duration: 52-week trial

Funding: Merck Sharp & Dohme Corp.

Country: not provided

Participants

Diagnosis: schizophrenia (DSM-IV)

N: 260

Age: over 18 years old

Sex: men and women

History: no details

Interventions

1. Asenapine (5 or 10 mg BID)

Outcomes

2. Olanzapine (20 mg QD)

3. Placebo

Global State

Mental State (mean change in PANSS total score; CDSS).

Cognitive functioning

Functioning

Adverse effects (vital signs, EPS, ISST, weight, ECG, physical exams and lab tests).

Quality of life (QLS, Q-LES-Q, PETIT).

Notes

NCT00156091

NCT01098110 

Methods

Allocation: random allocation

Blindness: double-blind

Duration: six week trial

Funding: Schering - Plough

Country: not provided

Participants

Diagnosis: schizophrenia (DSM-IV)

N: 528

Age: 20-64 years

Sex: men and women

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

43

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT01098110  (Continued)

History: no details

Interventions

1. Asenapine (5 or 10 mg BID)

2. Olanzapine (20 mg QD)

3. Placebo

Outcomes

Notes

Mental state (change in PANSS total score)

NCT01098110

BID - bis in die (twice daily).
CDSS - The Calgary depression scale for schizophrenia.
DSM-IV - Diagnostic and Statistical Manual - fourth edition.
ECG - Electrocardiogram.
EPS - Extrapyramidal symptoms.
ISST – InterSePT scale for suicidal thinking.
PANSS - Positive and negative syndrome scale.
PETIT- Personal evaluation of transitions in treatment.
QD - quaque die (everyday).
Q-LES-Q – Quality of life enjoyment and satisfaction questionnaire.
QLS - The quality of life scale for schizophrenia.

Characteristics of ongoing studies [ordered by study ID]

NCT01617187 

Trial name or title

A study of the efficacy and safety of asenapine in participants with an acute exacerbation of schizo-
phrenia. NCT01617187

Methods

Allocation: random allocation

Blindness: double-blind

Duration: six-week trial

Funding: Merck

Country: Croatia & Ukraine

Participants

Diagnosis: schizophrenia (DSM-IV)

N: estimated 354

Age: over 18 years old

Sex: men and women

History: no details

Interventions

1. Asenapine (2.5 mg BID)

2. Asenapine (5 mg BID)

3. Placebo

4. Olanzapine (15 mg QD)

Outcomes

Mental State (Change in PANSS total score; number of participants with greater than or equal to
30% reduction)

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

44

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

NCT01617187  (Continued)

Global State (Change in CGI-S score).

Starting date

Study start date: December 2012.

Contact information

Toll Free Number: 1888-577-8839

Notes

BID - bis in die (twice daily).
CGI-S – Clinical global impression – Severity scale.
DSM-IV - Diagnostic and Statistical Manual - fourth edition.
PANSS - Positive and Negative Syndrome Scale.
QD - quaque die (everyday).

D A T A   A N D   A N A L Y S E S

Comparison 1.   ASENAPINE versus PLACEBO

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

1 Global state: 1. No clinically impor-
tant change (CGI-I) - short-term (up to
12 weeks)

2 Global state: 2. Average change score
(CGI-S, high=poor)

2.1 short-term (up to 12 weeks)

2.2 medium-term (13 to 26 weeks)

3 Global state: 3. Relapse - medi-
um-term (13 to 26 weeks)

4 Global state: 4. Use of any concomi-
tant medication

4.1 short-term

4.2 medium-term

5 Global state: 5. Use of specific con-
comitant medication

5.1 acetaminophen - short-term

5.2 antiparkinsonian medication -
short-term

1

2

1

1

1

2

1

1

3

1

2

336

718

336

382

386

726

340

386

340

461

Risk Ratio (M-H, Fixed, 95%
CI)

0.81 [0.68, 0.97]

Mean Difference (IV, Fixed,
95% CI)

-0.50 [-0.62, -0.37]

Mean Difference (IV, Fixed,
95% CI)

-0.35 [-0.55, -0.15]

Mean Difference (IV, Fixed,
95% CI)

-0.60 [-0.77, -0.43]

Risk Ratio (M-H, Fixed, 95%
CI)

0.26 [0.18, 0.40]

Risk Ratio (M-H, Fixed, 95%
CI)

0.86 [0.76, 0.96]

Risk Ratio (M-H, Fixed, 95%
CI)

0.84 [0.74, 0.97]

Risk Ratio (M-H, Fixed, 95%
CI)

0.87 [0.71, 1.07]

Risk Ratio (M-H, Fixed, 95%
CI)

Subtotals only

Risk Ratio (M-H, Fixed, 95%
CI)

0.74 [0.48, 1.12]

Risk Ratio (M-H, Fixed, 95%
CI)

1.21 [0.78, 1.88]

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

45

 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

5.3 benzatropine - short-term

5.4 ibuprofen - short-term

5.5 lorazepam - short-term

5.6 lorazepam - medium-term

5.7 trihexyphenidyl - short-term

5.8 trihexyphenidyl - medium-term

5.9 zolpidem - short-term

5.10 zolpidem - medium-term

6 Mental state: 1. No clinically impor-
tant change (PANSS) - short-term

7 Mental state: 2. Average change in
total score (baseline-to-endpoint)
(PANSS, high=poor)

7.1 PANSS total score - short-term

7.2 PANSS total score - medium-term

8 Mental state: 3. Average change score
(baseline-to-endpoint) (various scales,
high=poor)

8.1 CDSS total score - short-term

8.2 CDSS total score - medium-term

8.3 PANSS Marder anxiety/depression
factor score - short-term

8.4 PANSS Marder anxiety/depression
factor score - medium-term

8.5 PANSS Marder disorganized
thought factor score - short-term

1

1

2

1

1

1

2

1

1

3

2

1

2

1

1

1

1

1

340

340

461

386

340

386

461

386

336

1009

627

382

336

382

336

382

336

Risk Ratio (M-H, Fixed, 95%
CI)

1.05 [0.43, 2.57]

Risk Ratio (M-H, Fixed, 95%
CI)

0.61 [0.30, 1.22]

Risk Ratio (M-H, Fixed, 95%
CI)

0.85 [0.71, 1.02]

Risk Ratio (M-H, Fixed, 95%
CI)

0.45 [0.16, 1.27]

Risk Ratio (M-H, Fixed, 95%
CI)

1.70 [0.83, 3.50]

Risk Ratio (M-H, Fixed, 95%
CI)

0.66 [0.19, 2.30]

Risk Ratio (M-H, Fixed, 95%
CI)

1.00 [0.71, 1.40]

Risk Ratio (M-H, Fixed, 95%
CI)

0.33 [0.07, 1.61]

Risk Ratio (M-H, Fixed, 95%
CI)

0.72 [0.59, 0.86]

Mean Difference (IV, Fixed,
95% CI)

-7.24 [-9.18, -5.29]

Mean Difference (IV, Fixed,
95% CI)

-3.77 [-6.50, -1.04]

Mean Difference (IV, Fixed,
95% CI)

-10.80 [-13.57,
-8.03]

Mean Difference (IV, Fixed,
95% CI)

Subtotals only

Mean Difference (IV, Fixed,
95% CI)

-0.86 [-1.62, -0.10]

Mean Difference (IV, Fixed,
95% CI)

-0.70 [-1.25, -0.15]

Mean Difference (IV, Fixed,
95% CI)

-0.55 [-1.26, 0.16]

Mean Difference (IV, Fixed,
95% CI)

-1.4 [-1.95, -0.85]

Mean Difference (IV, Fixed,
95% CI)

-1.25 [-2.20, -0.30]

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

46

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

8.6 PANSS Marder disorganized
thought factor score - medium-term

8.7 PANSS Marder hostility/excitement
factor score - short-term

8.8 PANSS Marder hostility/excitement
factor score - medium-term

8.9 PANSS Marder negative factor score
- short-term

8.10 PANSS Marder negative factor
score - medium-term

8.11 PANSS Marder positive factor
score - short-term

8.12 PANSS Marder positive factor
score - medium-term

9 Adverse effects: 1. Incidence of seri-
ous adverse effects

9.1 short-term

9.2 medium-term

10 Adverse effects: 2. Incidence of any
adverse effects

10.1 any adverse effects - short-term

10.2 any treatment-emergent adverse
effects - medium-term

10.3 any treatment-related adverse ef-
fects - short-term

10.4 any treatment-related adverse ef-
fects - medium-term

11 Adverse effects: 3. Incidence of ad-
verse effects by severity - short-term

11.1 mild adverse effects

11.2 moderate adverse effects

1

1

1

1

1

1

1

4

3

1

3

2

1

1

1

3

1

1

382

336

382

336

382

336

382

1030

644

386

461

386

340

386

340

340

Mean Difference (IV, Fixed,
95% CI)

-2.4 [-2.95, -1.85]

Mean Difference (IV, Fixed,
95% CI)

-0.5 [-1.21, 0.21]

Mean Difference (IV, Fixed,
95% CI)

-2.0 [-2.55, -1.45]

Mean Difference (IV, Fixed,
95% CI)

-1.10 [-2.29, 0.09]

Mean Difference (IV, Fixed,
95% CI)

-1.7 [-2.53, -0.87]

Mean Difference (IV, Fixed,
95% CI)

-2.40 [-3.83, -0.97]

Mean Difference (IV, Fixed,
95% CI)

-3.4 [-4.23, -2.57]

Risk Ratio (M-H, Fixed, 95%
CI)

0.65 [0.42, 1.00]

Risk Ratio (M-H, Fixed, 95%
CI)

1.12 [0.63, 2.00]

Risk Ratio (M-H, Fixed, 95%
CI)

0.29 [0.14, 0.63]

Risk Ratio (M-H, Fixed, 95%
CI)

Subtotals only

Risk Ratio (M-H, Fixed, 95%
CI)

0.99 [0.89, 1.11]

Risk Ratio (M-H, Fixed, 95%
CI)

0.83 [0.68, 1.01]

Risk Ratio (M-H, Fixed, 95%
CI)

1.18 [0.91, 1.52]

Risk Ratio (M-H, Fixed, 95%
CI)

0.84 [0.59, 1.19]

Risk Ratio (M-H, Fixed, 95%
CI)

Subtotals only

Risk Ratio (M-H, Fixed, 95%
CI)

0.88 [0.66, 1.18]

Risk Ratio (M-H, Fixed, 95%
CI)

1.01 [0.71, 1.42]

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

47

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

11.3 severe adverse effects

12 Adverse effects: 4. Specific adverse
effects - 4.1. Cardiovascular: incidence
- short-term

12.1 QTc interval >450ms

12.2 sinus tachycardia

13 Adverse effects: 4. Specific adverse
effects - 4.2. Gastrointestinal: inci-
dence - short-term

13.1 clinically significant gamma-glu-
tamyl transpeptidase levels

13.2 clinically significant alanine
aminotransferase levels

13.3 constipation

13.4 dyspepsia

13.5 vomiting

14 Adverse effects: 4. Specific adverse
effects - 4.3. Metabolic: incidence

14.1 clinically significant fasting glu-
cose levels - short-term

14.2 clinically significant fasting
triglycerides levels - short-term

14.3 clinically significant HbA1C levels
- short-term

14.4 clinically significant hyperpro-
lactinaemia - short-term

14.5 clinically significant hyperpro-
lactinaemia - medium-term

14.6 clinically significant weight gain -
short-term

14.7 clinically significant weight gain -
medium-term

3

2

2

1

3

1

1

1

1

2

4

3

1

1

2

1

3

1

644

232

121

183

183

121

121

461

641

183

183

458

386

623

386

Risk Ratio (M-H, Fixed, 95%
CI)

1.52 [0.80, 2.91]

Risk Difference (M-H, Fixed,
95% CI)

Subtotals only

Risk Difference (M-H, Fixed,
95% CI)

-0.01 [-0.07, 0.05]

Risk Difference (M-H, Fixed,
95% CI)

0.01 [-0.11, 0.12]

Risk Ratio (M-H, Fixed, 95%
CI)

Subtotals only

Risk Ratio (M-H, Fixed, 95%
CI)

3.62 [1.24, 10.57]

Risk Ratio (M-H, Fixed, 95%
CI)

2.58 [1.20, 5.56]

Risk Ratio (M-H, Fixed, 95%
CI)

1.05 [0.36, 3.08]

Risk Ratio (M-H, Fixed, 95%
CI)

0.84 [0.24, 2.98]

Risk Ratio (M-H, Fixed, 95%
CI)

1.31 [0.61, 2.84]

Risk Ratio (M-H, Fixed, 95%
CI)

Subtotals only

Risk Ratio (M-H, Fixed, 95%
CI)

2.24 [1.06, 4.75]

Risk Ratio (M-H, Fixed, 95%
CI)

8.27 [1.06, 64.77]

Risk Ratio (M-H, Fixed, 95%
CI)

7.23 [0.38, 138.03]

Risk Ratio (M-H, Fixed, 95%
CI)

3.28 [0.97, 11.06]

Risk Ratio (M-H, Fixed, 95%
CI)

0.62 [0.21, 1.86]

Risk Ratio (M-H, Fixed, 95%
CI)

3.48 [1.19, 10.15]

Risk Ratio (M-H, Fixed, 95%
CI)

6.93 [0.86, 55.77]

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

48

 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

14.8 clinically significant weight loss -
short-term

14.9 clinically significant weight loss -
medium-term

14.10 weight gain - medium-term

14.11 weight loss - medium-term

15 Adverse effects: 4. Specific adverse
effects - 4.4. Metabolic: average change
in prolactin levels (μg/L) (baseline-to-
endpoint) - short-term

16 Adverse effects: 4. Specific adverse
effects - 4.5. Metabolic: average change
in weight (kg) (baseline-to-endpoint)

16.1 short-term

16.2 medium-term

17 Adverse effects: 4. Specific adverse
effects - 4.6. Other specific adverse ef-
fects: incidence

17.1 agitation - short-term

17.2 agitation - medium-term

17.3 akathisia - short-term

17.4 akathisia - medium-term

17.5 anxiety - short-term

17.6 anxiety - medium-term

17.7 delusions - medium-term

17.8 dizziness - short-term

1

1

1

1

1

2

1

1

3

2

1

1

1

2

1

1

1

340

386

386

386

340

726

340

386

461

386

340

386

461

386

386

121

Risk Ratio (M-H, Fixed, 95%
CI)

0.85 [0.14, 5.02]

Risk Ratio (M-H, Fixed, 95%
CI)

0.33 [0.13, 0.81]

Risk Ratio (M-H, Fixed, 95%
CI)

1.84 [0.75, 4.51]

Risk Ratio (M-H, Fixed, 95%
CI)

0.43 [0.18, 1.03]

Mean Difference (IV, Fixed,
95% CI)

6.01 [-3.35, 15.37]

Mean Difference (IV, Fixed,
95% CI)

1.15 [0.54, 1.76]

Mean Difference (IV, Fixed,
95% CI)

1.05 [-0.03, 2.13]

Mean Difference (IV, Fixed,
95% CI)

1.2 [0.46, 1.94]

Risk Ratio (M-H, Fixed, 95%
CI)

Subtotals only

Risk Ratio (M-H, Fixed, 95%
CI)

0.50 [0.28, 0.89]

Risk Ratio (M-H, Fixed, 95%
CI)

0.36 [0.12, 1.11]

Risk Ratio (M-H, Fixed, 95%
CI)

1.84 [0.61, 5.53]

Risk Ratio (M-H, Fixed, 95%
CI)

1.32 [0.30, 5.82]

Risk Ratio (M-H, Fixed, 95%
CI)

1.01 [0.52, 1.96]

Risk Ratio (M-H, Fixed, 95%
CI)

0.75 [0.41, 1.40]

Risk Ratio (M-H, Fixed, 95%
CI)

0.18 [0.04, 0.80]

Risk Ratio (M-H, Fixed, 95%
CI)

0.58 [0.21, 1.64]

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

49

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

17.9 fatigue - short-term

17.10 hallucinations - medium-term

17.11 headache - short-term

17.12 headache - medium-term

17.13 insomnia - short-term

17.14 insomnia - medium-term

17.15 nausea - short-term

17.16 oral hypoesthesia - short-term

17.17 pain - short-term

17.18 psychosis - short-term

17.19 schizophrenia - medium-term

17.20 sedation - short-term

17.21 somnolence - short-term

17.22 somnolence - medium-term

17.23 upper respiratory tract infection
- short-term

17.24 worsening psychotic symptoms -
short-term

18 Adverse effects: 5. Extrapyramidal
symptoms - 5.1 Incidence

18.1 any extrapyramidal symptoms -
short-term

1

1

2

1

2

1

1

1

1

1

1

1

2

1

1

1

4

2

121

386

461

386

461

386

121

340

121

121

386

340

461

386

121

340

523

Risk Ratio (M-H, Fixed, 95%
CI)

0.53 [0.10, 2.76]

Risk Ratio (M-H, Fixed, 95%
CI)

0.08 [0.01, 0.58]

Risk Ratio (M-H, Fixed, 95%
CI)

0.39 [0.22, 0.71]

Risk Ratio (M-H, Fixed, 95%
CI)

2.97 [0.61, 14.53]

Risk Ratio (M-H, Fixed, 95%
CI)

0.81 [0.50, 1.31]

Risk Ratio (M-H, Fixed, 95%
CI)

0.46 [0.24, 0.88]

Risk Ratio (M-H, Fixed, 95%
CI)

1.44 [0.62, 3.34]

Risk Ratio (M-H, Fixed, 95%
CI)

1.89 [0.53, 6.74]

Risk Ratio (M-H, Fixed, 95%
CI)

0.79 [0.18, 3.37]

Risk Ratio (M-H, Fixed, 95%
CI)

1.58 [0.47, 5.31]

Risk Ratio (M-H, Fixed, 95%
CI)

0.29 [0.14, 0.59]

Risk Ratio (M-H, Fixed, 95%
CI)

0.68 [0.21, 2.18]

Risk Ratio (M-H, Fixed, 95%
CI)

1.88 [0.86, 4.08]

Risk Ratio (M-H, Fixed, 95%
CI)

0.49 [0.05, 5.41]

Risk Ratio (M-H, Fixed, 95%
CI)

1.40 [0.33, 6.00]

Risk Ratio (M-H, Fixed, 95%
CI)

0.51 [0.21, 1.22]

Risk Ratio (M-H, Fixed, 95%
CI)

Subtotals only

Risk Ratio (M-H, Fixed, 95%
CI)

1.74 [1.02, 2.96]

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

50

 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

18.2 any extrapyramidal symptoms -
medium-term

18.3 dystonia - short-term

18.4 hyperkinesia - short-term

18.5 hypertonia - short-term

18.6 muscle rigidity - short-term

18.7 Parkinsonism - short-term

18.8 Parkinsonism - medium-term

19 Adverse effects: 5. Extrapyrami-
dal symptoms - 5.2. Average change
(baseline-to-endpoint) (various scales,
high=poor) - short-term

19.1 AIMS

19.2 BAS

19.3 SAS

20 Adverse effects: 6. Incidence of
death (for any reason) - short-term

21 Leaving the study early

21.1 any reason - short-term

21.2 any reason - medium-term

1

1

1

1

1

1

1

1

1

1

1

2

6

5

1

21.3 due to adverse effects - short-term 3

21.4 due to adverse effects - medi-
um-term

1

21.5 due to lack of efficacy - short-term 2

386

340

121

121

340

340

386

333

333

333

523

1046

386

644

386

457

Risk Ratio (M-H, Fixed, 95%
CI)

0.66 [0.24, 1.82]

Risk Ratio (M-H, Fixed, 95%
CI)

7.39 [0.42, 130.15]

Risk Ratio (M-H, Fixed, 95%
CI)

0.0 [0.0, 0.0]

Risk Ratio (M-H, Fixed, 95%
CI)

0.21 [0.01, 4.28]

Risk Ratio (M-H, Fixed, 95%
CI)

8.53 [0.49, 148.12]

Risk Ratio (M-H, Fixed, 95%
CI)

1.51 [0.61, 3.76]

Risk Ratio (M-H, Fixed, 95%
CI)

0.33 [0.03, 3.14]

Mean Difference (IV, Fixed,
95% CI)

Subtotals only

Mean Difference (IV, Fixed,
95% CI)

-0.13 [-0.43, 0.17]

Mean Difference (IV, Fixed,
95% CI)

0.11 [-0.05, 0.27]

Mean Difference (IV, Fixed,
95% CI)

0.5 [-0.04, 1.04]

Risk Difference (M-H, Fixed,
95% CI)

-0.01 [-0.02, 0.01]

Risk Ratio (M-H, Fixed, 95%
CI)

Subtotals only

Risk Ratio (M-H, Fixed, 95%
CI)

0.91 [0.80, 1.04]

Risk Ratio (M-H, Fixed, 95%
CI)

0.49 [0.38, 0.62]

Risk Ratio (M-H, Fixed, 95%
CI)

0.89 [0.54, 1.47]

Risk Ratio (M-H, Fixed, 95%
CI)

0.30 [0.18, 0.50]

Risk Ratio (M-H, Fixed, 95%
CI)

0.56 [0.38, 0.81]

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

51

 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Outcome or subgroup title

No. of studies

No. of partici-
pants

Statistical method

Effect size

21.6 due to loss to follow up - medi-
um-term

21.7 due to other reasons - short-term

21.8 due to other reasons - medi-
um-term

21.9 due to relapse (not considered ad-
verse effect) - medium-term

21.10 due to specific adverse effect: re-
lapse - medium-term

21.11 due to specific adverse effect:
worsening of schizophrenia - medi-
um-term

21.12 due to withdrawal of consent -
medium-term

1

2

1

1

1

1

1

386

457

386

386

386

386

386

Risk Ratio (M-H, Fixed, 95%
CI)

0.99 [0.20, 4.84]

Risk Ratio (M-H, Fixed, 95%
CI)

1.22 [0.83, 1.80]

Risk Ratio (M-H, Fixed, 95%
CI)

0.84 [0.38, 1.82]

Risk Ratio (M-H, Fixed, 95%
CI)

0.25 [0.13, 0.49]

Risk Ratio (M-H, Fixed, 95%
CI)

0.27 [0.16, 0.47]

Risk Ratio (M-H, Fixed, 95%
CI)

0.25 [0.14, 0.45]

Risk Ratio (M-H, Fixed, 95%
CI)

1.57 [0.78, 3.14]

Analysis 1.1.   Comparison 1 ASENAPINE versus PLACEBO, Outcome 1 Global
state: 1. No clinically important change (CGI-I) - short-term (up to 12 weeks).

Study or subgroup

Asenapine

n/N

Placebo

n/N

Risk Ratio

M-H, Fixed, 95% CI

Kane 2010

115/214

81/122

Weight

Risk Ratio

M-H, Fixed, 95% CI

100%

0.81[0.68,0.97]

Total (95% CI)

214

122

100%

0.81[0.68,0.97]

Total events: 115 (Asenapine), 81 (Placebo)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=2.34(P=0.02)

Favours asenapine

0.5

0.7

1

1.5

2

Favours placebo

Analysis 1.2.   Comparison 1 ASENAPINE versus PLACEBO, Outcome
2 Global state: 2. Average change score (CGI-S, high=poor).

Study or subgroup

Asenapine

Placebo

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.2.1 short-term (up to 12 weeks)

Kane 2010

Subtotal ***

214

214

-1.1 (0.3)

122

122

-0.8 (1.1)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=3.46(P=0)

1.2.2 medium-term (13 to 26 weeks)

41.4%

41.4%

-0.35[-0.55,-0.15]

-0.35[-0.55,-0.15]

Favours asenapine

-1

-0.5

0

0.5

1

Favours placebo

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

52

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Asenapine

Placebo

Kane 2011

Subtotal ***

Mean(SD)

0.2 (0.8)

N

191

191

Mean(SD)

0.8 (0.8)

N

191

191

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

58.6%

58.6%

Fixed, 95% CI

-0.6[-0.77,-0.43]

-0.6[-0.77,-0.43]

Heterogeneity: Not applicable

Test for overall effect: Z=7.06(P<0.0001)

Total ***

405

313

Heterogeneity: Tau2=0; Chi2=3.59, df=1(P=0.06); I2=72.12%

Test for overall effect: Z=7.64(P<0.0001)

Test for subgroup differences: Chi2=3.59, df=1 (P=0.06), I2=72.12%

100%

-0.5[-0.62,-0.37]

Favours asenapine

-1

-0.5

0

0.5

1

Favours placebo

Analysis 1.3.   Comparison 1 ASENAPINE versus PLACEBO, Outcome
3 Global state: 3. Relapse - medium-term (13 to 26 weeks).

Study or subgroup

Asenapine

n/N

Placebo

n/N

Risk Ratio

M-H, Fixed, 95% CI

Kane 2011

24/194

90/192

Weight

Risk Ratio

M-H, Fixed, 95% CI

100%

0.26[0.18,0.4]

Total (95% CI)

194

192

100%

0.26[0.18,0.4]

Total events: 24 (Asenapine), 90 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=6.47(P<0.0001)

Favours asenapine

0.2

0.5

1

2

5

Favours placebo

Study or subgroup

1.4.1 short-term

Kane 2010

Subtotal (95% CI)

Analysis 1.4.   Comparison 1 ASENAPINE versus PLACEBO,
Outcome 4 Global state: 4. Use of any concomitant medication.

Asenapine

n/N

Placebo

n/N

Risk Ratio

M-H, Fixed, 95% CI

Weight

Risk Ratio

M-H, Fixed, 95% CI

143/217

217

96/123

123

54.45%

54.45%

0.84[0.74,0.97]

0.84[0.74,0.97]

Total events: 143 (Asenapine), 96 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=2.48(P=0.01)

1.4.2 medium-term

Kane 2011

Subtotal (95% CI)

Total events: 90 (Asenapine), 102 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=1.32(P=0.19)

90/194

194

102/192

192

45.55%

45.55%

0.87[0.71,1.07]

0.87[0.71,1.07]

Total (95% CI)

411

315

100%

0.86[0.76,0.96]

Total events: 233 (Asenapine), 198 (Placebo)

Heterogeneity: Tau2=0; Chi2=0.08, df=1(P=0.77); I2=0%

Test for overall effect: Z=2.56(P=0.01)

Favours asenapine

0.5

0.7

1

1.5

2

Favours placebo

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

53

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Asenapine

n/N

Placebo

n/N

Risk Ratio

M-H, Fixed, 95% CI

Weight

Risk Ratio

M-H, Fixed, 95% CI

Test for subgroup differences: Chi2=0.07, df=1 (P=0.78), I2=0%

Favours asenapine

0.5

0.7

1

1.5

2

Favours placebo

Analysis 1.5.   Comparison 1 ASENAPINE versus PLACEBO,
Outcome 5 Global state: 5. Use of specific concomitant medication.

Study or subgroup

Asenapine

n/N

Placebo

n/N

Risk Ratio

M-H, Fixed, 95% CI

Weight

Risk Ratio

M-H, Fixed, 95% CI

1.5.1 acetaminophen - short-term

Kane 2010

Subtotal (95% CI)

Total events: 39 (Asenapine), 30 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=1.42(P=0.16)

39/217

217

30/123

123

100%

100%

0.74[0.48,1.12]

0.74[0.48,1.12]

1.5.2 antiparkinsonian medication - short-term

Potkin 2007

Kane 2010

Subtotal (95% CI)

10/59

39/217

276

13/62

15/123

185

Total events: 49 (Asenapine), 28 (Placebo)

Heterogeneity: Tau2=0; Chi2=1.62, df=1(P=0.2); I2=38.24%

Test for overall effect: Z=0.84(P=0.4)

39.84%

60.16%

100%

0.81[0.38,1.7]

1.47[0.85,2.56]

1.21[0.78,1.88]

1.5.3 benzatropine - short-term

Kane 2010

Subtotal (95% CI)

Total events: 13 (Asenapine), 7 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.11(P=0.91)

1.5.4 ibuprofen - short-term

Kane 2010

Subtotal (95% CI)

Total events: 15 (Asenapine), 14 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=1.41(P=0.16)

13/217

217

7/123

123

100%

100%

1.05[0.43,2.57]

1.05[0.43,2.57]

15/217

217

14/123

123

100%

100%

0.61[0.3,1.22]

0.61[0.3,1.22]

1.5.5 lorazepam - short-term

Potkin 2007

Kane 2010

Subtotal (95% CI)

35/59

90/217

276

43/62

60/123

185

Total events: 125 (Asenapine), 103 (Placebo)

Heterogeneity: Tau2=0; Chi2=0, df=1(P=0.97); I2=0%

Test for overall effect: Z=1.72(P=0.08)

1.5.6 lorazepam - medium-term

Kane 2011

Subtotal (95% CI)

Total events: 5 (Asenapine), 11 (Placebo)

5/194

194

11/192

192

35.38%

64.62%

100%

0.86[0.65,1.12]

0.85[0.67,1.08]

0.85[0.71,1.02]

100%

100%

0.45[0.16,1.27]

0.45[0.16,1.27]

Favours asenapine

0.1

0.2

0.5

1

2

5

10

Favours placebo

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

54

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Asenapine

n/N

Placebo

n/N

Risk Ratio

M-H, Fixed, 95% CI

Weight

Risk Ratio

M-H, Fixed, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Z=1.51(P=0.13)

1.5.7 trihexyphenidyl - short-term

Kane 2010

Subtotal (95% CI)

Total events: 27 (Asenapine), 9 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=1.44(P=0.15)

27/217

217

9/123

123

100%

100%

1.7[0.83,3.5]

1.7[0.83,3.5]

1.5.8 trihexyphenidyl - medium-term

Kane 2011

Subtotal (95% CI)

4/194

194

6/192

192

Total events: 4 (Asenapine), 6 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.65(P=0.51)

1.5.9 zolpidem - short-term

Potkin 2007

Kane 2010

Subtotal (95% CI)

18/59

45/217

276

17/62

27/123

185

Total events: 63 (Asenapine), 44 (Placebo)

Heterogeneity: Tau2=0; Chi2=0.21, df=1(P=0.65); I2=0%

Test for overall effect: Z=0(P=1)

100%

100%

0.66[0.19,2.3]

0.66[0.19,2.3]

32.48%

67.52%

100%

1.11[0.64,1.95]

0.94[0.62,1.44]

1[0.71,1.4]

1.5.10 zolpidem - medium-term

Kane 2011

Subtotal (95% CI)

Total events: 2 (Asenapine), 6 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=1.37(P=0.17)

2/194

194

6/192

192

100%

100%

0.33[0.07,1.61]

0.33[0.07,1.61]

Favours asenapine

0.1

0.2

0.5

1

2

5

10

Favours placebo

Analysis 1.6.   Comparison 1 ASENAPINE versus PLACEBO, Outcome 6
Mental state: 1. No clinically important change (PANSS) - short-term.

Study or subgroup

Asenapine

n/N

Placebo

n/N

Risk Ratio

M-H, Fixed, 95% CI

Kane 2010

103/214

82/122

Weight

Risk Ratio

M-H, Fixed, 95% CI

100%

0.72[0.59,0.86]

Total (95% CI)

214

122

100%

0.72[0.59,0.86]

Total events: 103 (Asenapine), 82 (Placebo)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=3.51(P=0)

Favours asenapine

0.5

0.7

1

1.5

2

Favours placebo

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

55

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.7.   Comparison 1 ASENAPINE versus PLACEBO, Outcome 7 Mental
state: 2. Average change in total score (baseline-to-endpoint) (PANSS, high=poor).

Study or subgroup

Asenapine

Placebo

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.7.1 PANSS total score - short-term

NCT00156117

Kane 2010

Subtotal ***

-14 (15.9)

-15.5 (17.3)

198

214

412

Heterogeneity: Tau2=0; Chi2=0.42, df=1(P=0.52); I2=0%

Test for overall effect: Z=2.7(P=0.01)

1.7.2 PANSS total score - medium-term

Kane 2011

Subtotal ***

1.3 (13.8)

191

191

Heterogeneity: Not applicable

Test for overall effect: Z=7.64(P<0.0001)

-11.1 (15.7)

-10.8 (17.3)

12.1 (13.8)

93

122

215

191

191

25.1%

25.6%

50.7%

-2.86[-6.74,1.02]

-4.66[-8.51,-0.81]

-3.77[-6.5,-1.04]

49.3%

49.3%

-10.8[-13.57,-8.03]

-10.8[-13.57,-8.03]

Total ***

603

406

100%

-7.24[-9.18,-5.29]

Heterogeneity: Tau2=0; Chi2=12.95, df=2(P=0); I2=84.56%

Test for overall effect: Z=7.29(P<0.0001)

Test for subgroup differences: Chi2=12.53, df=1 (P=0), I2=92.02%

Favours asenapine

-10

-5

0

5

10

Favours placebo

Analysis 1.8.   Comparison 1 ASENAPINE versus PLACEBO, Outcome 8 Mental
state: 3. Average change score (baseline-to-endpoint) (various scales, high=poor).

Study or subgroup

Asenapine

Placebo

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.8.1 CDSS total score - short-term

Kane 2010

Subtotal ***

-1.5 (3.1)

214

214

Heterogeneity: Not applicable

Test for overall effect: Z=2.21(P=0.03)

1.8.2 CDSS total score - medium-term

Kane 2011

Subtotal ***

0.4 (2.8)

191

191

Heterogeneity: Not applicable

Test for overall effect: Z=2.48(P=0.01)

-0.6 (3.6)

1.1 (2.8)

122

122

191

191

1.8.3 PANSS Marder anxiety/depression factor score - short-term

Kane 2010

Subtotal ***

214

214

-2.5 (2.9)

122

122

-2 (3.3)

Heterogeneity: Not applicable

Test for overall effect: Z=1.53(P=0.13)

1.8.4 PANSS Marder anxiety/depression factor score - medium-term

Kane 2011

Subtotal ***

191

191

0.4 (2.8)

191

191

1.8 (2.8)

Heterogeneity: Not applicable

Test for overall effect: Z=4.96(P<0.0001)

100%

100%

-0.86[-1.62,-0.1]

-0.86[-1.62,-0.1]

100%

100%

-0.7[-1.25,-0.15]

-0.7[-1.25,-0.15]

100%

100%

-0.55[-1.26,0.16]

-0.55[-1.26,0.16]

100%

100%

-1.4[-1.95,-0.85]

-1.4[-1.95,-0.85]

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

56

Favours asenapine

-5

-2.5

0

2.5

5

Favours placebo

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Asenapine

Placebo

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.8.5 PANSS Marder disorganized thought factor score - short-term

Kane 2010

Subtotal ***

214

214

-4.4 (4)

122

122

-3.2 (4.4)

Heterogeneity: Not applicable

Test for overall effect: Z=2.58(P=0.01)

1.8.6 PANSS Marder disorganized thought factor score - medium-term

Kane 2011

Subtotal ***

191

191

0 (2.8)

191

191

2.4 (2.8)

Heterogeneity: Not applicable

Test for overall effect: Z=8.5(P<0.0001)

1.8.7 PANSS Marder hostility/excitement factor score - short-term

Kane 2010

Subtotal ***

214

214

-1.8 (2.9)

122

122

-1.3 (3.3)

Heterogeneity: Not applicable

Test for overall effect: Z=1.39(P=0.16)

1.8.8 PANSS Marder hostility/excitement factor score - medium-term

Kane 2011

Subtotal ***

0.4 (2.8)

191

191

Heterogeneity: Not applicable

Test for overall effect: Z=7.08(P<0.0001)

1.8.9 PANSS Marder negative factor score - short-term

Kane 2010

Subtotal ***

-4.4 (5.1)

214

214

Heterogeneity: Not applicable

Test for overall effect: Z=1.81(P=0.07)

2.4 (2.8)

-3.3 (5.5)

191

191

122

122

1.8.10 PANSS Marder negative factor score - medium-term

Kane 2011

Subtotal ***

191

191

0 (4.2)

191

191

1.7 (4.2)

Heterogeneity: Not applicable

Test for overall effect: Z=4(P<0.0001)

1.8.11 PANSS Marder positive factor score - short-term

Kane 2010

Subtotal ***

-7.5 (6.1)

214

214

Heterogeneity: Not applicable

Test for overall effect: Z=3.28(P=0)

1.8.12 PANSS Marder positive factor score - medium-term

Kane 2011

Subtotal ***

0.5 (4.2)

191

191

Heterogeneity: Not applicable

Test for overall effect: Z=8.01(P<0.0001)

-5.1 (6.6)

3.9 (4.2)

122

122

191

191

100%

100%

-1.25[-2.2,-0.3]

-1.25[-2.2,-0.3]

100%

100%

-2.4[-2.95,-1.85]

-2.4[-2.95,-1.85]

100%

100%

-0.5[-1.21,0.21]

-0.5[-1.21,0.21]

100%

100%

-2[-2.55,-1.45]

-2[-2.55,-1.45]

100%

100%

-1.1[-2.29,0.09]

-1.1[-2.29,0.09]

100%

100%

-1.7[-2.53,-0.87]

-1.7[-2.53,-0.87]

100%

100%

-2.4[-3.83,-0.97]

-2.4[-3.83,-0.97]

100%

100%

-3.4[-4.23,-2.57]

-3.4[-4.23,-2.57]

Favours asenapine

-5

-2.5

0

2.5

5

Favours placebo

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

57

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

1.9.1 short-term

NCT00151424

Potkin 2007

Kane 2010

Subtotal (95% CI)

Analysis 1.9.   Comparison 1 ASENAPINE versus PLACEBO,
Outcome 9 Adverse effects: 1. Incidence of serious adverse effects.

Asenapine

n/N

Placebo

n/N

Risk Ratio

M-H, Fixed, 95% CI

Weight

Risk Ratio

M-H, Fixed, 95% CI

6/90

5/59

16/217

366

3/93

6/62

9/123

278

6.22%

12.34%

24.22%

42.78%

2.07[0.53,8.01]

0.88[0.28,2.72]

1.01[0.46,2.21]

1.12[0.63,2]

Total events: 27 (Asenapine), 18 (Placebo)

Heterogeneity: Tau2=0; Chi2=1.04, df=2(P=0.6); I2=0%

Test for overall effect: Z=0.4(P=0.69)

1.9.2 medium-term

Kane 2011

Subtotal (95% CI)

Total events: 8 (Asenapine), 27 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=3.15(P=0)

8/194

194

27/192

192

57.22%

57.22%

0.29[0.14,0.63]

0.29[0.14,0.63]

Total (95% CI)

560

470

100%

0.65[0.42,1]

Total events: 35 (Asenapine), 45 (Placebo)

Heterogeneity: Tau2=0; Chi2=8.44, df=3(P=0.04); I2=64.46%

Test for overall effect: Z=1.94(P=0.05)

Test for subgroup differences: Chi2=7.58, df=1 (P=0.01), I2=86.8%

Favours asenapine

0.05

0.2

1

5

20

Favours placebo

Analysis 1.10.   Comparison 1 ASENAPINE versus PLACEBO,
Outcome 10 Adverse effects: 2. Incidence of any adverse effects.

Study or subgroup

Asenapine

n/N

Placebo

n/N

Risk Ratio

M-H, Fixed, 95% CI

Weight

Risk Ratio

M-H, Fixed, 95% CI

1.10.1 any adverse effects - short-term

Potkin 2007

Kane 2010

Subtotal (95% CI)

49/59

152/217

276

49/62

89/123

185

Total events: 201 (Asenapine), 138 (Placebo)

Heterogeneity: Tau2=0; Chi2=0.54, df=1(P=0.46); I2=0%

Test for overall effect: Z=0.13(P=0.89)

1.10.2 any treatment-emergent adverse effects - medium-term

Kane 2011

Subtotal (95% CI)

89/194

194

106/192

192

Total events: 89 (Asenapine), 106 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=1.82(P=0.07)

1.10.3 any treatment-related adverse effects - short-term

Kane 2010

Subtotal (95% CI)

104/217

217

50/123

123

Total events: 104 (Asenapine), 50 (Placebo)

29.61%

70.39%

100%

1.05[0.88,1.25]

0.97[0.84,1.11]

0.99[0.89,1.11]

100%

100%

0.83[0.68,1.01]

0.83[0.68,1.01]

100%

100%

1.18[0.91,1.52]

1.18[0.91,1.52]

Favours asenapine

0.5

0.7

1

1.5

2

Favours placebo

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

58

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Asenapine

n/N

Placebo

n/N

Risk Ratio

M-H, Fixed, 95% CI

Weight

Risk Ratio

M-H, Fixed, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Z=1.27(P=0.2)

1.10.4 any treatment-related adverse effects - medium-term

Kane 2011

Subtotal (95% CI)

44/194

194

52/192

192

Total events: 44 (Asenapine), 52 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=1(P=0.32)

100%

100%

0.84[0.59,1.19]

0.84[0.59,1.19]

Favours asenapine

0.5

0.7

1

1.5

2

Favours placebo

Analysis 1.11.   Comparison 1 ASENAPINE versus PLACEBO, Outcome 11
Adverse effects: 3. Incidence of adverse effects by severity - short-term.

Asenapine

n/N

Placebo

n/N

Risk Ratio

M-H, Fixed, 95% CI

Weight

Risk Ratio

M-H, Fixed, 95% CI

73/217

217

47/123

123

100%

100%

0.88[0.66,1.18]

0.88[0.66,1.18]

Study or subgroup

1.11.1 mild adverse effects

Kane 2010

Subtotal (95% CI)

Total events: 73 (Asenapine), 47 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.85(P=0.39)

1.11.2 moderate adverse effects

Kane 2010

Subtotal (95% CI)

Total events: 64 (Asenapine), 36 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.04(P=0.97)

64/217

217

36/123

123

100%

100%

1.01[0.71,1.42]

1.01[0.71,1.42]

1.11.3 severe adverse effects

NCT00151424

Potkin 2007

Kane 2010

Subtotal (95% CI)

4/90

7/59

15/217

366

3/93

4/62

6/123

278

Total events: 26 (Asenapine), 13 (Placebo)

Heterogeneity: Tau2=0; Chi2=0.14, df=2(P=0.93); I2=0%

Test for overall effect: Z=1.27(P=0.2)

20.34%

26.88%

52.78%

100%

1.38[0.32,5.98]

1.84[0.57,5.96]

1.42[0.56,3.56]

1.52[0.8,2.91]

Favours asenapine

0.05

0.2

1

5

20

Favours placebo

Analysis 1.12.   Comparison 1 ASENAPINE versus PLACEBO, Outcome 12 Adverse
effects: 4. Specific adverse effects - 4.1. Cardiovascular: incidence - short-term.

Study or subgroup

1.12.1 QTc interval >450ms

Asenapine

n/N

Placebo

n/N

Risk Difference

M-H, Fixed, 95% CI

Weight

Risk Difference

M-H, Fixed, 95% CI

Potkin 2007

5/59

6/62

55.78%

-0.01[-0.11,0.09]

Favours asenapine

-0.5

-0.25

0

0.25

0.5

Favours placebo

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

59

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Asenapine

n/N

Placebo

n/N

Risk Difference

M-H, Fixed, 95% CI

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Study or subgroup

Chapel 2009

Subtotal (95% CI)

0/76

135

Total events: 5 (Asenapine), 6 (Placebo)

Heterogeneity: Tau2=0; Chi2=0.11, df=1(P=0.74); I2=0%

Test for overall effect: Z=0.22(P=0.83)

1.12.2 sinus tachycardia

Potkin 2007

Subtotal (95% CI)

Total events: 7 (Asenapine), 7 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.1(P=0.92)

7/59

59

0/35

97

7/62

62

Cochrane Database of Systematic Reviews

Weight

Risk Difference

44.22%

100%

M-H, Fixed, 95% CI

0[-0.04,0.04]

-0.01[-0.07,0.05]

100%

100%

0.01[-0.11,0.12]

0.01[-0.11,0.12]

Favours asenapine

-0.5

-0.25

0

0.25

0.5

Favours placebo

Analysis 1.13.   Comparison 1 ASENAPINE versus PLACEBO, Outcome 13 Adverse
effects: 4. Specific adverse effects - 4.2. Gastrointestinal: incidence - short-term.

Study or subgroup

Asenapine

n/N

Placebo

n/N

Risk Ratio

M-H, Fixed, 95% CI

Weight

Risk Ratio

M-H, Fixed, 95% CI

1.13.1 clinically significant gamma-glutamyl transpeptidase levels

NCT00151424

Subtotal (95% CI)

14/90

90

Total events: 14 (Asenapine), 4 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=2.35(P=0.02)

1.13.2 clinically significant alanine aminotransferase levels

NCT00151424

Subtotal (95% CI)

Total events: 20 (Asenapine), 8 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=2.43(P=0.02)

1.13.3 constipation

Potkin 2007

Subtotal (95% CI)

Total events: 6 (Asenapine), 6 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.09(P=0.93)

1.13.4 dyspepsia

Potkin 2007

Subtotal (95% CI)

20/90

90

6/59

59

4/59

59

Total events: 4 (Asenapine), 5 (Placebo)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.27(P=0.79)

4/93

93

8/93

93

6/62

62

5/62

62

100%

100%

3.62[1.24,10.57]

3.62[1.24,10.57]

100%

100%

2.58[1.2,5.56]

2.58[1.2,5.56]

100%

100%

1.05[0.36,3.08]

1.05[0.36,3.08]

100%

100%

0.84[0.24,2.98]

0.84[0.24,2.98]

1.13.5 vomiting

Potkin 2007

8/59

7/62

64.06%

1.2[0.46,3.1]

Favours asenapine

0.001

0.1

1

10

1000

Favours placebo

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

60

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Kane 2010

Subtotal (95% CI)

Asenapine

n/N

Placebo

n/N

Risk Ratio

M-H, Fixed, 95% CI

8/217

276

3/123

185

Weight

Risk Ratio

35.94%

100%

M-H, Fixed, 95% CI

1.51[0.41,5.59]

1.31[0.61,2.84]

Total events: 16 (Asenapine), 10 (Placebo)

Heterogeneity: Tau2=0; Chi2=0.08, df=1(P=0.78); I2=0%

Test for overall effect: Z=0.69(P=0.49)

Favours asenapine

0.001

0.1

1

10

1000

Favours placebo

Analysis 1.14.   Comparison 1 ASENAPINE versus PLACEBO, Outcome 14
Adverse effects: 4. Specific adverse effects - 4.3. Metabolic: incidence.

Study or subgroup

Asenapine

n/N

Placebo

n/N

Risk Ratio

M-H, Fixed, 95% CI

Weight

Risk Ratio

M-H, Fixed, 95% CI

1.14.1 clinically significant fasting glucose levels - short-term

NCT00151424

Potkin 2007

Kane 2010

Subtotal (95% CI)

10/90

8/58

3/217

365

1/93

7/60

1/123

276

Total events: 21 (Asenapine), 9 (Placebo)

Heterogeneity: Tau2=0; Chi2=3.97, df=2(P=0.14); I2=49.62%

Test for overall effect: Z=2.1(P=0.04)

1.14.2 clinically significant fasting triglycerides levels - short-term

NCT00151424

Subtotal (95% CI)

8/90

90

Total events: 8 (Asenapine), 1 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=2.01(P=0.04)

1.14.3 clinically significant HbA1C levels - short-term

NCT00151424

Subtotal (95% CI)

3/90

90

Total events: 3 (Asenapine), 0 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=1.31(P=0.19)

1/93

93

0/93

93

1.14.4 clinically significant hyperprolactinaemia - short-term

Potkin 2007

Kane 2010

Subtotal (95% CI)

5/58

9/217

275

1/60

2/123

183

Total events: 14 (Asenapine), 3 (Placebo)

Heterogeneity: Tau2=0; Chi2=0.28, df=1(P=0.59); I2=0%

Test for overall effect: Z=1.91(P=0.06)

1.14.5 clinically significant hyperprolactinaemia - medium-term

Kane 2011

Subtotal (95% CI)

5/194

194

8/192

192

Total events: 5 (Asenapine), 8 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.86(P=0.39)

10.76%

75.28%

13.96%

100%

10.33[1.35,79.08]

1.18[0.46,3.05]

1.7[0.18,16.17]

2.24[1.06,4.75]

100%

100%

8.27[1.06,64.77]

8.27[1.06,64.77]

100%

100%

7.23[0.38,138.03]

7.23[0.38,138.03]

27.8%

72.2%

100%

5.17[0.62,42.94]

2.55[0.56,11.62]

3.28[0.97,11.06]

100%

100%

0.62[0.21,1.86]

0.62[0.21,1.86]

Favours asenapine

0.001

0.1

1

10

1000

Favours placebo

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

61

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Asenapine

n/N

Placebo

n/N

Risk Ratio

M-H, Fixed, 95% CI

Weight

Risk Ratio

M-H, Fixed, 95% CI

1.14.6 clinically significant weight gain - short-term

NCT00151424

Potkin 2007

Kane 2010

Subtotal (95% CI)

6/90

2/46

10/217

353

1/93

1/54

2/123

270

Total events: 18 (Asenapine), 4 (Placebo)

Heterogeneity: Tau2=0; Chi2=0.47, df=2(P=0.79); I2=0%

Test for overall effect: Z=2.28(P=0.02)

1.14.7 clinically significant weight gain - medium-term

Kane 2011

Subtotal (95% CI)

7/194

194

1/192

192

Total events: 7 (Asenapine), 1 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=1.82(P=0.07)

1.14.8 clinically significant weight loss - short-term

Kane 2010

Subtotal (95% CI)

3/217

217

2/123

123

Total events: 3 (Asenapine), 2 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.18(P=0.86)

1.14.9 clinically significant weight loss - medium-term

Kane 2011

Subtotal (95% CI)

6/194

194

18/192

192

22.07%

20.64%

57.29%

100%

6.2[0.76,50.48]

2.35[0.22,25.07]

2.83[0.63,12.73]

3.48[1.19,10.15]

100%

100%

6.93[0.86,55.77]

6.93[0.86,55.77]

100%

100%

0.85[0.14,5.02]

0.85[0.14,5.02]

100%

100%

0.33[0.13,0.81]

0.33[0.13,0.81]

Total events: 6 (Asenapine), 18 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=2.41(P=0.02)

1.14.10 weight gain - medium-term

Kane 2011

Subtotal (95% CI)

Total events: 13 (Asenapine), 7 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=1.33(P=0.18)

1.14.11 weight loss - medium-term

Kane 2011

Subtotal (95% CI)

Total events: 7 (Asenapine), 16 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=1.9(P=0.06)

13/194

194

7/192

192

100%

100%

1.84[0.75,4.51]

1.84[0.75,4.51]

7/194

194

16/192

192

100%

100%

0.43[0.18,1.03]

0.43[0.18,1.03]

Favours asenapine

0.001

0.1

1

10

1000

Favours placebo

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

62

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.15.   Comparison 1 ASENAPINE versus PLACEBO, Outcome 15 Adverse effects: 4. Specific adverse
effects - 4.4. Metabolic: average change in prolactin levels (μg/L) (baseline-to-endpoint) - short-term.

Study or subgroup

Asenapine

Placebo

N

Mean(SD)

N

Mean(SD)

217

-13.2 (39.7)

123

-19.2 (43.7)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

100%

6.01[-3.35,15.37]

Kane 2010

Total ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.26(P=0.21)

217

123

100%

6.01[-3.35,15.37]

Favours asenapine

-50

-25

0

25

50

Favours placebo

Analysis 1.16.   Comparison 1 ASENAPINE versus PLACEBO, Outcome 16 Adverse effects: 4.
Specific adverse effects - 4.5. Metabolic: average change in weight (kg) (baseline-to-endpoint).

Study or subgroup

Asenapine

Placebo

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.16.1 short-term

Kane 2010

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.91(P=0.06)

1.16.2 medium-term

Kane 2011

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=3.17(P=0)

217

217

0.7 (2.5)

123

123

-0.4 (5.8)

32.12%

32.12%

1.05[-0.03,2.13]

1.05[-0.03,2.13]

194

194

0 (3.4)

192

192

-1.2 (4)

67.88%

67.88%

1.2[0.46,1.94]

1.2[0.46,1.94]

Total ***

411

315

100%

1.15[0.54,1.76]

Heterogeneity: Tau2=0; Chi2=0.05, df=1(P=0.82); I2=0%

Test for overall effect: Z=3.7(P=0)

Test for subgroup differences: Chi2=0.05, df=1 (P=0.82), I2=0%

Favours asenapine

-5

-2.5

0

2.5

5

Favours placebo

Analysis 1.17.   Comparison 1 ASENAPINE versus PLACEBO, Outcome 17 Adverse
effects: 4. Specific adverse effects - 4.6. Other specific adverse effects: incidence.

Study or subgroup

1.17.1 agitation - short-term

Potkin 2007

Kane 2010

Subtotal (95% CI)

Asenapine

n/N

Placebo

n/N

Risk Ratio

M-H, Fixed, 95% CI

Weight

Risk Ratio

M-H, Fixed, 95% CI

9/59

7/217

276

15/62

11/123

185

51.02%

48.98%

100%

0.63[0.3,1.33]

0.36[0.14,0.91]

0.5[0.28,0.89]

Total events: 16 (Asenapine), 26 (Placebo)

Heterogeneity: Tau2=0; Chi2=0.86, df=1(P=0.36); I2=0%

Test for overall effect: Z=2.37(P=0.02)

1.17.2 agitation - medium-term

Favours asenapine

0.001

0.1

1

10

1000

Favours placebo

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

63

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Kane 2011

Subtotal (95% CI)

Asenapine

n/N

Placebo

n/N

Risk Ratio

M-H, Fixed, 95% CI

4/194

194

11/192

192

Weight

Risk Ratio

100%

100%

M-H, Fixed, 95% CI

0.36[0.12,1.11]

0.36[0.12,1.11]

Total events: 4 (Asenapine), 11 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=1.78(P=0.08)

1.17.3 akathisia - short-term

Kane 2010

Subtotal (95% CI)

13/217

217

4/123

123

Total events: 13 (Asenapine), 4 (Placebo)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=1.09(P=0.28)

100%

100%

1.84[0.61,5.53]

1.84[0.61,5.53]

1.17.4 akathisia - medium-term

Kane 2011

Subtotal (95% CI)

Total events: 4 (Asenapine), 3 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.37(P=0.71)

1.17.5 anxiety - short-term

Potkin 2007

Kane 2010

Subtotal (95% CI)

4/194

194

3/192

192

100%

100%

1.32[0.3,5.82]

1.32[0.3,5.82]

10/59

7/217

276

9/62

5/123

185

57.9%

42.1%

100%

1.17[0.51,2.67]

0.79[0.26,2.45]

1.01[0.52,1.96]

Total events: 17 (Asenapine), 14 (Placebo)

Heterogeneity: Tau2=0; Chi2=0.29, df=1(P=0.59); I2=0%

Test for overall effect: Z=0.03(P=0.98)

1.17.6 anxiety - medium-term

Kane 2011

Subtotal (95% CI)

Total events: 16 (Asenapine), 21 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.89(P=0.37)

1.17.7 delusions - medium-term

Kane 2011

Subtotal (95% CI)

Total events: 2 (Asenapine), 11 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=2.25(P=0.02)

1.17.8 dizziness - short-term

Potkin 2007

Subtotal (95% CI)

Total events: 5 (Asenapine), 9 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=1.02(P=0.31)

1.17.9 fatigue - short-term

Potkin 2007

Subtotal (95% CI)

16/194

194

21/192

192

100%

100%

0.75[0.41,1.4]

0.75[0.41,1.4]

2/194

194

11/192

192

100%

100%

0.18[0.04,0.8]

0.18[0.04,0.8]

5/59

59

2/59

59

9/62

62

4/62

62

100%

100%

0.58[0.21,1.64]

0.58[0.21,1.64]

100%

100%

0.53[0.1,2.76]

0.53[0.1,2.76]

Favours asenapine

0.001

0.1

1

10

1000

Favours placebo

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

64

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Asenapine

n/N

Placebo

n/N

Risk Ratio

M-H, Fixed, 95% CI

Weight

Risk Ratio

M-H, Fixed, 95% CI

Total events: 2 (Asenapine), 4 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.76(P=0.45)

1.17.10 hallucinations - medium-term

Kane 2011

Subtotal (95% CI)

1/194

194

13/192

192

Total events: 1 (Asenapine), 13 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=2.49(P=0.01)

1.17.11 headache - short-term

Potkin 2007

Kane 2010

Subtotal (95% CI)

8/59

6/217

276

17/62

12/123

185

Total events: 14 (Asenapine), 29 (Placebo)

Heterogeneity: Tau2=0; Chi2=0.8, df=1(P=0.37); I2=0%

Test for overall effect: Z=3.1(P=0)

100%

100%

0.08[0.01,0.58]

0.08[0.01,0.58]

51.98%

48.02%

100%

0.49[0.23,1.06]

0.28[0.11,0.74]

0.39[0.22,0.71]

1.17.12 headache - medium-term

Kane 2011

Subtotal (95% CI)

Total events: 6 (Asenapine), 2 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=1.34(P=0.18)

6/194

194

2/192

192

100%

100%

2.97[0.61,14.53]

2.97[0.61,14.53]

1.17.13 insomnia - short-term

Potkin 2007

Kane 2010

Subtotal (95% CI)

11/59

19/217

276

8/62

18/123

185

Total events: 30 (Asenapine), 26 (Placebo)

Heterogeneity: Tau2=0; Chi2=2.79, df=1(P=0.09); I2=64.21%

Test for overall effect: Z=0.85(P=0.4)

25.35%

74.65%

100%

1.44[0.62,3.34]

0.6[0.33,1.1]

0.81[0.5,1.31]

1.17.14 insomnia - medium-term

Kane 2011

Subtotal (95% CI)

Total events: 12 (Asenapine), 26 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=2.35(P=0.02)

1.17.15 nausea - short-term

Potkin 2007

Subtotal (95% CI)

Total events: 11 (Asenapine), 8 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.86(P=0.39)

12/194

194

26/192

192

100%

100%

0.46[0.24,0.88]

0.46[0.24,0.88]

11/59

59

8/62

62

100%

100%

1.44[0.62,3.34]

1.44[0.62,3.34]

1.17.16 oral hypoesthesia - short-term

Kane 2010

Subtotal (95% CI)

10/217

217

3/123

123

Total events: 10 (Asenapine), 3 (Placebo)

100%

100%

1.89[0.53,6.74]

1.89[0.53,6.74]

Favours asenapine

0.001

0.1

1

10

1000

Favours placebo

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

65

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Asenapine

n/N

Placebo

n/N

Risk Ratio

M-H, Fixed, 95% CI

Weight

Risk Ratio

M-H, Fixed, 95% CI

Heterogeneity: Not applicable

Test for overall effect: Z=0.98(P=0.33)

1.17.17 pain - short-term

Potkin 2007

Subtotal (95% CI)

Total events: 3 (Asenapine), 4 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.32(P=0.75)

1.17.18 psychosis - short-term

Potkin 2007

Subtotal (95% CI)

Total events: 6 (Asenapine), 4 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.73(P=0.46)

3/59

59

6/59

59

4/62

62

4/62

62

1.17.19 schizophrenia - medium-term

Kane 2011

Subtotal (95% CI)

9/194

194

31/192

192

100%

100%

0.79[0.18,3.37]

0.79[0.18,3.37]

100%

100%

1.58[0.47,5.31]

1.58[0.47,5.31]

100%

100%

0.29[0.14,0.59]

0.29[0.14,0.59]

Total events: 9 (Asenapine), 31 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=3.42(P=0)

1.17.20 sedation - short-term

Kane 2010

Subtotal (95% CI)

Total events: 6 (Asenapine), 5 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.65(P=0.52)

6/217

217

5/123

123

100%

100%

0.68[0.21,2.18]

0.68[0.21,2.18]

1.17.21 somnolence - short-term

Potkin 2007

Kane 2010

Subtotal (95% CI)

11/59

8/217

276

8/62

1/123

185

Total events: 19 (Asenapine), 9 (Placebo)

Heterogeneity: Tau2=0; Chi2=1.08, df=1(P=0.3); I2=7.02%

Test for overall effect: Z=1.59(P=0.11)

85.94%

14.06%

100%

1.44[0.62,3.34]

4.53[0.57,35.83]

1.88[0.86,4.08]

1.17.22 somnolence - medium-term

Kane 2011

Subtotal (95% CI)

Total events: 1 (Asenapine), 2 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.58(P=0.56)

1/194

194

2/192

192

100%

100%

0.49[0.05,5.41]

0.49[0.05,5.41]

1.17.23 upper respiratory tract infection - short-term

Potkin 2007

Subtotal (95% CI)

4/59

59

3/62

62

Total events: 4 (Asenapine), 3 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.45(P=0.65)

100%

100%

1.4[0.33,6]

1.4[0.33,6]

Favours asenapine

0.001

0.1

1

10

1000

Favours placebo

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

66

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Asenapine

n/N

Placebo

n/N

Risk Ratio

M-H, Fixed, 95% CI

Weight

Risk Ratio

M-H, Fixed, 95% CI

1.17.24 worsening psychotic symptoms - short-term

Kane 2010

Subtotal (95% CI)

9/217

217

10/123

123

Total events: 9 (Asenapine), 10 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=1.51(P=0.13)

100%

100%

0.51[0.21,1.22]

0.51[0.21,1.22]

Favours asenapine

0.001

0.1

1

10

1000

Favours placebo

Analysis 1.18.   Comparison 1 ASENAPINE versus PLACEBO, Outcome
18 Adverse effects: 5. Extrapyramidal symptoms - 5.1 Incidence.

Study or subgroup

Asenapine

n/N

Placebo

n/N

Risk Ratio

M-H, Fixed, 95% CI

Weight

Risk Ratio

M-H, Fixed, 95% CI

1.18.1 any extrapyramidal symptoms - short-term

NCT00151424

Kane 2010

Subtotal (95% CI)

9/90

36/217

307

5/93

12/123

216

Total events: 45 (Asenapine), 17 (Placebo)

Heterogeneity: Tau2=0; Chi2=0.02, df=1(P=0.89); I2=0%

Test for overall effect: Z=2.04(P=0.04)

1.18.2 any extrapyramidal symptoms - medium-term

Kane 2011

Subtotal (95% CI)

6/194

194

9/192

192

24.3%

75.7%

100%

1.86[0.65,5.34]

1.7[0.92,3.14]

1.74[1.02,2.96]

100%

100%

0.66[0.24,1.82]

0.66[0.24,1.82]

Total events: 6 (Asenapine), 9 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.8(P=0.42)

1.18.3 dystonia - short-term

Kane 2010

Subtotal (95% CI)

Total events: 6 (Asenapine), 0 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=1.37(P=0.17)

1.18.4 hyperkinesia - short-term

Potkin 2007

Subtotal (95% CI)

Total events: 0 (Asenapine), 0 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

1.18.5 hypertonia - short-term

Potkin 2007

Subtotal (95% CI)

Total events: 0 (Asenapine), 2 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=1.01(P=0.31)

6/217

217

0/123

123

100%

100%

7.39[0.42,130.15]

7.39[0.42,130.15]

0/59

59

0/59

59

0/62

62

2/62

62

Not estimable

Not estimable

100%

100%

0.21[0.01,4.28]

0.21[0.01,4.28]

Favours asenapine

0.001

0.1

1

10

1000

Favours placebo

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

67

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Asenapine

n/N

Placebo

n/N

Risk Ratio

M-H, Fixed, 95% CI

Weight

Risk Ratio

M-H, Fixed, 95% CI

1.18.6 muscle rigidity - short-term

Kane 2010

Subtotal (95% CI)

Total events: 7 (Asenapine), 0 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=1.47(P=0.14)

1.18.7 Parkinsonism - short-term

Kane 2010

Subtotal (95% CI)

Total events: 16 (Asenapine), 6 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.89(P=0.37)

1.18.8 Parkinsonism - medium-term

Kane 2011

Subtotal (95% CI)

Total events: 1 (Asenapine), 3 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.96(P=0.33)

7/217

217

0/123

123

100%

100%

8.53[0.49,148.12]

8.53[0.49,148.12]

16/217

217

6/123

123

100%

100%

1.51[0.61,3.76]

1.51[0.61,3.76]

1/194

194

3/192

192

100%

100%

0.33[0.03,3.14]

0.33[0.03,3.14]

Favours asenapine

0.001

0.1

1

10

1000

Favours placebo

Analysis 1.19.   Comparison 1 ASENAPINE versus PLACEBO, Outcome 19 Adverse effects: 5. Extrapyramidal
symptoms - 5.2. Average change (baseline-to-endpoint) (various scales, high=poor) - short-term.

Study or subgroup

Asenapine

Placebo

N

Mean(SD)

N

Mean(SD)

Mean Difference

Fixed, 95% CI

Weight

Mean Difference

Fixed, 95% CI

1.19.1 AIMS

Kane 2010

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=0.84(P=0.4)

1.19.2 BAS

Kane 2010

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.35(P=0.18)

1.19.3 SAS

Kane 2010

Subtotal ***

Heterogeneity: Not applicable

Test for overall effect: Z=1.8(P=0.07)

213

213

-0.1 (0.9)

120

120

0.1 (1.6)

100%

100%

-0.13[-0.43,0.17]

-0.13[-0.43,0.17]

213

213

0 (0.7)

120

120

-0.1 (0.7)

100%

100%

0.11[-0.05,0.27]

0.11[-0.05,0.27]

213

213

-0.1 (2.6)

120

120

-0.6 (2.3)

100%

100%

0.5[-0.04,1.04]

0.5[-0.04,1.04]

Favours asenapine

-2

-1

0

1

2

Favours placebo

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

68

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Analysis 1.20.   Comparison 1 ASENAPINE versus PLACEBO, Outcome
20 Adverse effects: 6. Incidence of death (for any reason) - short-term.

Study or subgroup

NCT00151424

Kane 2010

Total (95% CI)

Asenapine

n/N

Placebo

n/N

Risk Difference

M-H, Fixed, 95% CI

0/90

0/217

307

0/93

1/123

216

Weight

Risk Difference

36.81%

63.19%

M-H, Fixed, 95% CI

0[-0.02,0.02]

-0.01[-0.03,0.01]

100%

-0.01[-0.02,0.01]

Total events: 0 (Asenapine), 1 (Placebo)

Heterogeneity: Tau2=0; Chi2=0.31, df=1(P=0.58); I2=0%

Test for overall effect: Z=0.67(P=0.5)

Favours asenapine

-0.1

-0.05

0

0.05

0.1

Favours placebo

Analysis 1.21.   Comparison 1 ASENAPINE versus PLACEBO, Outcome 21 Leaving the study early.

Study or subgroup

Asenapine

n/N

Placebo

n/N

Risk Ratio

M-H, Fixed, 95% CI

Weight

Risk Ratio

M-H, Fixed, 95% CI

1.21.1 any reason - short-term

NCT00151424

NCT00156117

Potkin 2007

Chapel 2009

Kane 2010

Subtotal (95% CI)

48/90

93/198

32/59

20/76

79/217

640

45/93

54/93

41/62

4/35

54/123

406

Total events: 272 (Asenapine), 198 (Placebo)

Heterogeneity: Tau2=0; Chi2=7.02, df=4(P=0.13); I2=43.04%

Test for overall effect: Z=1.42(P=0.15)

19.07%

31.66%

17.22%

2.36%

29.69%

100%

1.1[0.83,1.47]

0.81[0.64,1.02]

0.82[0.61,1.1]

2.3[0.85,6.23]

0.83[0.64,1.08]

0.91[0.8,1.04]

59/194

194

120/192

192

100%

100%

0.49[0.38,0.62]

0.49[0.38,0.62]

1.21.2 any reason - medium-term

Kane 2011

Subtotal (95% CI)

Total events: 59 (Asenapine), 120 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=5.9(P<0.0001)

1.21.3 due to adverse effects - short-term

NCT00151424

Potkin 2007

Kane 2010

Subtotal (95% CI)

8/90

6/59

15/217

366

5/93

7/62

13/123

278

Total events: 29 (Asenapine), 25 (Placebo)

Heterogeneity: Tau2=0; Chi2=1.99, df=2(P=0.37); I2=0%

Test for overall effect: Z=0.47(P=0.64)

1.21.4 due to adverse effects - medium-term

Kane 2011

Subtotal (95% CI)

16/194

194

53/192

192

Total events: 16 (Asenapine), 53 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=4.53(P<0.0001)

17.35%

24.09%

58.56%

100%

1.65[0.56,4.86]

0.9[0.32,2.52]

0.65[0.32,1.33]

0.89[0.54,1.47]

100%

100%

0.3[0.18,0.5]

0.3[0.18,0.5]

Favours asenapine

0.2

0.5

1

2

5

Favours placebo

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

69

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Asenapine

n/N

Placebo

n/N

Risk Ratio

M-H, Fixed, 95% CI

Weight

Risk Ratio

M-H, Fixed, 95% CI

1.21.5 due to lack of efficacy - short-term

Potkin 2007

Kane 2010

Subtotal (95% CI)

9/59

31/214

273

18/62

31/122

184

Total events: 40 (Asenapine), 49 (Placebo)

Heterogeneity: Tau2=0; Chi2=0.04, df=1(P=0.85); I2=0%

Test for overall effect: Z=3.04(P=0)

1.21.6 due to loss to follow up - medium-term

Kane 2011

Subtotal (95% CI)

3/194

194

3/192

192

Total events: 3 (Asenapine), 3 (Placebo)

Heterogeneity: Tau2=0; Chi2=0, df=0(P<0.0001); I2=100%

Test for overall effect: Z=0.01(P=0.99)

1.21.7 due to other reasons - short-term

Potkin 2007

Kane 2010

Subtotal (95% CI)

17/59

41/214

273

16/62

18/122

184

Total events: 58 (Asenapine), 34 (Placebo)

Heterogeneity: Tau2=0; Chi2=0.15, df=1(P=0.7); I2=0%

Test for overall effect: Z=1.04(P=0.3)

1.21.8 due to other reasons - medium-term

Kane 2011

Subtotal (95% CI)

11/194

194

13/192

192

Total events: 11 (Asenapine), 13 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=0.45(P=0.65)

1.21.9 due to relapse (not considered adverse effect) - medium-term

Kane 2011

Subtotal (95% CI)

10/194

194

39/192

192

Total events: 10 (Asenapine), 39 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=4.04(P<0.0001)

1.21.10 due to specific adverse effect: relapse - medium-term

Kane 2011

Subtotal (95% CI)

14/194

194

51/192

192

Total events: 14 (Asenapine), 51 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=4.59(P<0.0001)

1.21.11 due to specific adverse effect: worsening of schizophrenia -
medium-term

Kane 2011

Subtotal (95% CI)

13/194

194

51/192

192

Total events: 13 (Asenapine), 51 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=4.69(P<0.0001)

30.77%

69.23%

100%

0.53[0.26,1.08]

0.57[0.37,0.89]

0.56[0.38,0.81]

100%

100%

0.99[0.2,4.84]

0.99[0.2,4.84]

40.49%

59.51%

100%

1.12[0.62,2]

1.3[0.78,2.16]

1.22[0.83,1.8]

100%

100%

0.84[0.38,1.82]

0.84[0.38,1.82]

100%

100%

0.25[0.13,0.49]

0.25[0.13,0.49]

100%

100%

0.27[0.16,0.47]

0.27[0.16,0.47]

100%

100%

0.25[0.14,0.45]

0.25[0.14,0.45]

Favours asenapine

0.2

0.5

1

2

5

Favours placebo

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

70

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Study or subgroup

Asenapine

n/N

Placebo

n/N

Risk Ratio

M-H, Fixed, 95% CI

Weight

Risk Ratio

M-H, Fixed, 95% CI

1.21.12 due to withdrawal of consent - medium-term

Kane 2011

Subtotal (95% CI)

19/194

194

12/192

192

Total events: 19 (Asenapine), 12 (Placebo)

Heterogeneity: Not applicable

Test for overall effect: Z=1.27(P=0.21)

100%

100%

1.57[0.78,3.14]

1.57[0.78,3.14]

Favours asenapine

0.2

0.5

1

2

5

Favours placebo

A D D I T I O N A L   T A B L E S

Table 1.   Studies in this review which are relevant to others 

Study

Comparison

adults

with schizophrenia

Relevant existing
Cochrane review

adolescents

Chapel 2009; NCT00156065; NCT01142596;
Kane 2010; NCT00156117; NCT01617187

Asenapine dose

NCT00156065; Kane 2010

Asenapine versus haloperidol

Cazorla 2008; NCT00151424; NCT00156117;
NCT00156091; NCT01098110; NCT01617187

Asenapine versus olanzapine

Chapel 2009

Potkin 2007

NCT01190254

Asenapine versus quetiapine

Asenapine versus risperidone

Kane 2010

Haloperidol versus placebo

NCT00151424; NCT00156117; NCT00156091;
NCT01098110; NCT01617187

Olanzapine versus placebo

Chapel 2009

Potkin 2007

Quetiapine versus placebo

Risperidone versus placebo

None underway

Kumar 2012

Preda 2010

Asenapine dose

None underway

Asenapine versus
placebo

None underway

Adams 2013

Duggan 2005

Lankappa 2012

Rattehalli 2010

C O N T R I B U T I O N S   O F   A U T H O R S

Alistair  Hay:  Screening  retrieved  papers  against  eligibility  criteria,  extracting  qualitative  and  quantitative  data  from  papers,  writing  to
authors of papers for additional information, providing additional data about papers (conversion of P values and SE to usable SD where
appropriate, calculating average values for studies involving multiple asenapine arms), obtaining and screening of data from unpublished
studies, entering qualitative and quantitative data into RevMan, analysis of data (summary of findings and meta-analyses), interpretation
of data, providing a methodological perspective, writing the protocol/review (use of RevMan HAL software for results section, writing the

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

71

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

abstract and discussion sections), liaison with Cochrane Schizophrenia Group (contact with Trials Search Coordinator for access to papers,
and with course leader).

Amy Byers: Screening retrieved papers against eligibility criteria, appraising the quality of papers (identifying characteristics of studies and
risks of bias), extracting qualitative and quantitative data from papers, entering qualitative data into RevMan, analysis of data (summary
of findings), interpretation of data, providing a methodological perspective, writing the protocol/review (completing 'Characteristics of
studies' tables and 'Risk of bias' tables, writing the abstract, results and discussion sections), liaison with Cochrane Schizophrenia Group
(organised meetings with course leader).

Marco Sereno: Screening retrieved papers against eligibility criteria, identifying additional papers through handsearching, appraising the
quality of papers (identifying characteristics of studies and risks of bias), providing additional data about papers (calculating average values
for studies involving multiple asenapine arms), extracting qualitative and quantitative data from papers, obtaining and screening of data
on unpublished studies, entering qualitative and quantitative data into RevMan, analysis of quantitative data (meta-analyses and summary
of findings), interpretation of data, providing a methodological perspective, writing the protocol/review (writing the abstract, background
and discussion sections).

Manpreet Basra: Screening retrieved papers against eligibility criteria, providing additional data about papers (identified all relevant scales
in studies), entering data into RevMan, interpretation of data, providing a methodological perspective, writing the protocol/review (writing
the abstract, results and discussion sections).

Snigdha Dutta: Screening retrieved papers against eligibility criteria, appraising quality of papers (identifying characteristics of studies
and risks of bias), extracting qualitative data, entering qualitative data into RevMan, analysis of quantitative data (summary of findings),
interpretation of data, providing a methodological perspective, writing the protocol/review (completing 'Characteristics of studies' tables
and 'Risk of bias' tables and figures, writing the abstract, results and discussion sections).

Iram Jalil: see Acknowledgements.

D E C L A R A T I O N S   O F   I N T E R E S T

Alistair Hay – none known.

Amy Byers – none known.

Marco Sereno – none known.

Manpreet Basra – none known.

Snigdha Dutta – none known.

S O U R C E S   O F   S U P P O R T

Internal sources

• University of Nottingham, UK.

External sources

• No sources of support supplied

D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W

After seeking advice, we used the Mantel-Haenszel method to compute Risk Differences (RD) rather than Risk Ratio (RR) for binary outcomes
in which at least one study had zero events in both asenapine and placebo trial arms. This included 1.12.1 QTc interval > 450ms and 1.21
Adverse effects: 6. Incidence of death.

I N D E X   T E R M S

Medical Subject Headings (MeSH)

Antipsychotic Agents  [adverse effects]  [*therapeutic use];  Dibenzocycloheptenes;  Heterocyclic Compounds, 4 or More Rings  [adverse
effects]  [*therapeutic use];  Psychotic Disorders  [drug therapy];  Randomized Controlled Trials as Topic;  Schizophrenia  [*drug therapy];
  Treatment Outcome

MeSH check words

Adult; Humans

Asenapine versus placebo for schizophrenia (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

72
